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Thermodynamics and Kinetics of
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by
S. Patrick Walton
Submitted to the Department of Chemical Engineering
on October 11, 2001 in partial fulfillment of the
Requirements for the Degree of Doctor of Science in
Chemical Engineering
Abstract
Antisense oligonucleotides have the potential to selectively inhibit the expression of any
gene with a known sequence. Antisense-based therapies are under development for the treatment
of infectious diseases as well as complex genetic disorders. Although there have been some
remarkable successes, realizing this potential is proving difficult because of problems with
oligonucleotide stability, specificity, affinity, and delivery. Each of these limitations has been
addressed experimentally through the use of chemically-modified oligonucleotides and
oligonucleotide conjugates, with much success in enhancing oligonucleotide efficacy. These
early studies have shown that selection of target site, once considered a trivial problem, is critical
to the success of antisense strategies.
It has become clear that the efficacy of antisense oligonucleotides is a strong function of
the structure of the target mRNA. Though single-stranded, RNA molecules are typically folded
into complex three-dimensional structures, formed primarily by intramolecular Watson-Crick
base-pairing. If an oligonucleotide is complementary to a sequence embedded in the three
dimensional structure, the oligonucleotide may not be able to bind to its target site and exert its
therapeutic effect. Because the majority of the structure of RNA molecules is due to Watson-
Crick base-pairing, relatively accurate predictions of these folding interactions can be made from
algorithms that locate the structure with the most favorable free energy of folding.
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Taking advantage of the predictability of RNA structures, this thesis addresses the
problem of antisense target site selection, first from a theoretical and subsequently an
experimental standpoint. A thermodynamic model to predict the binding affinity of
oligonucleotides for their target mRNA is described and validated using multiple in vitro and
cell-culture based experimental data sets. Subsequently, direct experimental comparisons with
theoretical predictions are made on the well-characterized rabbit-~-globin (RBG) mRNA, using a
novel, centrifugal, binding affinity assay. The importance of the hybridization kinetics is also
explored, as is the role of association kinetics in defining the rate of cleavage by the enzyme
ribonuclease H (RNase H). Finally, the applicability of the model in identifying biologically
active oligonucleotides is demonstrated.
Thesis Co-Supervisor: Martin L. Yarmush
Title: Helen Andrus Benedict Professor of Surgery and Bioengineering, Harvard Medical School
Thesis Co-Supervisor: Gregory N. Stephanopoulos
Title: Professor of Chemical Engineering
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1. Introduction
l.A. Significance
Despite numerous advances in the prevention, diagnosis, and treatment of human disease,
there remains a wide range of conditions for which no satisfactory therapeutic options exist.
Currently, over 34 million people suffer with HIV/AIDS with roughly 5 million new infections
each year [1]. In the United States, men have a 50% chance of developing cancer in their
lifetimes; women have a 33% chance [2]. It is estimated that 600,000 people in America
currently suffer from Crohn's disease/inflammatory bowel disease, annually [3]. Multiple Organ
Dysfunction Syndrome (MODS) is the leading cause of death in post-bum patients [4, 5]. The
promise of biotechnological therapeutics may lead to treatments for any or all of these diseases.
Many developing technologies are based on the hybridization of oligonucleotides for
their targets. Two notable techniques, oligonucleotide microarrays for solid phase functional
genomic applications and molecular beacons for solution phase diagnostics, typify the types of
ways in which oligonucleotides are applied in biotechnology. Oligonucleotide and cDNA arrays
have revolutionized the way in which cellular physiology is quantified. These microscale
methods allow researchers to perform the equivalent of thousands of simultaneous Northern
blots. However, use of oligonucleotide arrays is not without its pitfalls. In particular for
oligonucleotide arrays, many oligonucleotides are chosen randomly to target each gene and the
level of that gene quantified based on the ensemble average of all of the points. Variability in
the hybridization levels for these oligonucleotides reduces the accuracy in assigning a level to the
transcript, limiting the information content from these costly experiments. Further understanding
of the impact of oligonucleotide sequence and mRNA target structure on the hybridization of the
probes for their target would ensure that the most accurate calls are made and the most
information extracted from every array.
Molecular beacons are hairpin oligonucleotides with a fluorescent molecule tethered to
one end and a quenching molecule to the other. Upon binding of the targeted RNA, the hairpin
unfolds and the fluorescent molecule signals the presence of the mRNA of interest. The rapid
and high-affinity hybridization of these beacons for their target is central to their effectiveness in
detecting potentially low-abundance transcripts, such as oncogene products in the detection of
potentially cancerous tissue. Other solution-phase hybridization techniques, such as in the use of
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ribozymes, rely on a strong interaction between the oligonucleotide and the target. If the
complementary region on the transcript is a "poor" one, time and money will have been wasted
on the synthesis and testing of a molecule that never had a chance of exerting its therapeutic
effect.
A promising, but relatively young, technology that is being examined as a potential
treatment for each of these diseases is termed antisense technology. The principle of antisense is
based on the hybridization of short, DNA oligonucleotides to mRNA molecules to exert a
desired effect. The simplicity of design of antisense molecules arises from the specificity of
intermolecular Watson-Crick base-pairing. Though antisense mediated gene inhibition was first
seen in the 1970's, development of commercial therapeutics began to proliferate in the 1990's
with companies being founded or branching out into the field. A decade of research and
development of antisense has produced hundreds of clinical trials of dozens of candidates but
only one approved therapeutic, which has since generated only $560K worldwide in revenues
[6]. With roughly 6 years of clinical research required to bring a single product to market, it has
been estimated that bringing a single product to market costs approximately $500MM. Hence,
product failure in late stage trials can doom a company. Methods for designing and selecting
optimized candidate oligonucleotides would enhance the likelihood that clinically viable
molecules will result.
Traditional in vitro and cell-culture screening methods are insufficient for confidently
identifying the most active oligonucleotides, the desirable starting point for further optimization
of stability and delivery. A strong need exists for rapid and quantitative methods for identifying
those sequences with the highest likelihood for exerting a strong biological effect in the clinical
setting. The structured methodology for selection and evaluation of antisense oligonucleotide
candidates described here will reduce the number of sequences that must be tested in vitro while
offering insight into the biophysics of antisense oligonucleotide interactions with its target
mRNA.
l.B. Background
With the completion of the draft human genome [7], biomedical science is entering an era
in which the knowledge and application of genomic information will be critical in the
development of new therapeutics [8]. Antisense oligonucleotides (short 15-25 nt pieces of DNA)
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take immediate advantage of this wealth of information. These molecules utilize Watson-Crick
base-pairing to a target mRNA to achieve a therapeutic effect, typically by the reduction of
protein expression from the targeted mRNA, as was definitively shown over 20 years ago [9].
While the use of antisense oligonucleotides has many attractive features as a novel molecular
therapeutic, technical barriers have inhibited antisense drug development. A 1997 conference on
antisense concluded with much discussion of a data gap that existed between industry and
science, in particular, the need for fundamental understanding of the mechanism by which the
molecules achieve their therapeutic effect [10-12]. The development of antisense therapeutics
will follow from intense scientific study of the mechanisms by which these molecules exert their
effect. Understanding the limitations to oligonucleotide efficacy will allow the directed
engineering of their structure to achieve optimal activity with minimal non-specific effects.
1.B.1. Antisense Principle
Zamecnik and Stephenson were the first to use antisense DNA to modulate gene
expression, inhibiting Rous sarcoma virus replication in chick embryo fibroblasts [9].
Surprisingly, the cells had internalized the antisense DNA, which was interrupting the viral life
cycle. Natural antisense inhibition was first observed in bacteria as a means of regulating the
replication of plasmid DNA [13, 14]. Antisense RNA, encoded on expression plasmids that
were transfected into mouse cells, successfully blocked expression of target genes [15]. These
early successes launched what is now a significant effort to expand the use of antisense
molecules for research and therapeutic purposes, primarily with DNA oligonucleotides. When
introduced to the target cells, they are internalized and hybridize with their complementary
sequence, as shown in Figure 1-1. Translation of the target mRNA is inhibited by preventing
ribosomal binding and procession and/or inducing cleavage by an enzyme, RNase H, that
specifically degrades the RNA strand in an RNA-DNA hybrid [16]. While this mechanism is
simple in concept, the challenges and outstanding issues in oligonucleotide development have
slowed the development of viable therapeutics.
Antisense inhibition is based on the complementary hybridization of the oligonucleotide
for its target mRNA. However, to achieve this effect, the oligonucleotide must negotiate a
complicated path to reach its target (Figure 1-2). Oligonucleotides are typically administered to
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Figure 1-1: Antisense principle
Antisense oligonucleotides are administered to cells where they are internalized and gain
access to the cytoplasm and nucleus. The oligonucleotides then hybridize specifically
with their target mRNA to reduce or eliminate the translation of the gene product. Levels
of protein are reduced subsequent to the reduction of mRNA levels via enzymatic
cleavage. Alternatively, protein levels can be reduced by steric inhibition of ribosomal
binding and progression.
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the extracellular medium and must diffuse to reach the cell surface. in vitro experiments
performed in the presence of serum will cause extracellular degradation of the oligonucleotides
due to the presence of serum nucleases [17]. Upon reaching the cell surface, oligonucleotides
will bind to either scavenger receptors or to adsorbed bovine serum albumin [18-21]. The mode
of internalization is either via adsorptive endocytosis or receptor-mediated endocytosis [22-24].
Regardless, the oligonucleotides must escape vesicular structures to reach the cytoplasm, though
the mechanisms for this process remain in doubt [25, 26]. Having finally accessed the
cytoplasm, oligonucleotides can then diffuse to locate their intracellular target from among the
RNAs in the cell, with the majority of the effect occurring subsequent to accumulation of the
oligonucleotides in the nucleus, where the majority of RNase H activity is localized [27, 28].
Upon reaching its target mRNA, the oligonucleotide must then hybridize with sufficient
affinity to exert an effect. Though oligonucleotides as small as 7 nt have been shown to exert an
antisense effect [29], the general range of oligonucleotide length is 15-25 nt [8, 16]. This length
balances the need for genomic uniqueness with possible partial hybridization of the
oligonucleotide [30]. As RNase H activation requires hybridization of only 4-5 nt [31],
oligonucleotides of excessive length have the potential to show marked non-targeted effects still
based on specific interactions. The rate and affinity of the hybridization of the oligonucleotide to
its specific target versus other targets will determine the therapeutic specificity as well as the
efficacy of a particular oligonucleotide in a therapeutic context.
l.B.l.a. Molecular Aspects of A 1ltis ellse Mechanism
In all of the phases of trafficking and binding of antisense oligonucleotides, particular
molecules and intermolecular interactions determine the success of the oligonucleotides in
achieving their desired effect. As is shown schematically in Figure 1-2, oligonucleotides
encounter lipids, carbohydrates, proteins, as well as other nucleic acids in locating their target,
and the interactions of the oligonucleotides with each of these different species affect them
distinctly. Researchers have sought to take advantage of all of these molecular interactions and
processes to enhance oligonucleotide efficacy. Any discussion of the principle of antisense,
therefore, must begin with a discussion of the molecular aspects of the mechanism.
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Figure 1-2: Processing of Antisense Oligonucleotides
Oligonucleotides are generally administered to the extracellular medium of cells and
must avoid degradation to reach and adsorb on the cell surface whereupon it is
internalized. Upon reaching the cytoplasm, intracellular nucleases degrade the
oligonucleotide as it is trafficked to reach its target within the mRNA pool. If unable to
escape the endocytic vesicle, the oligonucleotide will be trafficked to the lysosome where
it will be either resecreted or degraded by lysosomal acid hydrolases. If able to reach the
cellular mRNAs, it will then either hybridize with its target specifically or with an
unintended target specifically or non-specifically. The selectivity will be a function of
the length of the oligonucleotide and its affinity for its target. It is expected that the only
step in the processing of antisense oligonucleotides that is largely sequence dependent is
the hybridization reaction, with all other processes being somewhat equal regardless of
the oligonucleotide sequence.
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1.B.l.a.i. Surface Adsorption and Uptake
Antisense oligonucleotides when administered to cells are found to associate with cell
membranes and membrane proteins prior to internalization [24]. Binding has been shown to
occur with both specific cellular receptors and with non-specific proteins, such as bovine serum
albumin (BSA), a molecule very relevant to cell culture studies [18, 32, 33]. Membrane
association is followed by endocytosis via both temperature dependent and independent
mechanisms [24, 34]. Liposomal release to the cytoplasm is inefficient and results in the
majority of oligonucleotides being degraded in the endolysosomal compartments [35]. The exact
mechanism for release in the absence of lipid delivery vehicles is not well-established and has
been afforded little study due to its inherent inefficiency.
1.B.l.a.ii. Intracellular Trafficking and Nuclear Localization
Having escaped from the liposomal compartments, oligonucleotides then tend to move
primarily by diffusion through the cytoplasm, though studies have shown that the process can be
energy-dependent [36]. Trafficking of oligonucleotides is characterized typically using a two-
compartment model, where the shallow compartment with half-life of 5-10 minutes and a deep
compartment with half-life of 2-5 hours [37]. Nuclear localization generally occurs rapidly as
the oligonucleotides associate with nuclear proteins and remain resident in the nucleus for long
periods (> 2 days for nuclease stable analogues) [36, 38, 39]. The residence time in the nucleus
is particularly critical to the activity of oligonucleotides, as it has been shown that mRNA
reduction by RNase H primarily occurs subsequent to nuclear accumulation [27, 28].
1.B.l.a.iii. Target hybridization and RNase H Cleavage
Once resident in the nucleus, the oligonucleotide encounters a huge mixture of mRNA
and DNA molecules and must interact specifically only with those transcripts to which it is
targeted. Though it has been seen that single mismatches in complementarity can reduce binding
affinity by 500-fold in some cases, non-specific hybridization is still a significant issue [40].
With the massive excess of mRNA targets relative to genomic DNA targets and the increased
affinity of oligonucleotides for target RNA relative to complementary DNA, non-specific
interactions with genomic targets are minimized [41].
Subsequent to hybridization, RNA strands hybridized to oligonucleotides are recognized
and cleaved by a specific enzyme, RNase H [42]. This enzyme appears to recognize the
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fonnation of A-B fonn duplex character, as 2' -methoxy and other modified oligonucleotides do
not initiate cleavage by this enzyme [31]. A minimum of 5-6 bases are required to fonn a
suitable substrate for the enzyme to act upon its target [31,43]. RNase H cleavage of the target
mRNA is often the dominant inhibitory mechanism, with steric contributions alone often being
insufficient [31].
1.B.2. Antisense Oligonucleotide Development
Since the first published examples of antisense inhibition of protein expression [9], a
wealth of research has been done into applying these molecules to the inhibition of many gene
products. The work has primarily focused on those diseases that do not have satisfactory
treatments from current methodologies, including many fonns of cancer, viral infections, and
others. In the course of these studies, a number of clinical trials have resulted, with FDA
approval of one antisense therapeutic for the treatment of cytomegalovirus-induced retinitis in
immune-compromised patients. The results of these studies have indicated that to produce
oligonucleotides with the highest possible activity, it is necessary to optimize delivery to the
appropriate organ/cells, to modify oligonucleotides for enhanced nuclease stability and target
affinity, and to select the appropriate target site on the mRNA.
l.B.2.b. Oligonucleotide Delivery
In a therapeutic context, oligonucleotides must be delivered to the appropriate target
tissue, associate with the target cells, and be internalized. In vitro studies using chemical and
mechanical penneabilization support the hypothesis that cellular uptake limits oligonucleotide
efficacy [36,44-46]. Oligonucleotides must then negotiate the intracellular trafficking
mechanisms to reach the cytoplasm and nucleus, with the majority of the effect resulting
following localization in the nucleus [27]. Achieving the necessary oligonucleotide
concentration to enact an effect is limited by many factors, including nuclease degradation,
protein adsorption, and charge repulsion between the negatively-charged oligonucleotide and the
negatively-charged cell surface. Issues of systemic and cellular delivery are being addressed by
a number of different methods, including chemical modification of oligonucleotides to increase
their hydrophobicity and nuclease stability; conjugation of oligonucleotides to molecules that
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enhance biological half-life, cellular association, and endocytosis; and encapsulation of the
oligonucleotide in various carriers, primarily cationic lipids or liposomes.
l.B.2.b.i. Chemical Modification
It was initially believed that increasing the hydrophobicity of oligonucleotides would
enhance their association with lipid membranes as well as potentially allowing them to diffuse
freely through the plasma membrane. This was accomplished using methylphosphonate
backbone oligonucleotides. Despite their neutral backbone charge and their stability to nucleases
[17], cellular uptake of MP oligonucleotides was shown to be very inefficient, with uptake
primarily trapping the oligonucleotides in pinocytic vesicles with little or no nuclear
accumulation after 4 h [24,47].
l.B.2.b.ii. Conjugation
Early attempts at conjugation also focused on enhancing the oligonucleotide
hydrophobicity. Oligonucleotides conjugated to cholesterol derivatives (chol-oligonucleotides)
have improved association with cell membranes and internalization by cells [48-50].
Oligonucleotides conjugated with polycations such as poly-L-Iysine (PLL) also have improved
cellular uptake and efficacy [51, 52]. Conjugation to proteins can enhance the efficiency and
specificity of delivery while potentially mitigating the toxicity of the PLL moiety [53].
Oligonucleotide-PLL complexes have been conjugated to transferrin to inhibit c-myb in human
leukemia (~-60) cells, with the expression of c-myb greatly reduced [54]. This approach has
also been undertaken using specific cellular receptors, such as the asialoglycoprotein (ASGP)
receptor, EGF receptor, or IGFI receptor, with success [54-61]. Cellular signal peptide
conjugates have also been used to mediate specific trafficking within cells. Nuclear targeting
peptide was conjugated to an oligonucleotide to enhance its nuclear localization in Paramecium
[62]. This strategy has also been tested with non-covalent conjugates of oligonucleotide with
PLL conjugated to the signal import peptide from Kaposi fibroblast growth factor with positive
results [63]. Recent success at the lipofection of non-dividing cells with plasmid using a
nonclassical nuclear localization signal suggests another potential conjugate for oligonucleotide
deli very [64].
l.B.2.b.iii. Encapsulation into carriers
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A standard in vitro means to deliver oligonucleotides is lipofection. Oligonucleotides are
mixed with cationic lipids that condense around the negatively charged oligonucleotide forming
a lipid vesicle (liposome). The positively charged lipids reduce the electrostatic repulsion
between the oligonucleotide and the cell surface. Oligonucleotides then separate from the
liposomes following cellular internalization via adsorptive endocytosis [33, 57, 65-69].
Incorporation into liposomes has been shown to enhance efficacy by as much as 1000-fold in the
inhibition of ICAM-l and HIV-l [70,71]. Targeted liposomes have also been examined as a
method for enhancing specific, cellular delivery [20, 72].
i.B.2. b. iv. intracellular Trafficking
When material contained within vesicles enters the cell, it has two primary intracellular
destinations: the cellular lysosomes and the Golgi apparatus. For the vast majority of species,
the destination is the cellular lysosomes where acid hydrolases break down polymeric species
such as proteins and nucleic acids to their monomeric constituents. One well-studied example of
this mechanism is the LDL receptor [73]. Variants on this theme include many growth factor
receptors in which both the ligand and receptor are destroyed upon internalization [74] and the
mannose-6-phosphate receptor that binds lysosomal enzymes that were accidentally secreted and
transports them to the lysosomes where they gain their hydrolytic function. Some free endocytic
vesicles fuse with the trans Golgi body. Studies have shown that membrane proteins can be
returned to the Golgi and become re-sialated [75, 76]. Ligands bound to membrane proteins
could also be trafficked to the trans Golgi where they would re-enter the secretory pathway. Of
these trafficking patterns, neither can completely describe the path oligonucleotides must
traverse to achieve their therapeutic effect as neither provides a process whereby the vesicular
contents are able to access the cytoplasm. Elucidation of the mechanism by which
oligonucleotides enter the cytoplasm will substantially increase the understanding of their
mechanism of action.
l.B.2.c. Oligonucleotide Modifications
To address the issues of stability to nuclease degradation and affinity for their target
mRNA, natural phosphodiester (PO) oligonucleotides have been chemically modified in each of
their primary functional regions, the phosphodiester backbone, the ribose ring, and the
nucleoside base. It has been found that these modifications can affect the ability of the
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oligonucleotide to activate RNase H. As such, the focus has been on using multiple
modifications throughout the oligonucleotide as well as chimeric oligonucleotides that have
different modifications along the length of the oligonucleotide to achieve the desired stability,
affinity, and RNase H activation. Figure 1-3 shows some of the modifications that have been
examined in antisense studies.
1.B.2.c.i. Backbone Modifications
Natural oligonucleotides have a phosphodiester backbone that is susceptible to nuclease
degradation, having a half-life as short as fifteen minutes [80-84]. The need for oligonucleotides
that are stable in vivo prompted the development of chemical derivatives of the phosphodiester
backbone. The first derivatives were methylphosphonate and phosphorothioate backbone
oligonucleotides. Over time, however, little attention has been afforded to methylphosphonates,
as they appear less therapeutically viable due to their poor cellular uptake and the inability of
their duplexes to be recognized by RNase H [82, 85].
Phosphorothioate (PS) oligonucleotides, with a sulfur atom substituted for a non-bridge
backbone oxygen atom, are the current standard for antisense applications. PS oligonucleotides
have half-lives> 5h [80]. However, this increased stability comes at the cost of reduced affinity,
increased non-specific association with proteins, and greater toxicity and in vivo complications
[86-88]. Nonetheless, all ongoing clinical trials utilize oligonucleotides with at least some of the
bases having the PS backbone (http://www.clinicaltrials.gov).
Another backbone modification replaces one of the backbone oxygens by an amino group
in what are called phosphoramidate (PN) oligonucleotides. These can take two forms, where
either the non-bridging oxygen in the backbone or the 3' oxygen of the ribose ring is replaced by
a nitrogen [89-94]. Though very stable to nuclease degradation [90], backbone PN molecules
have lower affinity for their target mRNA molecules and have received little recent attention as
N3' -P5' PN oligonucleotides have similar nuclease resistance with increased target affinity [93].
PN oligonucleotides also show reduced non-specific protein binding versus PS oligonucleotides
[92]. In situations where RNase H activation is not required for antisense effect, it has been
shown that PN oligonucleotides have greater efficacy than PS, and many other modified species
[95].
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Figure 1-3: Analogues of natural oligonucleotides
(A) Backbone modifications in which the phosphorus bridge atom is retained. (B)
Backbone modifications in which the phosphorus bridge atom is replaced. (C) 2' ribose
modifications. (D) Peptide nucleic acids - the entire backbone is replaced with amino
acids. See Table 1-1 for legend.
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Table 1-1: The names and key characteristics of several oligonucleotide analogues
Columns X, Y, Z reference Figure 1-3. Replace the designated letter in Figure 1-3 with
the molecule indicated in the Table 1-1 to determine the chemical structure of the
oligonucleotide. [31, 40, 77-79]
Phosphorus Analogues RNaseH Nuclease Chiral ~TM/Mod Charge X Y Z
(Fig 1-3A) activation resistance center vs. PO rOC]
Phosphodiester (PO) Yes No No -- Negative 0- 0 P
Phosphorothioate (PS) Yes Yes Yes - 1 Negative S- O P
Methvlphosphonate (MP) No Yes Yes Negativel Neutral CH3 0 P
Phosphoramidate (PN) No Yes Yes -3 Neutral NH-R 0 P
Phosphorodithioate Yes Yes No - 1+ Negative S- 5 P
Phosphoethyltriester No Yes Yes Positive Neutral 0-C2Hs 0 P
Phosphoroselenoate Yes Yes Yes Negative Negative Se- 0 P
Non-Phosphorus
Analoeues (Fie. 1-3B)
Formacetal ? Yes No -3 Neutral 0 0 CHz
3' Thioformacetal ? Yes No -3 Neutral S 0 CHz
5'-N-carbamate ? Yes No Eitherl Neutral 0 NH C=O
Sulfonate ? Yes No Depends Neutral 0 CH2 S02
Sulfamate ? Yes No Negative Neutral 0 NH S02
Sulfoxide ? Yes No Negative Neutral CHz CH2 SO
Sulfide ? Yes No Negative Neutral CHz CHz S
2' Modified Analogues
(Fie.I-3C)
Fluoro No Yes N/A + 2-3 N/A3 F
Methoxv No Yes N/A +2 N/A3 0-CH3
Propoxy No Yes N/A +3 N/A3 0-(CH2)zCH3
Pentoxv No Yes N/A +2 N/A3 0-(CH)4CH3
O-allyl No Yes N/A +2 N/A3 0-CH=CH2
Methoxvethoxv No Yes N/A +3 N/A3 0-(CH2)2-()-CH3
a-analoeues No Yes N/A1 Negative N/A3 N/A4 N/A4 N/A4
Peptide Nucleic Acids No Yes No Positive Positive:l N/Ao N/Ao N/Ao
(PNA) (Fie. I-3D)
? = Unknown
IDepends on stereochemistry but affinities are generally lower than PO.
2Varies with buffer and other experimental conditions
3 Chirality and charge depends on backbone structure used.
4 Structure not drawn; the bond between the sugar and base (an N-glycosidic bond) of a-analogues has the reverse
orientation (a-configuration) from natural «(3-configuration) oligonucleotides.
s Typically, the C-terminus is covalently linked to a positively charged lysine residue, giving the PNA a positive
charge.
6 See Figure I-3D for chemical structure.
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1.B.2.c.ii. Ribose Modifications
Ribose modifications are used to generate oligonucleotides that have RNA-like character
while not being as susceptible to nuclease degradation. Modifications to the sugar ring that have
been tested have primarily focused on the 2' position, though the 4' position has received some
minor attention [96]. Studies have investigated 2' -halide and 2' -O-alkyl substitutions, such as
2' -fluoro, 2' -O-methyl, 2' -O-propyl, 2' -O-pentyl, 2' -O-deoxy, 2' -O-allyl and 2' -O-methoxyethyl
[31,97-100]. Half-lives of2' modified oligonucleotides have been found to approach that ofPS
oligonucleotides [81, 87, 101]. Fully 2' -modified oligonucleotides act only through steric
inhibition, with no activation of RNase H, but have been found to be very effective despite this
limitation [31, 100, 102].
A novel class of 2' modified oligonucleotides called locked nucleic acids have recently
received attention. The structure is termed "locked" because the modification locks the furanose
ring into a 3' -endo conformation by linking the 2' carbon to the 4' carbon [103]. The binding
affinity of these molecules for their target has been reported to be the highest yet recorded,
through decreased entropic costs of association with the target [104]. The specificity of this
interaction remains in doubt, suggesting that therapeutics developed with this technology would
need to be carefully chosen to avoid non-specific hybridization and potential side-effects. [103].
1.B.2.c.iii. Base Modifications
Modifications to the nucleoside bases have been tested primarily at the 5 and 6 positions
of the base, e.g., 5-methyl, 5-bromo-2'-deoxycytidine and 7'-deazaguanosine and 7'-
deazaadenosine, 5-propynyl, 5-methyl, 6-azathymidine, and 5,6-dimethyl-2'-deoxyuridine [29,
85, 105]. Increased nuclease stability from base modifications is typically exchanged for a loss
of hybridization activity and/or duplex stability. Base modified oligonucleotides have shown
some efficacy, including in the use of an oligonucleotide as short as a heptanucleotide [29], but
have not received as much continuing attention as other modifications have proven more
effective in enhancing oligonucleotide properties.
1.B.2.c.iv. Chimeric Oligonucleotides
Chimeric oligonucleotides take advantage of the properties of multiple modifications in
the same molecule. Earlier chimeric oligonucleotides used end caps of nuclease resistant bases
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with unmodified central bases [106]. It was found that oligonucleotides protected at their 3' ends
resisted degradation more so than those protected at their 5' ends [107]. More recently, "mixed-
backbone" oligonucleotides (also termed second-generation oligonucleotides) have been
sYnthesized with both backbone (primarily PS) and sugar modifications [31, 108]. These
molecules have improved binding affinity for their target over fully PS oligonucleotides while
maintaining the ability to initiate RNase H cleavage of the RNA. When tested in the inhibition
of c-fos, chimeric oligonucleotides with central PO linkages and capped PS linkages proved to
have lower toxicity than fully PS oligonucleotides [109]. Circular "dumbbell" DNAIRNA
chimeras have been shown to be active in the inhibition of HIV-1 replication [110].
1.B.2.c. v. Other Modifications and Conjugates
One of the most promising new antisense technologies utilizes a multiply modified
oligonucleotide chemistry called morpholino antisense oligonucleotides [111]. These species
replace the ribose sugar ring with a 6-membered morpholino ring and utilize the
phosphoramidate backbone modification. With so many modifications, no cellular nuclease has
been found that cleaves morpholino oligonucleotides [111, 112]. These molecules have shown
activity in both cell culture and in vivo [113-116]. The mechanism of in vivo activity is not well
understood, though, as it has been found that morpholino oligonucleotides do not enter cells
easily and are typically administered by scrape or syringe loading [117, 118]. Though still
limited as antisense molecules, morpholino oligonucleotides have already become established as
a powerful biotechnological tool for functional genomics "knockdown" studies [112, 119-124].
Recent work with alternative modifications has sought to use new mechanisms of
inhibition to generate a therapeutic effect. These alternative mechanisms seek to avoid
"irrelevant cleavage" arising from RNase H cleavage of hybridization stretches as short as 5 - 6
nt [31]. In particular, 2' -5' linked polyadenylate (2-5A) has been shown to activate another
cellular enzyme, RNase L [125]. In this case, the enzyme recognizes the (2-5A) sequence, so,
the activity of RNase L can be directed at a particular transcript by conjugating to a specific
oligonucleotide complementary to the target of interest, e.g., telomerase, bcr/abl mRNA, and
cellular protein kinase mRNAs [125-128]. It has also been found that (2-5A) synthesized with
PNA can stimulate RNase L activity and confer additional stability to the construct [129, 130].
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Another "alternative mechanism" relies on the activity of the enzyme RNase P that
cleaves pre-tRNA into its mature form. This enzyme, comprised of both protein and RNA
components, recognizes the specific structure of the tRNA molecule in exerting its effect [131].
This structure is mimicked in application by synthesizing an oligonucleotide with a similar
structure called the external guide sequence (EGS). When the arms of the EGS are hybridized
by complementarity to the target RNA, the structure resembles that of a pre-tRNA, and the
enzyme cleaves the targeted strand [132]. The EGS sequence is roughly 30 nt in length,
however, so further development of this technology will depend on the ability to cheaply
construct longer oligonucleotides for testing and to modify the EGS for nuclease resistance and
affinity [131, 133].
Oligonucleotides covalently linked to active groups (e.g., intercalators such as acridine,
photoactivated crosslinking agents such as psoralens and chelating agents such as EDT A-Fe)
have also been investigated as potential antisense molecules [134]. The reader is directed to
several reviews for a comprehensive treatment of chemically modified oligonucleotides [40, 134-
137]. Oligonucleotides can also be conjugated to other species, such as proteins or
lipids/cholesterol. This can enhance nuclease stability, membrane association, and
internalization by cells [48, 50, 56, 138-141].
1.B.2.d. Target Site Selection
Choosing an appropriate target site in an mRNA has traditionally been a largely empirical
process. Two primary factors determine whether a region within the target mRNA is a good
target site: the sequence uniqueness and the ability of the oligonucleotide to exert the desired
therapeutic effec,t. While specificity has been traditionally argued statistically, the ever-
increasing availability of genome sequence information will permit direct comparison of
potential target sequences to the entirety of the genome. To compare the efficacies of multiple
candidate oligonucleotides, both experimental and theoretical metrics have been chosen. Of the
experimental methods, both in vitro and cell-culture based screening assays have been
developed. Theoretical metrics have evolved from satisfying basic heuristics to complex
structurally-based affinity prediction methods.
1.B.2.d.i. Specificity of Oligonucleotides
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(1)
(2)
The specificity of antisense-based therapeutic strategies is its most appealing aspect. The
selection of a specific site was traditionally argued statistically based on the assumption of an
even distribution of the 4 nucleotides throughout the genome [142]. Since each position in a
given sequence can be occupied by any of four nucleotides (A, C, G or U), the total number of
different possible sequences of length N bases is 4N• Letting R equal the total number of bases in
a given mRNA pool and assuming that it is a random and equal mixture of the four nucleotides,
then the frequency (F) of occurrence in that pool of a sequence of length N is given by:
F=~
4N
Assuming a typical human cell will have no more than 104 unique mRNA species with an
average length of 2000 bases, R is approximately equal to 2xl07• Therefore, for a sequence to be
unique (F < 1), N must be greater than or equal to 13 bases [142]. However, oligonucleotides
cannot be made arbitrarily long, because longer oligonucleotides are more likely to contain
internal sequences complementary to non-targeted RNA molecules. This has also been
expressed mathematically [142]. The expected number of complementary sites (S) of length L
for an oligonucleotide of length N in an mRNA pool with R bases is given by:
S = [(N - L+ I)XR]
4L
For example, an 18-mer (N = 18) has 6 internal 13-mers. Since a 13-mer is expected to occur 0.3
times in an mRNA pool containing 2 x 107 bases, the 18-mer is expected to match 1.8 (i.e. 6 x
0.3) 13-mers in the mRNA pool. Equation (2) also gives this result (N = 18, L= 13, and R = 2 X
107; therefore, S = 1.8).
Woolf et al. have demonstrated that significant degradation of non-targeted mRNAs can
occur [142]. They compared the effectiveness of three different 25-mers in suppressing the
expression of fibronectin mRNA in Xenopus oocytes. Nearly 80% of the fibronectin mRNA was
degraded after the oocytes were microinjected with a 25-mer in which all 25 of its bases were
complementary to the mRNA. However, when the oocytes were microinjected with 25-mers that
had only 17 or 14 complementary bases flanked by random sequences, greater than 30% of their
fibronectin mRNA was still degraded. They also showed that a single mismatch in an
oligonucleotide did not completely eliminate its antisense effect. Over 40% of the target mRNA
was degraded when oocytes were treated with a 13-mer with one internal mismatch, though the
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mismatch left a 9 base consecutive complementary sequence that showed nearly the same
activity as a 13-mer with 10 complementary bases in succession.
The efforts to sequence the human genome have begun to provide more information
about the actual specificity of oligonucleotides. It is possible to scan for sequences against all of
the genomic information available using resources such as BLAST at the National Center for
Biotechnology Information [143](http://www.ncbi.nlm.nih.gov). The results will determine the
uniqueness of the oligonucleotide within the known database sequences. As the completeness of
the databases grows, computational comparisons of target RNA sequences against the database
will provide more reliable assessments of the uniqueness of these target sequences within the
genome.
1.B.2.d.ii. Oligonucleotide Evaluation and Comparison
Active antisense oligonucleotides are typically identified from a group of candidates,
perhaps 20-50 sequences, by trial and error using a cell-culture based screening assay [28, 144,
145]. The candidates are chosen with no a priori knowledge or guidance. The assays required
to evaluate these oligonucleotides can require significant time and cost and often yield few active
oligonucleotides, even outside of the context of cells [8]. Little guidance is available from the
mRNA, either, given that active molecules have been identified in the 5' and 3' UTRs as well as
around the start codon and within the coding sequence [146, 147]. Thus, random cell-culture
based experimental screening has given way to in vitro experimental and theoretical evaluation
of oligonucleotide binding affinity and target accessibility.
l.B.2.d.ii.a. in vitro Experimental Comparison
To test the affinity of oligonucleotides for their target mRNA in vitro, methods have been
developed that can provide both detailed information of a few oligonucleotides or general
information comparing a large-number of oligonucleotide candidates. One small-scale technique
that is used to measure oligonucleotide hybridization strength is melting temperature
measurement, where higher transition temperatures reflect increased hybridization strength
[108]. This method only examines the intermolecular hybridization strength and only does so at
non-physiologic temperatures. For these reasons, melting temperature is, at best, an incomplete
metric for evaluating the relative hybridization strengths of oligonucleotides.
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Though developed for evaluating the affinity of proteins for other proteins, nucleic acids,
and small molecules [148, 149], the gel-motility shift assay is also a useful method for evaluating
the affinity of oligonucleotides for their target mRNA [150, 151]. In this technique, radiolabeled
oligonucleotide is hybridized with the target mRNA at different concentrations. After
equilibrium has been reached, bound oligonucleotide is separated from free oligonucleotide by
electrophoresis, the movement of the bound oligonucleotide being restricted by its association
with the larger mRNA species. The affinity of each oligonucleotide is then extracted from the
fractional binding data at each mRNA concentration (KD = the [RNA] at which 50% of the
oligonucleotide is bound). This assay is limited by the difficulty in analyzing a large number of
samples as well as by the buffers that can be used. The most problematic weakness, though,
arises from the fact that the signal for detection is a function of oligonucleotide concentration.
With the small volumes that can be loaded onto an electrophoresis gel and the difficulty and
expense in uniformly labeling oligonucleotides, the assay cannot measure the affinities of the
highest affinity oligonucleotides (KD < 0.01 nM), and there exists little flexibility to enhance the
sensitivity.
Of the large-scale, combinatorial techniques that have been applied, these can be
separated into two separate types, those that utilize RNase H screening and those that involve
hybridization to arrays. Each of these techniques identifies those oligonucleotides that hybridize
with high affinity for their target. Though RNase 1 cleavage of single stranded regions on the
RNA has also been examined as a possible method for identifying accessible regions on the
RNA [152], RNase H has proven a much more successful method. For RNase H screening
experiments, semi-random libraries of oligonucleotides are hybridized with a target mRNA in
the presence of the enzyme [153]. The resulting fragments are sequenced to locate those regions
on the mRNA that are particularly susceptible to cleavage, typically showing significant
cleavage in fewer than 30 minutes, the longest typical reaction time. This technique has been
shown to identify reagents effective in cell culture and in vivo with roughly 30-50% accuracy
[153, 154]. These results confirm the kinetic nature of the hybridization reaction and the need
for oligonucleotides to bind quickly to exert a therapeutic effect. However, no judgment
regarding the relative affinities of these molecules can be made, as hybridization has not been
allowed to reach equilibrium for all the oligonucleotides.
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In contrast, oligonucleotide array experiments are specifically designed to identify those
oligonucleotides that bind most tightly at equilibrium conditions. Radiolabeled mRNA at a
concentration that will discriminate among the oligonucleotides is hybridized to an array of
oligonucleotides that have been immobilized on a solid substrate, e.g., a glass slide [155, 156].
Following incubation for an extended time, e.g., 16 hours, the slide is washed to remove non-
specifically adsorbed material and exposed for radiographic detection of the bound mRNA.
Those regions that show the highest radiographic intensity are the regions containing the
oligonucleotides of highest affinity for the mRNA. The oligonucleotides of highest affinity have
proven effective antisense reagents in cell culture and in vivo [156, 157]. The significant
experimental cost of preparing the arrays precludes widespread use of this technique. Also, as
the RNA is only applied at a single concentration and no measure of the fractional binding of the
mRNA and oligonucleotide can be determined, measurement of exact binding affinities for each
oligonucleotide is challenging, leaving the oligonucleotides to be grouped into classes of high,
moderate, and low binding affinity.
l.B.2.d.ii.b. Theoretical comparison
The application of theoretical methods has progressed from simple techniques examining
the primary sequence of the target mRNA to those that account for the role of structure in the
hybridization process. Early studies applying these simpler metrics for selection have proven
only slightly more successful that pure random choice. Over time, the sophistication of
secondary structural prediction has been enhanced and the incorporation of and comparison to
experimental data sets of sufficient size have proven that theoretical methods of selection can
provide valuable guidance in selecting those oligonucleotides that will be most active in cell-
culture and in vivo.
loB.2.d.ii.b.i. Primary Sequence Motifs and G/C Content
The translational start codon is the initial primary sequence target chosen for many
antisense screens, particularly those using cell-culture based screening assays. Oligonucleotides
a~e chosen in the region of the start codon and slightly upstream and downstream with the
expectation that prevention of translation initiation will most effectively prevent translation
progression [58]. Also, it has been proposed that the region around the start codon tends to be
more structurally flexible than the remainder of the RNA to avoid inhibiting ribosomal binding
33
[58]. However, the high rate of failure sequences and recent data from oligonucleotide array
experiments [157] suggest that this proposal is not generally accurate, and, therefore,
oligonucleotides in this region should be no more effective, in general, than oligonucleotides
targeting any region along the mRNA.
In studies where large sets of experimental data have been reviewed and analyzed
statistically, primary sequence motifs have been identified that are found to occur frequently in
those oligonucleotides that show activity in cell culture experiments [158, 159]. These four-base
motifs (CCAC, TCCC, ACTC, GCCA, CTCT) are C-rich and proposed to enhance the formation
of A-form heteroduplexes and the recruitment of RNase H to cleave the target mRNA. Though
the statistical analyses confirm the significance of these motifs, the correlation coefficients are at
most 0.3, indicating that selection of oligonucleotides by this metric will still yield a large
proportion of failures.
Another first-order method for selecting oligonucleotides with high affinity for the target
mRNA is to select those with high GC content. The additional hydrogen bond in a G/C pair
provides additional stability to the intermolecular complex and thereby results in a more stable
hybrid. Success using GC selection is sporadic [160] and could also result in molecules that
achieve their action through the formation of structural elements such as the tetra-guanine motif
[161-163]. Also, use of this metric or any of the primary sequence techniques ignores the
prominent role of RNA structure in the association of oligonucleotides with the RNA.
1.B.2.d.ii.b.ii. Secondary Structural Prediction
In comparison to primary sequence based comparison strategies, incorporation of
secondary structure information provides additional complexity and enhanced accuracy in
locating those regions on the mRNA that will be good target sites for antisense oligonucleotides.
Secondary structures are those structures that form from the Watson-Crick base-pairing that
occurs within the RNA molecule. Secondary structural features tend to form more quickly than
tertiary features and have been shown to provide the majority of the three-dimensional character
of RNA molecules [164], though in some cases, tertiary structure formation can alter existing
secondary structures [165, 166]. Reasonably accurate predictions of the RNA secondary
structure can be computed from free-energy minimization, and these predictions form the basis
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of computational evaluation of oligonucleotide binding affinity and candidate oligonucleotide
selection [167-169].
Prediction of RNA secondary structure was described in the literature as early as 1981
[170]. Using a dynamic programming algorithm, all possible structures are iteratively folded and
their free energies calculated using nearest-neighbor thermodynamic parameters measured in
vitro using small RNAs [171-173]. The resulting structures can be shown in tree diagrams for
viewing a single structure (Figure 1-4) or in "dot-plot" format (Figure 1-5) to more completely
describe the flexibility of the RNA and the reliability of the predicted structure and the overall
flexibility of the molecular structure.
Several researchers have sought to use RNA structural predictions as a basis for selecting
effective antisense oligonucleotides. The earliest methods focused on examining the structure of
the target mRNA and identifying structural or energetic features that suggested a good target
region for antisense inhibition, e.g., targeting regions predicted to be single-stranded [174].
When examining the 30 most energetically favorable folded structures, regions were identified
that had a high probability of being unpaired [175]. This method was only found to be useful in
identifying those oligonucleotides that were active in reducing in vitro translation when RNase H
was present. The lack of inhibition in the absence of RNase H suggests that the oligonucleotides
identified may form partial heteroduplexes of 4 or more bases in those regions that are
kinetically accessible and will activate RNase H but do not form sufficiently stable complexes to
prevent ribosomal binding and progression. Unpaired percentage, then, is not an effective metric
for identifying those oligonucleotides that hybridize completely and can act through both
inhibitory mechanisms. Also, it has been shown that regions predicted to be double-stranded are,
in some instances, more susceptible targets for antisense inhibition than single-stranded regions
[176, 177]. More sophisticated methods have since focused on incorporating the energies of
folding into defining those regions that should be targeted by antisense.
A metric called "local folding potential" was proposed to identify those regions in the
mRNA that showed structural flexibility in a large number of the most favorable, predicted
structures [178]. The free energy of folding for 400 nt overlapping segments along the mRNA
was calculated and averaged for each position along the mRNA. Correlation was found between
low folding potential, i.e., regions very likely to be free of significant secondary structure, and
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Figure 1-4: Predicted secondary structure of the RBG mRNA
The most-energetically favorable conformation of RNA molecules is highly folded. The
majority of RNA folding results from intermolecular base pairing. For this 510 nt
transcript, the longest single-stranded region is 12 nt. Any oligonucleotide of typical
length (15-25 nt) will have to disturb native structure to exert its therapeutic effect. The
accessibility of a region on the target will be a function of both its double-stranded and
single-stranded regions and their interactions with the oligonucleotide.
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Figure 1-5: "Energy dot plot" of the RBG mRNA
In this depiction, a base pair between nucleotide X and nucleotide Y is indicated by a dot
at the two corresponding positions on the grid, (X , Y) and (Y ,X). The base pairs
occurring in the minimum free energy (optimal) structure are shown alone in the lower
triangle, while the upper triangle includes the optimal and suboptimal structures within a
user-defined free energy interval of the minimum. Regions in the upper triangle that are
densely spotted indicate significant structural flexibility while sparse regions indicate
very stable structural elements.
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those antisense RNAs that were found to be inhibitory. Concomitantly, regions of high folding
potential were found to be poor antisense targets. This confirms the strong role of the structure
of the target mRNA in determining those sequences that will show inhibitory activity. It is this
highly ordered structure that provides the basis for establishing a rational framework for
selection of oligonucleotides with high binding affinity described here.
1. C. Approach and Specific Aims
The objective of the work was to establish a methodology for the rational selection and
evaluation of oligonucleotides to be used as antisense therapeutics. The selection method
focused on applying a thermodYnamic model to analyze the energetics of hybridization and
identify those oligonucleotides that are predicted to have the highest binding affinity for their
target mRNA. Despite the highly kinetic nature of the antisense mechanism, it was expected that
the most discriminating step in the activity of oligonucleotides would be the hybridization
interaction. If this interaction could be accurately predicted, it would provide a foundation for
selection of optimally active oligonucleotides. Idealizations would be required in the
development of any theoretical construct, and, therefore, in vitro testing would be required to
support the continuing study of selected candidates. Subsequent cell culture testing of candidate
molecules would confirm the reliability of the in vitro measurements and further support the use
of the predictive methodology as a simplified method for the selection of candidate antisense
oligonucleotides.
The Specific Aims of the project were to:
1. Develop a method for selection of optimally active oligonucleotides against a candidate
mRNA based on the molecular thermodynamics of the hybridization event.
Theoretical techniques applied to this point have failed to recognize oligonucleotide
hybridization as a stepwise process involving intermolecular interactions between the
oligonucleotide and mRNA as well as structural rearrangements of both molecules and the
heteroduplex. In most cases, the use of theoretical predictions has been dismissed as not helpful
in identifying candidates or inaccurate in comparison to empirical measurements [156, 179].
Taking advantage of the ability to predict folded structures of mRNAs and oligonucleotides and
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obtain the free energies for these folded structures, it was decided that molecular
thermodynamics would accurately describe hybridization if based on a complete thermodynamic
cycle. Results are shown to correlate well with data from the literature on two systems,
particularly in the identification of those oligonucleotides measured to have the highest binding
affinities.
2. Measure in vitro binding affinities and kinetics and compare with thermodynamic
predictions.
The accuracy of the thermodynamic predictions was measured in idealized conditions in
vitro using a novel centrifugal-based assay. The assay also proved useful in measuring the
kinetics of hybridization. Itwas found that the binding affinity is primarily determined by the
association kinetics and that those molecules that associate with the fastest kinetics also activate
RNase H cleavage of the mRNA most quickly.
3. Measure antisense inhibition in cell-culture to determine if selection of antisense
oligonucleotides by thermodynamic prediction increases the success rate over random
selection.
Oligonucleotides of two different chemistries were selected using the thermodynamic
method and applied to inhibit the expression of three genes, lactate dehydrogenase isozymes A
and B, as well as cell-surface signaling receptor, gp130. In each case, mRNA levels and protein
activity were measured. Of the 5 oligonucleotides expected to exert a biological effect, 4
showed significant inhibition of their target mRNA at sub-micromolar concentration. In all
cases, reduced protein activity was associated with reduced mRNA levels. Nonsense
oligonucleotides and oligonucleotides expected not to show activity did not significantly inhibit
at either the protein or mRNA levels, reinforcing both the sequence specificity of the inhibition
and the utility of the thermodynamic predictions for selecting acti ve candidate molecules. The
success rate was roughly 80% relative to 15% estimated for random selection.
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2. Development of Thermodynamic Model of Oligonucleotide Binding
2.A. Abstract
Antisense oligonucleotides, which act through the pairing of complementary bases to an
RNA target sequence, are showing great promise in research and clinical applications. However,
the selection of effective antisense oligonucleotides has proven more difficult than initially
presumed. We have developed a prediction algorithm to identify those sequences with the
highest predicted binding affinity for their target mRNA based on a thermodynamic cycle that
accounts for the energetics of structural alterations in both the target mRNA and the
oligonucleotide. The model was used to predict the binding affinity of antisense
oligonucleotides complementary to the rabbit ~-globin (RBG) and mouse tumor necrosis factor-
a (TNFa) mRNAs, for which large experimental data sets were available. Of the top ten
candidates identified by the algorithm for the RBG mRNA, six were the most strongly binding
sequences determined from an experimental assay. The prediction for the TNFa mRNA also
identified high affinity sequences with .....60% accuracy. Computational prediction of antisense
efficacy is more cost efficient and faster than in vitro or in vivo selection and can potentially
speed the development of sequences for both research and clinical applications.
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2.B. Introduction
Oligonucleotides, single-stranded DNA molecules typically 15-20 nucleotides (nt) in
length, can be used as antisense molecules to affect gene expression upstream of protein
synthesis. When exogenously added to cells, these oligonucleotides are designed to be
internalized, bind to their complementary target by Watson-Crick base pairing, and inhibit the
production of the protein encoded by the target mRNA. Currently, antisense oligonucleotides
are being developed as clinical therapeutics against refractory diseases such as cancer and mv,
but they are also powerful tools for analyzing and manipulating gene expression in applied
biotechnology research [180].
The ideal antisense oligonucleotide would have the greatest specific inhibition of gene
expression at the minimum possible concentration. To date, active oligonucleotides have been
chosen empirically by trial-and-error using an in vitro or in vivo assay. The sequences of the
oligonucleotides are often selected using heuristics such as targeting the start codon of the
mRNA. However, only a small proportion of attempted antisense oligonucleotides provide
sequence specific inhibition at reasonable concentrations [160, 181, 182]. As a result, the
selection of effective antisense sequences based on affinity for their target RNA has received
increasing attention.
Binding affinity can be measured by a number of empirical screening approaches based
on the direct hybridization of candidate oligonucleotides to target mRNA. These include small
scale methods, including gel shift assays [150] and melting temperature measurements [108], and
large scale techniques, such as incubation of the target mRNA with combinatorial libraries [177,
183] or oligonucleotide arrays [156, 184]. These screens have also found a relatively low
proportion of antisense sequences to exhibit high affinity for their target, suggesting that affinity
is indeed a limiting factor in antisense effectiveness. Though these screens can identify
oligonucleotides with high target affinity, they are quite elaborate, and concerted searches of all
possible oligonucleotides remain a major experimental challenge. Hence, theoretical strategies
are also being considered.
The first such strategy focuses on selecting oligonucleotides with high GC content.
However, this simple rule has proven only marginally successful [160]. Also, this method of
selection could also result in molecules that achieve their action non-specifically, e.g., by acting
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through a tetra-guanine structural motif [161]. Predictions of RNA folding structures have been
used in design strategies that are based on finding locations on the mRNA predicted to be single-
stranded, and, presumably, accessible to oligonucleotide binding [175, 178]. However, it has
been shown that regions predicted to be double-stranded are, in some instances, more susceptible
targets for antisense inhibition than single-stranded regions [176, 177]. Therefore, considering
the RNA target alone is insufficient to identify good binding sites for oligonucleotides.
We have developed a method that uses the RNA secondary structure prediction
algorithm, mfold [167, 168], and an appropriate thermodynamic cycle to predict the free energy
of hybridization between an antisense oligonucleotide and its target mRNA. The key feature that
is distinct from previous approaches is that the method described here accounts for restructuring
of the RNA after being bound by the antisense oligonucleotide. Using the rabbit B-globin (RBG)
and mouse tumor necrosis factor-a (TNFa) mRNAs as model systems for which sufficiently
large experimental data sets were available, we have used this method to identify, theoretically,
those oligonucleotide sequences which most strongly bound their RNA targets. We found that
the model accurately predicted the general trend in binding affinity for all oligonucleotide
sequences and clearly distinguished the highest affinity sequences from those of low affinity.
Furthermore, we found that accounting for all of the steps in the thermodynamic cycle was
necessary for the most accurate predictions.
2.C. Theory and Methods
The goal of our model was to predict the free energy of hybridization of an antisense
oligonucleotide to its target RNA, given the sequence of the RNA. The sequence of the RBG
mRNA was provided by the investigators of the experimental study [156]. The TNFa mRNA
sequence was obtained from GenBank (Accession #: M13049). As the free energy is a
thermodynamic state variable, any free energy change can be represented as the sum of all steps
required to make the change, regardless of whether the steps correspond to the path followed in
the actual process. The basic framework of the decomposition is shown in Figure 2-1. In this
case, the processes are the unfolding of the structured RNA and any oligonucleotide structure,
which have unfavorable free energies of ~G~N and ~G~s' respectively, and the binding of the
oligonucleotide to the exposed target sequence followed by the refolding of the RNA to a new
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Figure 2-1: Thermodynamic construct describing oligonucleotide:mRNA hybridization
M == mRNA; 0 = oligonucleotide; H = oligonucleotide:mRNA hybrid. S = structured; U
= unstructured. In the hybridization process, structured mRNA molecules hybridize to
oligonucleotides that mayor may not have some stable intermolecular folding to form a
hybrid with the most favorable, constrained folded structure. In the first conceptual steps,
these two molecules are "unfolded" to make the target site on the mRNA and the
oligonucleotide single-stranded, with associated free energy costs LlG~N and tlG~s .
These molecules can then hybridize with free energy LlG~H' Finally, the unstructured
hybrid refolds to the most energetically favorable conformation available with free
energy LlG;E' The sum of these energy terms, LlG;o, is related to the intermolecular
dissociation constant by LlG;o = RT In(K D)'
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minimum energy structure, which have favorable free energies of ilG~H and ilG~, respectively.
The summation of these energy terms yields the total energy for the hybridization, ilG;o.
An RNA molecule is folded into a minimum energy structure that is dictated primarily by
the intramolecular base-pairing configuration. The structural energies for unfolding and
refolding were found using the secondary structural prediction algorithm, mfoZd [167, 168]. The
dynamic program generates the minimum free energy folded mRNA structure by calculating,
using established thermodynamic parameters, the energy for all possible configurations of
intramolecular base pairs in the mRNA [168]. The first part of the calculation, the fill algorithm,
calculates the folding free energy of the base-pairing that occurs between any two
pentanucleotides. It then recursively calculates the energies for the possible hexanucleotide
hybridization patterns, and so on. The traceback algorithm then searches all of the accumulated
free energies and constructs the minimum free energy structure from the possible base-pairing
patterns identified. Suboptimal free energy structures can then be constructed by selecting base-
pairing motifs that are not contained in the global minimum free energy structure. The limits on
the allowed suboptimality and the number of tracebacks are user-specified, as is the parameter
dictating how "close" in final structure folding computations are allowed to be. In addition to
locating the optimal folded structure, the dynamic program allows user-specified constraints to
the structure, permitting incorporation of chemical and enzymatic structural information into the
predictions to ensure the greatest accuracy of the prediction.
The mRNA folding free energies, ilG~ and ilG;E' were calculated using the minimum
free energy structures predicted from mfoZd at 37°C. ilG~N was taken to be the negative of the
folding free energy for the sequence without constraints (98.2 kcal/mole) and is independent of
the targeted sequence in the mRNA. For each 17mer oligonucleotide within the first 122 nt of
the RBG mRNA, ilG;H was calculated by summing the individual nearest neighbor components
for each base pair using parameters correlated for DNA:RNA hybridization [185]. Any
oligonucleotide dimerization was ignored. To determine ilG;E for each oligonucleotide:RNA
hybrid, the "Single Prohibit" function of mfoZd was used to specify the targeted bases of the
mRNA as being unavailable for intramolecular base pairing. Thus, ilG;E corresponds to the
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minimum free energy structure computed under these constrained conditions. ~G~s accounts
for any secondary structural features of the 17-mer oligonucleotides and was determined for each
oligonucleotide using the mfold program with nearest-neighbor parameters for DNA [186]. Only
positive ~G~s values (i.e., favorable oligonucleotide folding energies) were included in ~G;o
calculations. The total free energy for binding of the oligonucleotide to the mRNA, ~G;o' was
calculated as the sum of the unfolding (RNA and oligonucleotide), hybridization, and
restructuring energies:
(1)
Though in reality the structural changes of the RNA will not follow the path assumed in the
model, this representation of the process accounts for the energetics of any structural changes
that will occur, if both the initial and final structures of the RNA are the ones that are
thermodynamically most favored.
In calculating ~G~N and ~G;E' the whole RNA sequence was not used. The sequence
was segmented into separate domains, and only the domain containing the oligonucleotide target
sequence was refolded to a new structure. Domains of short-range interactions were chosen
from the "energy dot plot" created by mfold (Figure 2-2). The domains are characterized by a
large density of potential folding structures between the endpoints of the domain with few
intramolecular interactions outside of this region [187]. For the 608 nt RBG mRNA, three
domains were observed, the first consisting of the first 314 nt. Since the sequences investigated
using the oligonucleotide array assay [156] and in our predictions here were all within the first
122 nt, only this first domain was used in the folding calculations.
For the RBG mRNA, the model predictions were compared to experimental data
generated by incubating radiolabeled RBG mRNA with a glass slide on which were immobilized
all possible complementary oligonucleotides of length 1-17 nt [156]. The radiographic intensity,
I, measured with a PhosphoImager, is proportional to the number of hybrids, H, over a large
range, and we assume that this proportionality held in their experiment. To develop a correlation
between our predictions and these results, we use the equilibrium relationship between binding
affinity KH of a particular oligonucleotide sequence with surface concentration 0 to the target
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Figure 2-2: "Energy dot plot" for Southern transcript of the RBG rnRNA
Each dot represents a potential base pair that can occur in any structure with a calculated
folding free energy within 12 kcal/mole of the minimum folding free energy. Dots
appearing in the lower triangle are those base pairs that occur in the minimum free energy
structure. Long-range base pairing has been ignored by defining regions of primarily
self-contained folding as delineated by the thick black lines at nt 314 and 425. The
region of folding between nt 314 and 425 is particularly stable, showing few if any
alternati ve foldings.
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RNA, present at bulk concentration M:
H _LlGro
K =--=e RT
H OM
(2)
At equilibrium, the bulk concentration of rnRNA may be less than at the beginning of the
experiment but nonetheless has some finite value. The total amount of oligonucleotide OT is
distributed between unbound oligonucleotide 0 and hybridized species H. Thus, equation (2)
can be rearranged to give an expression for H:
(3)
Furthermore, no saturation of oligonucleotide binding was observed. For low concentration of
mRNA relative to the dissociation constant (MKH « 1), the concentration of hybrids is
approximatel y:
(4)
The concentration of RBG mRNA used was very low (l00 pM), so this may be justified
for KH < 10lD M-1• The fact that the intensities displayed in Figures 2-3 and 2-4 do not show a
clustering at high values suggests that the oligonucleotides are not being saturated and, therefore,
that these assumptions are approximately correct. Even if this condition is not strictly accurate
(for high affinity binding), the general correlations of this paper and the ranking of predicted
energies will still be valid.
Combining (2) and (4) yields the relationship between the free energy and the number of
hybrids:
(5)
As a result, the computational results are presented as - ~G;o versus In(Z), since the intensity on
the radiograph should be proportional to the number of hybrids formed.
Predictions were also compared to binding affinity data for 12-mers complementary to
the TNFa rnRNA [150]. These data were generated using a gel-shift assay to determine KD, the
concentration of mRNA at which 50% of the oligonucleotide was bound to the mRNA. The
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Figure 2-3: Comparison of experimental (In(Intensity)) and predicted free energy terms
All of the figures show the negative of the free energy component.
a) - ~G~H' b) - (~G~N+~G;E) c) - ~G~s ' and d) - ~G;o. Listed position is the 5'-
terminal base of the mRNA to which the 3' -terminal base of the oligonucleotide
hybridizes. --In(Intensity), ------- - ~Go. R2 values calculated from curve fits of
plots of negative free energy versus In(Intensity) for each component. Each component
contributes to the accuracy of the model. However, no component as accurately models
the data as the overall free energy, - ~G;o (Figure 2-3d).
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Figure 2-4: Correlation of experimental (In(Intensity)) and predicted (-~GTO) binding)
A). Without considering oligonucleotide structure contribution. B.) Including
oligonucleotide structure contribution. The contribution from oligonucleotide structure
only affects the predicted free energy values for a fraction of the oligonucleotides, but
correlation is noticeably improved.
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"energy dot plot" indicated that the mRNA consisted of 2 domains (808 and 524 bases). The
corresponding ~G~N values for the 808 base and 524 base segments were 241.9 and 136.7
kcallmole, respecti vely.
2.D. Results
2.D.!. Correlation of predictions with oligonucleotide array for RBG mRNA
Initially, we compared the model predictions to the most extensive set of antisense
oligonucleotide:mRNA binding affinity data available [156]. The data set was produced using a
glass slide on which were immobilized all oligonucleotides complementary to 1-17 nt segments
of the first 122 bases of the RBG mRNA. To this array, radiolabeled mRNA was added and its
binding to each oligonucleotide quantified using a PhosphoImager and image analysis software.
Under the conditions of the experiment, the natural logarithm of the measured intensity, I, can be
considered to be roughly proportional to the equilibrium constant for the hybridization (see
Methods). Binding was found to be strongest for the longest oligonucleotides, with no marked
variation of the loci of binding with length.
As a result, we focused our efforts on the prediction of ~G;o for each 17mer
oligonucleotide fully complementary to segments within the first 122 bases of the REG mRNA.
The measured In(I) and the predicted free energy components are plotted as a function of
position along the mRNA in Figure 2-3. The position values correspond to the 5' base of the
targeted sequence on the mRNA. Each component of the free energy correlates with some
portions of the intensity profile (Figures 2-3a - 2-3c). However, the aggregate, ~G;o' most
closely mimics the form of the intensity profile, both in the locations and relative magnitudes of
the local maxima and minima (Figure 2-3d). The correlation between ~G;o and the In(I) is
shown explicitly in Figure 2-4. Indeed, there is a statistically significant positive correlation
between the two quantities, as determined by a t-test with ex = 0.0005 [188]. From Equation 5,
the slope of the line in Figure 2-4 should equal RT, which is -0.6 kcal/mole at 37°C. The curve
fit has a slope of 2.0 :t 0.6, which is somewhat higher but reasonable given the simplifications in
the derivation of the equation.
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2.D.2. Predictions applied to selection of candidate oligonucleotides
For use as biological research tools and as candidate therapeutic molecules, antisense
oligonucleotides should have the highest possible affinity for their target. As shown in Table 2-
1, the six highest affinity sequences located by the oligonucleotide array assay [156] were among
the ten lowest predicted total free energies (dG;o values). More generally, the assay identified
three loci of high affinity binding (ca. nt 50, 75, and 100), and each of these is represented
among the top ten predictions. Taken alone, the direct hybridization free energy (dG;H ) is a
relatively poor predictor of the observed binding, though it does predict that the locus around nt
100 should have high affinity (Table 2-1, Figure 2-3a). The sum of the unfolding and refolding
free energies, which we term the restructuring free energy, is also an important contribution to
the overall free energy (Table 2-1, Figure 2-3b). The restructuring free energy is overall a much
better predictor of the overall energetics and high affinity binding sites. In particular, this
quantity is most favorable for the sequences exhibiting the highest affinity binding, in the region
around nucleotide 50 (Table 2-1, Figure 2-3b). Though not an important contribution for the
highest affinity binding positions, the oligonucleotide structural energy (~G;s ) greatly reduces
the affinity of some other oligonucleotides (Tables 2-1 and 2-2, Figure 2-3c, and Discussion). A
common rule of thumb is to select candidate antisense sequences based on their GC content.
This was also a poor predictor of observed binding affinity, capturing only one high affinity
sequence at position 100 (Table 2-2).
The results for the TNFa mRNA further support the need to include each of the free
energy components (Table 2-3). In the case of this limited data set, none of the component free
energies shows an identifiable trend mimicking the trend in the Ko values. However, the
predicted values of ~Gro still effectively identify high affinity binding sequences, identifying
four of the most strongly bound sequences among those tested. Importantly, the sequences found
to have poor binding affinity experimentally (Ko >10000 nM) were ranked as fourteen of the
lowest twenty in free energy among the tested sequences (data not shown).
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*fh' h ff .T bI 2 1 C I I da e - : a cu ate energetIcs 0 19l a lnlty sequences
Position Intensity tlGo + (~G~N+~G~) tlG;H tlGo t Rank GC contentTO OS
52 1101 -15.4 5.2 -20.6 9 8
50 919 -16.7 5.2 -21.9 2 8
51 870 -16.6 5.2 -21.8 3 8
53 613 -16.0 5.2 -21.2 4 8
101 433 -15.8 10.1 -26.2 0.3 7 11
100 431 -15.7 10.1 -27.0 1.2 8 12
102 405 -15.3 9.8 -25.1 11 10
72 381 -11.6 9.1 -21.7 1.0 60 9
73 376 -13.5 7.6 -21.1 36 9
104 355 -15.3 9.8 -25.1 11 10
*All energies in kcal/mole. Position corresponds to the 5' -terminal base of the targeted region on the mRNA (3'-
terminal base of the oligonucleotide). GC content indicates the number of G and C nucleotides in the 17mer
oligonucleotide. Rank indicates the order of the predicted ~G;o values among the 106 sequences tested
experimentally, with the lowest free energy #1. Intensity data from Milner et al (1997).
tOnly positive energies were considered in accounting for ~G~s'
*Bold, italicized values are among the top ten sequences according to model predictions.
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*. h h' h GCT bI 2 2 A I . fa e - nalysIs 0 sequences WIt Ig! content
Position Intensity ~G;o (~G~N+~G~) ~G;H ~G;s GC content
86 23 -11.3 12.9 -24.3 0.1 12
88 35 -9.9 14.2 -24.2 0.1 12
90 19 -10.6 13.3 -24.4 0.5 12
91 16 -9.4 14.3 -24.6 0.9 12
92 22 -11.5 13.4 -25.8 0.9 12
93 21 -10.3 14.3 -25.8 1.2 12
94 64 -9.6 14.3 -27.4 3.5 12
95 30 -8.6 13.5 -26.8 4.7 12
97 25 -11.6 10.1 -26.6 4.9 12
98 41 -13.8 10.1 -28.6 4.7 12
99 157 -14.5 10.1 -28.1 3.5 12
100 431 -15.7 10.1 -27.0 1.2 12
*All energies in kcal/mole. Position corresponds to the 5' -terminal base of the targeted region on the mRNA (3'-
terminal base of the oligonucleotide).
*TNFfh' h ff .T bI 2 3 C I I da e - a cu ate energetIcs 0 IgJ a InIty mouse a sequences
Name KD ~Go t (~G~N+~G~) ~G;H ~Go t Rank GC contentTO OS
8-12-PD 90 -5.8 8.3 -14.2 0.1 18 7
25-12-PD 150 -12.4 7.0 -19.4 0 3 10
5-12-PD 500 -11.3 8.3 -19.6 0 6 10
13-12-PD 1500 -11.4 2.1 -13.5 0 5 7
11-12-PD 1600 -14.2 5.2 -19.4 0 2 10
*All energies in kcal/mole. GC content indicates the number ofG and C nucleotides in the 12mer oligonucleotide.
Rank indicates the order of the predicted ~G;o values among the 26 sequences tested experimentally, with the
lowest free energy #1. Oligonucleotide names and KD data from Stull et al. (1996).
tOnly positive energies were considered in accounting for ~G~s'
:j:KD values in nM.
53
2.E. Discussion
The task of simply and accurately selecting potent antisense oligonucleotides, without
conducting costly and time-consuming experiments, is one of the many barriers that inhibits the
rapid development of antisense constructs in the clinical setting. The work described here
provides a method by which candidate oligonucleotides can be chosen from the entire population
of possible sequences. The majority of successful studies published in the literature describe
experimental evaluation of a number of oligonucleotides (typically n > 5) before locating a
sequence that demonstrates the desired biological activity [160, 181, 189]. Even in such cases
where an active sequence can be located, there are no guarantees that this sequence provides
optimal activity, i.e., that it is maximally active at a lower dose than all other candidates.
Though cellular uptake, intracellular trafficking, and degradation also greatly affect the activity
of oligonucleotides, binding to the target is critical to ensuring the activity of antisense
oligonucleotides, whether through ribonuclease H mediated or steric events [190]. Using the
computational strategy outlined, six of the ten sequences that were selected for the RBG mRNA
had the strongest binding to their target under the experimental conditions. For the TNFa.
mRNA, the model also effectively distinguished between the highest and lowest affinity
sequences identified experimentally. Successful prediction of antisense oligonucleotide binding
affinity has previously been unsuccessful and is commonly considered beyond current
capabilities [179, 190]. In this light, the success reported here is a significant improvement over
the predictive and heuristic methods that have been used previously.
The binding of an antisense oligonucleotide to its target mRNA is a structurally complex
event. As can be seen from the predicted secondary structure of the RBG mRNA (Figure 2-5),
the molecule is able to form an intramolecular base pairing structure with no contiguous stretches
of greater than 8 single-stranded nucleotides. In order for a 17mer antisense oligonucleotide to
bind to its target mRNA, some segment of the native structure must first unfold. Binding of the
oligonucleotide to the mRNA creates a constraint on the intramolecular base pairing such that the
original base-pairing configuration (of the remaining nucleotides) may no longer be the
thermodynamic minimum. Our thermodynamic cycle accounts for this entire process by
incorporating the RNA unfolding and refolding free energies (dG~N and dGRE), in addition to
54
Figure 2-5: Minilnum free energy structure of the first 314 bases of rabbit ~-globin mRNA
The structure was generated using the program mfold with the following parameters:
percent suboptimality = 10, window = 0, folding temperature = 37°C, and salt
concentration = 1M NaCI (no divalent ions). The folding free energy (-~GUN) was -98.2
kcallmole. The folding structure is characterized by very few single-stranded regions.
Subsequent rearrangements due to oligonucleotide hybridization will result in the
formation of a new optimal structure constrained by the presence of the oligonucleotide.
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the hybridization free energy (LlG~H ) of the oligonucleotide:RNA complex. Because the mfold
program computes the energies of complete folding and unfolding, the values of the LlG~ and
LlG~E terms are individually large in magnitude and not meaningful, but their sum provides a
measure of the energetic cost of restructuring the mRNA to accommodate the oligonucleotide.
Indeed, we find that the restructuring free energy (LlG~ + LlG~ ) can be an important
determinant of the overall affinity (Table 2-1, Figure 2-3b). It is the incorporation of the
energetics of RNA restructuring that distinguishes our model from others.
Interestingly, in the paper from which the RBG data set was derived, the authors note that
the results did not correlate with thermodynamic predictions [156J. Though details were not
offered in the paper, it appears that their calculation only accounted for the hybridization of the
oligonucleotide and the mRNA (D,.G~H). With no other energetic contributions and predicted
D,.G~H values typically -30 to -15 kcal/mole, the binding of the rnRNA to the oligonucleotide
should have Ko values of 10-22 to 10-11 M; in practice, binding with this affinity is not observed,
suggesting that other contributions must also be important. Adding D,.G~N + D,.G~ (-10
kcallmole), the overall Ko should be 10-15 to 10-4 M, which compares favorably with the range
found experimentally (Table 2-3 and [150]). Additional contributions from oligonucleotide
structure (0 - 5 kcallmole) could reduce the binding affinity further, completely preventing
oligonucleotide binding at reasonable concentrations.
One heuristic technique for antisense sequence selection is to test oligonucleotides that
bridge the start codon. For the RBG mRNA, the start codon is at positions 60-62. From the
experimental data, the four most strongly binding oligonucleotides all cross the start codon,
indicating that using this heuristic here could result in selection of very good candidate
sequences. Yet, among the fifteen 17-mers which bridge the start codon, only those fOUf are
among the highest affinity oligonucleotides. Therefore, it is quite possible that in a random
selection of, e.g., five sequences, none of these would have been chosen. For the TNFa mRNA,
the start codon also contains high-affinity sequences, 8-12-PD and 5-12-PD (Table 2-3), but the
3' -UTR contains the second highest affinity sequence, 25-12-PD. Also, in other cases,
oligonucleotide analogues targeting either of the two start codons of a fusion protein proved less
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effective than an analogue targeting the 5' -UTR [191]. Clearly, both the experimental data and
our predictions show that loci outside of the start codon region should also be considered.
Another heuristic technique often employed for the selection of candidate antisense
oligonucleotides is to explore the target RNA for regions of high GC content, on the notion that
GC and CG base pairs are stronger than TA or AU pairs. There are twelve sequences in the
RBG mRNA of seventeen bases in length containing a total of twelve guanines and cytosines.
Of these twelve sequences localized around the GC-rich region between bases 90 and 102, only
one was among the ten strongest binding (Table 2-1). As expected, the DNA-RNA hybridization
(~G;H) is strongest in this region (Table 2-1, 2-2), but it is among the most costly for
restructuring the mRNA (~G~N + ~G;E ) (Table 2-1, 2-2). The oligonucleotides targeting this
region also have the highest cost for oligonucleotide structure (Table 2-2), greatly reducing their
ability to bind to the RNA target. In this context, it is plausible that high GC content may be
somewhat contra-indicative of antisense affinity, because intramolecular (both RNA-RNA and
oligonucleotide-oligonucleotide) GC (or GUff) pairs need to broken to allow for the formation
of RNA-DNA pairs (Le., ~G~N and ~G;s are particularly unfavorable). Although several of the
highest affinity TNFa sequences have high GC content (Table 2-3), GC content is an imprecise
predictor of oligonucleotide affinity.
Others have used mRNA secondary structure predictions as a basis for predicting
effective antisense sequences. The simplest approach is one in which the minimum free energy
structure predicted by mfold or a similar algorithm is used to select antisense sequences
complementary to single stranded regions. An extension of this approach was applied by
Jaroszewski, et al. [175], who considered the 30 lowest free energy structures of RBG mRNA as
an ensemble and identified those bases that were least likely to form intramolecular base pairs.
The effectiveness of phosphorothioate antisense oligonucleotides against RBG seemed to
correlate with the unpaired base percentage of the target for an in vitro translation assay using
wheat germ extract but surprisingly not in a similar one using rabbit reticulocyte lysate.
However, their data set was small, and unpaired base percentage is at best a qualitative index for
the antisense binding process. A more quantitative approach was developed by Sczakiel, et al.
[178], who considered the folding free energy (dubbed local folding potential, but essentially-
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ilGUN in our model) of short segments of RNA and used the rankings of those as a basis for
predicting the effectiveness of antisense RNA target sequences. However, this approach does
not account for the energetics of the direct DNA:RNA interactions (dG~H)' As our method
accounted for both the flexibility of the target structure and the binding affinity of the
oligonucleotide to the target, it more accurately models the hybridization than these other
techniques.
Initially, contributions to the energetics of either intramolecular (hairpin) or
intermolecular (dimer) structure formation on the part of the oligonucleotide were ignored, with
the expectation that short (17-mer and 12-mer) molecules would not have significant structural
features. Though it appears that this assumption was sufficient for the 12-mers from the TNFa.
data set (Table 2-3, column 6), incorporation of the energetics of hairpin formation improved the
accuracy of the model formulation for the oligonucleotides in the RBG system. The formation of
oligonucleotide dimers was considered to be unlikely and ignored in this system, as the array
experiment used covalently immobilized oligonucleotides. Incorporation of the unfolding
energy for the 38 (of 112) sequences with a positive dG~s resulted in higher correlation with
In(l) (Figure 2-4b vs. Figure 2-4a) and better prediction of the highest affinity sequences. For
those sequences in the GC-rich region between bases 90 and 102, dG~s exceeded 3 kcal/mole
for five oligonucleotides (Table 2-2) with hairpins of up to 5 base pairs. A number of these
sequences were identified as strong candidates when considering only the structural features of
the RNA. However, the measured intensities are in the background of the experiment, with the
exception of oligonucleotide 100, which has only a 1.2 kcallmole (3 base pairs) dG~s
contribution (Table 2-2), suggesting that the binding of the RNA to the oligonucleotide was
prevented by the stable intramolecular structure formed by the oligonucleotide. Because of the
increased relative importance of end-effects, prediction of dG~s may not be as accurate for short
oligonucleotides as it would be for longer single-stranded species, e.g., primers, so further
refinement of the energies from this contribution may be possible. This may improve the overall
success rate, as two more of the ten highest affinity sequences were ranked in a tie at 11th in the
predictions (Table 2-1).
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While the success of our model in predicting oligonucleotide binding affinity for these
systems is notable, agreement between the model and experiments is imperfect, suggesting that
elements of the binding process are not being taken into account or are not being treated
accurately by the model. The correlation is best for sequences with the highest binding affinity,
presumably where the measurements are the most accurate. However, even at the high
intensities, there are regions where the model and measurements are not in agreement. The
model formulation does not account for any effects of tertiary structure on the accessibility of the
target sequences by the oligonucleotides. Though base pairing and stacking have been shown to
be the main components of the folded structure of RNA [192], the formation of tertiary structural
features in the presence of Mg2+ ions has been shown to result in secondary structures that
disagree with thermodynamic predictions [165]. In particular, the lack of information regarding
the potential formation of pseudoknots could have enough of an effect on the energetics to
influence the agreement between model and experiment. It is also possible that an antisense
oligonucleotide could "cross react" with non-targeted regions of the mRNA. However, a
homology analysis of the RBG mRNA indicated that nonspecific binding is unlikely for this
experimental system. Interestingly, the sequences for which the prediction was unsatisfactory,
positions 72 and 73 in Table 2-1, were ranked very highly in predictions for shorter
oligonucleotides. As such, it is possible that the local concentration of mRNA in the vicinity of
these positions was enhanced by the binding of the mRNA to shorter oligonucleotides
immobilized adjacent on the array, resulting in an increased binding to the 17mers at this
position. Alternatively, stable binding could have been achieved with partial hybridization, a
factor not taken into account by the model predictions. Additional effects that could influence
agreement between theory and experiment include those arising from the buffer composition
(principally its pH and ionic strength) as well as ones relating to the definition of folding
domains (see Methods).
The success rate in this study - -60% accuracy in prediction of active oligonucleotides-
is a solid advance over commonly used heuristics, though applicability of our methodology to a
wide spectrum of mRNA remains to be proven. Providing such validation requires large
experimental data sets, which are generally lacking. In addition to filling this void, we are
working towards addressing the question of whether high affinity binding in cell free assays
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corresponds to high affinity binding within a living cell. In the few cases where extensive
comparison has been made, agreement between in vitro experiments and intracellular data
suggests that binding affinity is a useful predictor of antisense activity [193]. The computational
strategy described here provides a convenient, inexpensive method for selecting candidate
oligonucleotides to guide further exploration. If the high affinity sequences predicted by this
method prove effective in vivo, this approach could positively impact the development of
antisense oligonucleotides for diagnostic and therapeutic purposes.
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3. Analysis of in vitro Binding Affinity and Kinetics
3.A. Abstract
Antisense oligonucleotides act as exogenous inhibitors of gene expression by binding to a
complementary sequence on the target mRNA, preventing translation into protein. Antisense
technology is being applied successfully as a research tool and as a molecular therapeutic. Yet, a
quantitative understanding of binding energetics between short oligonucleotides and longer
mRNA targets is lacking, and selecting a high affinity antisense oligonucleotide sequence from
the many possibilities complementary to a particular RNA is a critical step in designing an
effective antisense inhibitor. Here, we report measurements of the thermodynamics and kinetics
of hybridization of a number of oligonucleotides complementary to the rabbit-~-globin (RBG)
mRNA using a novel binding assay. A wide range of equilibrium dissociation constants were
observed, and association rate constants within the measurable range correlated strongly with
binding affinity. In addition, a significant correlation was observed of measured binding
affinities with binding affinity values predicted using a thermodynamic model involving DNA
and RNA unfolding, oligonucleotide hybridization, and RNA restructuring to a final free energy
minimum. In contrast to the behavior observed with short oligonucleotides, the association rate
constant increased with temperature, suggesting that the kinetics of association are related to
disrupting the native structure of the target RNA. The rate of cleavage of the RBG mRNA in the
presence of ribonuclease H and oligonucleotides of varying association kinetics displayed
apparent first-order kinetics, with the rate constant exhibiting binding-limited behavior at low
association rates and reaction-limited behavior at higher rates. Implications for the rational
design of effective antisense reagents are discussed.
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3.B. Introduction
With ever increasing amounts of genome sequence information becoming available, the
potential exists to use antisense oligonucleotides for the inhibition of gene expression in a wide
variety of therapeutic and biotechnological applications. Antisense oligonucleotides hybridize to
their target mRNA by Watson-Crick base pairing and inhibit translation of the mRNA by
enzymatic and steric means [195]. Traditionally, active antisense oligonucleotides have been
identified by trial and error of a number (20-50) of sequences [28, 144], and this practice
continues [196]. These methods are time consuming and typically suffer from a low rate of
success. Although the criteria for activity are somewhat subjective and depend on the system
and application, most estimates are that fewer than 15% of tested oligonucleotides are
sufficiently active to warrant further investigation [28]. While extensive research has identified
barriers presented by cells to oligonucleotide entry and activity, even tests outside of the context
of cells do not often yield oligonucleotides with sufficient efficacy [8]. Recent efforts have
focused on applying RNA and oligonucleotide structural information as a means of identifying
those sequences that should be particularly active against a target mRNA [144].
Whereas understanding of molecular recognition in protein-protein interactions has been
aided by structural information determined by X-ray crystallography and NMR, no such
information is available for the understanding of oligonucleotide:mRNA interactions. In the
absence of direct structural data, inferences regarding RNA structure have been derived from
minimum free-energy theoretical predictions of RNA folding, which are in turn validated using
indirect comparative, enzymatic, and chemical methods, in some cases also using
oligonucleotides as structural probes [171, 183, 187, 197-200]. Several researchers have sought
to use RNA structural predictions as a basis for selecting effective antisense oligonucleotides, but
simple inspection of folded structure does not reveal any general relationships with antisense
effectiveness. A more productive approach is to use this information in a thermodynamically
consistent model, which accounts for unfolding of oligonucleotide and RNA molecules to expose
bases need for hybridization, the base pairing between the deoxyribonucleotides of the antisense
molecule and the ribonucleotides of the target, and restructuring of the bound target to a new free
energy minimum [169,201]. Summing the free energies of each of these steps gives a total free
energy for antisense binding to a particular sequence on a target mRNA. Predictions are then
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generated for many possible antisense oligonucleotides binding to particular mRNA species. To
date, such predictions have been compared to several data sets, with significant correlations
observed between predicted free energy and measured binding, RNase H activation, and
antisense efficacy [147,169,201]. These promising results point to the role ofRNA structural
flexibility as a key factor in determining the accessibility of RNA to antisense binding but
highlight the importance of accounting for the whole process simultaneously. Nonetheless, there
clearly exists a need for more thorough investigation, both experimental and theoretical, of the
biophysics involved in the interaction of short oligonucleotides with their full-length mRNA
targets.
Towards this end, we chose to study the affinity and kinetics of hybridization of 17-mer
DNA oligonucleotides complementary to in vitro transcribed rabbit ~-globin (RBG) mRNA, a
well-studied mRNA found to exhibit considerable variability in both oligonucleotide binding
affinity and in vitro antisense efficacy depending on the complementary oligonucleotide
sequence chosen [156, 202, 203]. To measure binding in solution quantitatively and rapidly, we
developed an assay that uses the rapid and efficient separation of free oligonucleotide from
hybridized oligonucleotide by centrifugation through size-selective membranes. We used this
assay to investigate the affinities and kinetics of binding of a panel of oligonucleotides targeting
regions of various characters (base composition and predicted structure) on the RBG mRNA. In
addition, we studied the dynamics of RBG mRNA cleavage in the presence of oligonucleotides
of varying association kinetics and a constant level of ribonuclease H, which recognizes
DNA:RNA duplexes and is believed to playa significant role in the antisense mechanism in vivo.
Confident prediction and measurement of hybridization affinity and kinetics will reduce the
number of failure sequences tested in antisense assays and improve the likelihood of identifying
those sequences that will be active most rapidly at the lowest possible concentrations.
3.C. Materials and Methods
Oligonucleotide:mRNA hybridization free energy prediction. The method used for free
energy predictions was described in detail in an earlier publication [201]. Briefly, and in general
terms, the energies of folding for the target mRNA and oligonucleotide were calculated using the
nearest-neighbor algorithm developed by Zuker et aI, mfold [167, 168]. The algorithm was
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applied using thermodynamic parameters available with mfold 2.3, using the "N Best" program
with a sort percentage of 10, 1 traceback, and a window size of 0, at a temperature of 37°C.
The energies of folding were used to calculate the overall free energy of antisense
binding (f~G%tal) by considering: the free energies of RNA unfolding (t1Gounjold), the negative of
which was computed by mfold); the corresponding energy of oligonucleotide unfolding
(t1Gooligo), computed analogously, except with DNA rather than RNA parameters [186]; the free
energy for the intermolecular interaction of the oligonucleotide and the mRNA (t1Gohyb), which
was computed using nearest-neighbor parameters for DNA:RNA hybrids [185]; and the energy
to refold the mRNA into a new minimum energy structure with the constraint of the antisense
oligonucleotide bound to its complement (t1Gorestruct). Thus, t1GOtotal is given by the sum:
(1)
The path by which free energies are calculated (i.e., involving complete unfolding of the
RNA) does not correspond to the physical situation, but the thermodynamic cycle will provide
the correct total free energy, if equilibrium is truly attained and the assumed before and after
states are correct. For the purposes of comparing the ability of various target regions on the
mRNA to accommodate an oligonucleotide, the sum (t1Gounjold + t1Gorestruct) is used and termed
the "RNA structure cost". Because the initial RNA folded state is at its minimum free energy,
the RNA structure cost is always non-negative. The t1Gooligo term is likewise non-negative,
though frequently zero, and the t1Gohyb is always negative. Thus, there is a balance between
unfavorable (costs) and favorable (gains) contributions to t1GOtotal.
Oligonucleotide preparation. Oligonucleotides were obtained from Life Technologies,
prepared at 200 nmol scale and purified by HPLC. Before use, the lyophilized oligonucleotides
were resuspended to 100 JlM concentration in Tris-EDTA (TE, pH = 8.0) buffer per the
manufacturer's instructions. Prior to labeling, all oligonucleotides were stored at -20°C.
Oligonucleotides were 5' -labeled with 33p_y_ATP(NEN Life Science Products, Boston, MA)
using T4 polynucleotide kinase (PNK) and standard forward reaction conditions (Promega,
Madison, WI). Unincorporated label was removed from the reaction by separation on a Chroma-
Spin 10+STE column (Clontech Laboratories, Palo Alto, CA). Oligonucleotides were then
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phenol-chloroform extracted and ethanol precipitated with ammonium acetate to ensure complete
removal of PNK and any other contaminating buffer components. If necessary, an additional
purification was performed using NucAway Spin Columns (Ambion, Austin, TX).
Oligonucleotides were resuspended in TE and the purity verified by electrophoresis. Labeled
oligonucleotides were stored at 4°C for daily use. Position label refers to the 5' base of the
mRNA to which the 3' base of the oligonucleotide is complementary.
cDNA preparation and in vitro transcription: The pSV2RbetaG clone was obtained from
ATCC (ATCC#: 37646). The RBG encoding insert was extracted by double digestion with
HindIII and Bgm. The gel-purified insert was ligated into the pSP73 vector (Promega). The
new vector was transformed into competent cells, and vector-carrying clones were selected from
individual colonies growing on agar-amp50 plates. Clone 73-10-1-1 was grown into large-
volume cultures, as needed, and the plasmid purified by Maxi-prep (Qiagen, Valencia, CA). The
insert sequence was verified by positive and negative strand sequencing (Massachusetts General
Hospital DNA Sequencing Core Facility). The plasmid was linearized using Bglll, and the
mRNA was transcribed with the MegaScript in vitro transcription system (Ambion), per the
manufacturers instructions. RNA was distributed into aliquots and stored at -SO°C. RNA purity
was confirmed by denaturing PAGE using TBE-Urea Ready Gels (Bio-Rad, Hercules, CA).
Hybridization Reactions: Hybridization reactions were performed in 96-well, Non-
Binding Surface plates (Coming, Acton, MA). This minimized adsorption of the nucleic acids,
which was observed when microcentrifuge tubes were used to perform the hybridizations. All
hybridization reactions were performed in 1M NaCI, 0.5 mM EDTA, and 20 mM sodium
cacodylate, pH 7.0. Equilibrium hybridization reactions were performed for at least 16h, but no
more than 20h; no differences were seen in the degree of hybridization for any of the
oligonucleotides throughout this time period. Kinetic hybridization reactions were performed at
a concentration of mRNA sufficient to generate 100% binding of the oligonucleotide at
equilibrium. In each case, an mRNA-containing and an oligonucleotide-alone control
hybridization were performed for the same time period (see Data Analysis). Oligonucleotides
were used at the minimum detectable concentration, typically within 2 weeks of the calibration
date of the radioactivity. This resulted in oligonucleotide concentrations of 2-4 pM. In
situations where minimum oligonucleotide concentrations were required (where the measured KD
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Figure 3-1: Centrifugal separation assay
Solutions of varying concentration of mRNA and a fixed concentration of 5' _33p_
oligonucleotide are added to individual wells of a non-binding surface plate, which is
maintained at constant temperature during the incubation time. 100 J.lLof hybridization
volume are added to the centrifugal membrane and centrifuged for a time sufficient to
separate fractions into approximately equal volumes. After collecting the permeate, the
membrane is inverted into a new centrifuge tube and centrifuged again to collect the
retentate. The volumes and cpm of the retentate and permeate fractions are then
measured, and the fraction bound determined by material balance.
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under these conditions with selected oligonucleotides to ensure that equivalent KD and ka values
were achieved in the RNase H and hybridization buffers (data not shown). Three units of RNase
H was added to the oligonucleotide solution, after which RNA was added and an initial sample
taken, defining time O. Subsequently, six aliquots were taken at various times and added to
formamide-containing gel-loading buffer to stop the cleavage reaction. The samples were then
run on a 10% TBE-Urea Ready Gel (Bio-Rad) and post-stained using SYBR Gold nucleic acid
gel stain (Molecular Probes). Fluorescence was measured using the Fluor-S system and
quantitated using the Multi-Analyst software package (Bio-Rad). The band intensities were
expressed as a fraction of the maximum measured band intensity (maximum amount of cleaved
product) to normalize for differences in staining and exposure.
Data analysis: Following centrifugal separation, the radioactivity (cpm) and volume of
each fraction were measured. Two key principles are necessary to quantify the fraction of
oligonucleotide bound to mRNA from these measurements. First, the permeate fraction is
assumed to contain only free oligonucleotide, while the retentate contained free oligonucleotide
and any bound oligonucleotide. This assumption was verified by electrophoresis. Therefore, the
(radioactive) label in the retentate (R) and permeate (P) is distributed as
R = Rbound +Rfree
P = Pfree
(2)
(3)
where the subscripts "bound" and "free" refer to the state of the oligonucleotide. Second, the
separation is assumed to occur rapidly, such that dissociation of bound hybrids does not occur
during the separation. The concentrations of free oligonucleotide in the retentate and permeate
after centrifugal separation are then assumed to be related by a membrane distribution
coefficient, Kmemb:
[ ]
Rfr~efree oli 0K = g retentate = VR
memb [free oligo] ~V
permeate
p
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(4)
where VR and Vp are the volumes of the retentate and permeate fractions, respectively. The value
of Kmemb is determined experimentally in each sequence of measurements on a labeled
oligonucleotide sample in the absence of RNA. This quantity reduces to unity if the
concentrations in each fraction are exactly equal, as should be the case for a membrane pore size
much larger than required for the oligonucleotide. Indeed, the measured values of Kmemb ranged
from 0.95-1.10. For kinetic experiments, the Kmemb was measured for each distinct time point,
though no consistent variation was observed with time.
The fraction of bound oligonucleotide (in the hybridization reaction, before separation) is
given by:
f = Rbound
R+P
(5)
Combining Eq.2-4 and 2-5 provides the expression used to determine fraction bound, in
terms of measured quantities:
(6)
The equilibrium dissociation constant, KD, for the binding of each oligonucleotide to the
RBG mRNA (at total concentration Mr) was determined by applying a mass action law. The
data reported were calculated by fitting the fraction bound data to:
f = MT (7)
MT+KD
Fits were made to composite data sets for at least two independent experimental runs,
resulting a total of 12-25 data points per KD value. It is assumed that the concentration of free
mRNA remains unchanged throughout the experiment. Since this requires the mRNA
concentration to be substantially greater than the oligonucleotide concentration (the practical
minimum for which was about 2 pM), we estimate that the lower limit on the range of
measurable KD values is approximately 0.005-0.010 nM. To ensure an accurate fit, fraction
bound data were normalized to 100% by dividing by the maximum measured fraction bound
(typically 0.96 - 0.98) before being fit by Eq. 7.
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Kinetic data were fit using a second-order rate law for the formation of duplexes (D)
from oligonucleotides (0) and rnRNA (M). As in the equilibrium experiments, it was assumed
that rnRNA concentration remains unchanged over time such that a pseudo-first order condition
occurs:
(8)
where ka is the second order association rate constant, kd is the first order dissociation rate
constant, and the pseudo-first order rate constant, k~, is equal to k~ = kaM r. Applying the
condition kd = KDka, imposing an initial condition of no bound oligonucleotide, and solving for
fraction bound gives:
wherehq is the equilibrium value given by Eq. 7, and kfit is given by:
k - k~ _ kaMr
fit - -I. - -1.-
eq eq
(9)
(10)
Therefore, the fraction bound was measured over a range of times during two
independent experimental runs, the composite data fit to Eq. 9, and the second-order association
rate constant, ka, determined using Eq. 10.
The cleavage of RNA by ribonuclease H in the presence of antisense oligonucleotide was
observed to follow first order kinetics, as can be derived from mechanistic arguments (See
Appendix 3-1.). Because the appearance of cleavage product could be quantified more
accurately than the disappearance of full-length RNA, the former was used and fit to an equation
of the form:
(11)
where X is the fractional increase in cleavage product and kef! is the effective first order rate
constant.
All data fits were performed using Kaleida Graph software (Synergy Software, Reading,
PA).
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3.D. Results
3.D.!. Centrifugal assay description and validation
To date, a paucity of experimental data exists regarding the interactions between antisense
oligonucleotides and their complementary, but structured, messenger RNAs in solution. To
measure the binding of an oligonucleotide for its target mRNA, it is important to be able to
separate hybridized oligonucleotides from free. Traditionally, this is accomplished with a gel-
motility shift assay. However, limited sample volumes and constraints of usable buffers make
this technique relatively inflexible. We have developed a centrifugal separation method (Figure
3-1) designed to separate bound oligonucleotide from free in a faster, more quantitative, and
more sensitive fashion than the gel-shift assay. The basic premise of the assay is to perform a
rapid separation, such that free oligonucleotides pass through a semi-permeable membrane,
while bound oligonucleotides are prevented from permeating due to the size of the RNA to
which they are bound; the fraction bound is then computed from measurements of label in each
compartment with equilibrium and mass balance relationships (see Materials and Methods).
After verifying that oligonucleotides completely permeated and that the rabbit ~-globin
(RBG) mRNA was completely rejected by the membrane under use, we compared the binding
curves measured with the centrifugal separation technique with those from a gel-shift assay.
Figure 3-2a shows a typical gel-shift assay using a 17-mer oligonucleotide targeting position
2590n the RBG mRNA (in this paper, we refer to position as the 5'-end of the mRNA, thus, 3'-
end of the oligonucleotide). In the gel-shift assay, radiolabeled oligonucleotide that is bound to
RNA experiences a decrease in electrophoretic mobility and is retained at the top of the gel. As
expected, with increasing mRNA concentration, the quantity of radioactivity in the bound
fraction increases. The fraction bound was calculated from the band intensities and compared
with the binding curve measured for the same oligonucleotide-mRNA interaction using the
centrifugal separation assay (Figure 3-2b). The slight (log scale) discrepancy between the two
methods was consistent for a range of binding curves, with the centrifugal technique measuring
higher KD values (by a factor of 1.2 - 3). The slightly higher KD values for the centrifugal assay
could reflect incomplete equilibration between the retentate and permeate (though our results in
the absence of mRNA suggest this is unlikely) or the difference in buffer conditions used for the
gel-shift assay, where the samples were mixed with loading buffer before electrophoresis.
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Figure 3-2: Comparison between gel-shift and centrifugal assays
A.) Radiographic image of a 4-20% gradient polyacrylamide gel showing bound and free
oligonucleotide with increasing concentration of RBG mRNA. b.) Fraction of
oligonucleotide bound as measured by each assay vs. free mRNA concentration (assumed
unchanged from initial concentration). Data points normalized to maximum binding,
typically 96-98% (see Methods). (e) gel-shift assay, (0) centrifugal assay. Curves
show the fits of Eq. 7 to each of the data sets. The KD values obtained from curve fits are
given in Table 3-1.
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Next, we used the centrifugal assay to study the binding of a panel of oligonucleotides
complementary to the RBG mRNA. These included a selection of those previously studied in an
oligonucleotide array (Milner et aI., 1997) and several more chosen to provide a diversity of
predicted affinities and predicted structural characteristics. A range of KD values spanning
nearly five orders of magnitude was accessible with this binding assay (Table 3-1). As a control,
we also measured the binding curves for several nonsense oligonucleotides, which are identical
in base composition to their antisense counterparts but are in scrambled sequence and hence
should not hybridize to their target. Indeed, binding was not seen for nonsense sequences
corresponding to oligonucleotides 33, 58, 59, 103, and 107 at the highest tested mRNA
concentration, confirming the requirement of sequence complementarity for binding of
oligonucleotides to their target mRNA.
3.D.2. Correlation of predicted free energies with measured binding affinities
Also listed in Table 3-1 are the KD values calculated from the free energies of binding
predicted with our molecular thermodynamic model (Methods and [201]). While not in
quantitative agreement with measured values, the predictions generally distinguish between
oligonucleotides with large differences in affinity. When the predicted affinity values are ranked
and assigned a percentile score (the sequence of highest affinity is at 99 and the median is 50),
this score correlates fairly well with measured affinity (Figure 3-3a). When examining those
oligonucleotides with measured KD values less than 0.1 nM, in only one case was the percentile
score less than 78, with two of these oligonucleotides within the highest 2%. From these results,
we infer that using model predictions as a means to select high affinity oligonucleotides is likely
to result in a fraction of false positives and false negatives, but overall should reduce greatly the
number of sequences to be tested.
3.D.3. Correlation of predicted free energies with solid-phase binding intensity
Previously, the loci of binding of labeled RBG mRNA were determined by exposure to
an oligonucleotide array on which were immobilized all antisense sequences up to 17 nucleotides
in length spanning the first 121 bases of the particular RBG transcript employed [156]. The
results were reported for each oligonucleotide in terms of a radiographic intensity, roughly
proportional to amount bound, which ranged from ....11 to 1000 arbitrary intensity units with a
73
h RBG mRNA 37°Cf rT bi 3 1 E 'rb' b' d'a e - : ~qUII num In Ing 0 0 Igonuc eot! es to t e at
Target Position Measured Kn (nM) Predicted Kn (nM) Percentile 'I<
58 0.011 :t 0.001 0.0014 84
59 0.012 :t 0.002 0.010 78
49 0.015 :t 0.002 2.1x10-~ 98
259 0.019 :t 0.002 0.0024 82
84 0.021 :t 0.002 0.0062 79
79 0.031 :t 0.004 15 30
139 0.072 :t 0.006 3.6x10-6 99
448 0.10:t 0.02 2.4x10-4 92
438 0.22:t 0.02 7.8x10-~ 95
217 0.22:t 0.02 0.11 62
107 0.54:t 0.07 , 1.8 42
33 1.1 :t 0.3 4.8 34
98 2.7:t 0.4 200 22
147 7.3 :to.9 2.9x10-4 91
103 310:t 30# 240 21
407 550:t 50# >10000 2
33Non »150 N/A*
58Non »150 N/A*
59Non »150 N/A*
lO3Non »150 N/As
lO7Non »150 N/A*
Rank of predicted affinity out of 494 sequences. An oligonucleotide with the highest predicted affinity
would have percentile score of 99, Le., the oligonucleotide would be in the 99th percentile.
#Extrapolated values, based on the fractional binding curve at mRNA concentrations < 150 nM. For
nonsense sequences, no extrapolation could be made as no measurable binding was detected at any
concentration tested.
sNI A - No value could be predicted as no specific binding interaction could be defined.
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Figure 3-3a: Equilibrium dissociation constant correlations
Correlation of percentile score (see text for definition) from thermodynamic binding
affinity predictions with measured KD values. Error bars represent the uncertainty for the
nonlinear fit of each KD value based on a composite data set of 12-25 points each. The
logarithmic curve fit to the data has equation: y = -14.510g(x) +56.7; R2 = 0.44. The
utility of the thermodynamic predictions in identifying high-affinity oligonucleotides is
demonstrated, despite the lack of strong correlation between the predicted percentile
score and the measured affinities.
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mean intensity of .....150. In the array experiment, an mRNA concentration of 0.1 nM was used.
Because of the relationship between fraction bound and dissociation constant (Eq. 7) the array
experiment probably only distinguishes among equilibrium dissociation constants in the range
0.01 nM < KD < 1.0 nM. In comparing nine oligonucleotides whose binding was measured by
each assay, a general correlation is observed between equilibrium dissociation constant and
binding intensity (Figure 3-3b). In general, the highest affinity oligonucleotides in our
measurements correspond to those exhibiting high binding in the array format, though the more
limited dynamic range of the latter prevents a solid quantitative comparison. Specifically, the
oligonucleotide in the lower right comer appears to be out of line, but this is because its binding
intensity in the array format is in the background. Another cause of variation could be due to
altered mRNA structure resulting from somewhat different 5' and 3' sequences of the in vitro
transcript used in the solid phase assay versus that used in our measurements. This could be
particularly important for oligonucleotide 49 (the point in the lower left quadrant of Figure 3-3b),
whose target sequence is predicted to interact with the 5' end of the transcript used in the array
assay but not in the transcript used in the present study. Differences could also be due to slight
variations in the hybridization buffers and temperatures used, or to enhanced oligonucleotide-
oligonucleotide interactions in the context of the solid phase.
3.D.4. Measurement of oligonucleotide binding kinetics
The kinetics of oligonucleotide binding to target mRNA may also be quite important in
antisense applications. The dYnamics of delivery and degradation dictate that oligonucleotides
must not only bind with sufficient affinity but also with sufficiently rapid kinetics to have an
effect in living cells. Particularly stable intramolecular structure within the target regions on the
mRNA would limit oligonucleotide accessibility and result in a much slower approach to
equilibrium, if equilibrium is ever reached. The components of the free energy of binding that
we compute include the free energies of unfolding the native RNA molecule, unfolding the
native oligonucleotide molecule, binding the oligonucleotide to the RNA, and refolding the RNA
to a final minimum energy conformation (Eq. 1). The sum of the first and last of these is always
non-negative and is the RNA structure cost, the second is the oligonucleotide cost, and the third
is the energetic gain from hybridization. These three net contributions are summarized in Table
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Figure 3-3b: Equilibrium dissociation constant correlations
Correlation of solution-phase binding affinity measurements with binding intensity of
RBG mRNA to a solid-phase oligonucleotide array. Binding intensity data was obtained
from Milner, et al [156] and is in arbitrary units. The correlation between the measured
intensities using the solid-phase oligonucleotide array and the solution-phase reinforces
the reliability of the centrifugal assay. Also, the overall agreement suggests that use of
solid-phase measurements is a reliable predictor of solution-phase affinities.
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3-2 for all of the intermediate affinity oligonucleotides, on which kinetic experiments were
subsequently performed.
To determine the role of mRNA structure in controlling the hybridization kinetics, eight
oligonucleotides with varying predicted RNA structure costs and energetic gains, but generally
intermediate affinities (as we found these were most amenable to accurate kinetic determination)
were chosen for kinetic study. Association kinetics for each of these oligonucleotides were
measured using the centrifugal assay for a number of time points leading up to equilibrium.
Because the RNA concentration was much greater than the oligonucleotide concentration, the
fraction bound vs. time profiles followed pseudo-first order behavior (Figure 3-4a and Eq. 9),
from which second-order rate constants were obtained with knowledge of the RNA concentration
and equilibrium fraction bound (Eq. 10). For all of the oligonucleotides studied, the association
rate increased with temperature. Since duplex stability decreases with temperature, the increase
in ka with temperature can be interpreted as the decrease in intramolecular RNA base pairing,
thus making target sites more accessible to hybridization by oligonucleotide. The rate constants
appeared to obey an Arrhenius law over the temperature range studied, although not enough data
points were generated to obtain accurate values for the activation energy (Figure 3-4b).
Second-order association rate constants were found to correlate strongly with overall
affinity (Figure 3-5), and the values are similar to those measured in previous studies of
oligonucleotide hybridization [204, 205]. Because of the correlation between association rate
constant, ka, and equilibrium dissociation constant, KD, the dissociation rate constant, kd (=kaKD),
is relatively constant for almost all of the oligonucleotides studied (Table 3-3). The one
exception is oligonucleotide 33, which exhibited unusually rapid association kinetics. RNA
folding calculations suggest that this might be explained by the very low energetic cost of
altering the RNA structure, combined with no cost for altering oligonucleotide structure (i.e., no
hairpins or other stable secondary structures are formed).
3.D.5.Measurement of RNase H cleavage kinetics
The importance of RNase H in the action of antisense oligonucleotides in cell culture is
well-established [206]. To understand the relationship between the kinetics of hybridization and
the dynamics of RNase H-mediated cleavage of oligonucleotide:mRNA duplexes, hybridization
experiments were performed in the presence of RNase H at 37°C. As can be seen for
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Table 3-2: Predicted thennodynamics for oligonucleotides to the RBG mRNA at 37°C
RNA Structure Cost Oligonucleotide Intennolecular
Target (dGounjold Structure Cost Hybridization Gain
Position Total* + dGorestruct) (dGoo/igo) (dG°/zvb)
259 -16.5 8.8 1.4 -26.7
139 -20.5 8.8 0 -29.3
448 -17.9 2.6 0.9 -21.4
438 -18.6 5.4 0.7 -24.7
107 -12.4 13.4 1.2 -27
33 -11.8 2.7 0 -14.5
98 -9.5 14.2 0.9 -24.6
147 -17.8 11.3 2.1 -31.2
*All energies listed in kcallmole.
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Figure 3-4a: Kinetics of hybridization vary with temperature
Kinetics of hybridization are shown for oligonucleotide 259 binding to the RBG mRNA
at (e) 4°C, (.) 25°C, (.) 37°C, and (X) 50°C. Curves represent the fits to Eq. 9.
Increases in temperature (e.g., in melting temperature measurements) destabilize
intermolecular hybridization. Increased hybridization, then, points to the destabilization
of the native mRNA structure to allow enhanced oligonucleotide association.
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Figure 3-4b: Kinetics of hybridization vary with temperature
Arrhenius plot for oligonucleotides (e) 139, (.) 147, (X) 259, and (+) 448. For all of
the oligonucleotides tested, the association rate increased with temperature in agreement
with a typical Arrhenius law. However, too limited a temperature range was used to
provide accurate measurement of the associated activation energies.
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Figure 3-5: Correlation of association rate constant with equilibrium dissociation constant
Second-order association rate constants and equilibrium dissociation constants were
determined as described in the text for a panel of oligonucleotides targeting regions of the
RBG mRNA with varying predicted structural characteristics. The dotted line is the
power law regression: ka = 1.4KD-O.99 (R2 = 0.94). The square symbol and arrow represent
oligonucleotide 33, for which binding was very rapid and ka could only be bounded.
Strong correlation between association kinetics and equilibrium affinity demonstrates the
importance of the mRNA secondary structure in defining the strength of the
intermolecular interaction.
82
.dki t' fIt d rdRN H IT bI 3 3 Aa e - ssoc1at1on an ase Ceavage ne lCS0 se ec e o 11onuc eot1 es at
Tar2et Position Kn (nM) ka (104M.1• S.1) kd * (10.5 S.1) RNase H keff (10.4 S.1)
259 0.019 :t 0.002 45 :t 30 0.87 4.6 :to.9
139 0.072 :t 0.006 21 :t 4 1.5 4.1 :t 1
448 0.10:t 0.02 17:t 2 1.8 3.0:t 0.3
438 0.22:t 0.02 5.0 :to.8 1.1 3.8 :to.5
107 0.54:t 0.07 5.7 :to.8 3.1 1.8:t0.4
33 1.1 :t 0.3 >45# >50 6.5 :t 2
98 2.7 :t 0.4 0.53 :t 0.09 1.4 0.48:t 0.05
147 7.3 :t 0.9 0.13 :t 0.02 0.99 0.47:t 0.07
*Estimated from measured KD and ka values.
#Kinetics too rapid for accurate correlation; listed as higher than the highest value that was reliably measured.
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Figure 3-6: Kinetics of Rase H cleavage in the presence of oligonucleotides
A.) Typical Rase H cleavage pattern showing the full-length rnRNA (510 nt), and the
two cleavage product (139 nt, 371 nt, left; 147 nt, 363 nt, right). In each case, the lanes
from left to right represent time points of 0, 15 minutes, 30 minutes, 1 hour, 2 hours, 4
hours. Marker (from bottom) 100, 200, 300, 400, 500, 750, 1000 nt. B.) Rates of
cleavage of the full-length rnR A. Points show normalized intensity (see Methods) of
the smaller cleavage product band for oligonucleotides ( ) 33, (e) 259, and (0) 147.
First-order initial cleavage rate constants, keff, obtained from the fits of the data to Eq. 11,
are shown in Table 3-3.
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oligonucleotides 139 and 147, cleavage by RNase H results in the formation of two bands
corresponding in each case to the length of the regions upstream and downstream of the target
site of the oligonucleotide (Figure 3-6a). For all oligonucleotides tested, the appearance of
cleavage product followed first-order kinetics (Figure 3-6b), but complete degradation was never
observed, possibly due to loss of enzyme activity or product inhibition. The effective rate
constants for RNase H cleavage, kef!' are listed in Table 3-3. Although there is some scatter, the
kef! values are relatively insensitive to the association rate constants, except at low values of ka
(Figure 3-7); this behavior is predicted by the putative reaction scheme (Appendix 3-1) and
corresponds to binding-limited and reaction-limited cases at low and high ka, respectively.
3.E. Discussion
There has been relatively little study of the interactions between long rnRNA molecules
(500-4000 nt) and short oligonucleotides (12-25 nt). In mechanistic studies of hybridization,
such as those from which nearest-neighbor parameters are determined, short oligonucleotides
(typically 6-8 nt) of similar length have been used [200, 207]. This situation is quite different
from that for antisense hybridization, where a highly structured mRNA hybridizes with a
minimally structured and much shorter oligonucleotide. The selection of hybridization site
becomes critical, as each oligonucleotide encounters a different structural landscape on the
mRNA. Using our centrifugal assay, we have shown that a panel of 17 nt oligonucleotides
complementary to the RBG mRNA exhibits affinities (or, equivalently, equilibrium dissociation
constants) spanning nearly five orders of magnitude. Furthermore, for oligonucleotides targeting
regions overlapping by as many as 13 out of 17 nt, affinity can vary over IOO-fold (e.g., Table 3-
1, oligonucleotides 103 and 107). Similarly, association rate constants were found to vary over
several orders of magnitude, and in general these mirror the variation in affinity. It is to be
expected that such drastic differences in affinity and association kinetics will lead to the types of
variability in antisense efficacy often seen in the data from oligonucleotides selected randomly
from the target sequence, even if the search is constrained to a small region of the target mRNA.
We and others have found that thermodYnamic prediction of the binding affinity of
oligonucleotides for their target mR As increases the likelihood of finding antisense sequences
of high affinity, ribonuclease H activity, and efficacy in cell culture [169, 201]. In this paper,
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Figure 3-7: Correlation of RNase H cleavage with association rate constant
The association rates and RNase H cleavage kinetics were measured for a panel of
antisense oligonucleotides. The solid line represents the expected variation in keff in the
binding limited regime (Eq. 17, Appendix 3-1, no adjustable parameters), and the dotted
line represents a constant kef! in the reaction limited regime (Eq. 21, Appendix 3-1, with
the maximum fit to the data at the three highest ka values.
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thermodynamic predictions, which correspond to free solution conditions under 1 M NaCI, were
tested for the first time with experimental measurements made under comparable conditions.
The range of dissociation constants observed experimentally (0.01 :::;KD:::; 550 nM) was
significantly smaller than the range predicted from the model (4x10-6:::; KD:::; 104 nM), though for
a number of oligonucleotides the predictions were indeed of the right order of magnitude (Table
3-1). In light of the unrealistically wide range of predicted dissociation constants, it seemed
more reasonable to express the predictions as a ranking, or percentile score, which indicates
those oligonucleotides that should have lower and higher affinity on a relative scale. On this
basis, there is a positive correlation with solution binding affinity (Figure 3-3a), but the
correlation is of moderate power, similar to comparisons of our predictions with binding
measured by an oligonucleotide array [201], or with ribonuclease H susceptibility [169] and
activity in cell culture [147]. Taken together, these results suggest that the limitation in using
binding affinity predictions to select antisense reagents is not the differences in binding in
solution vs. in cells [193] or the sequence-dependent processing of oligonucleotides by cells, but
the imperfect ability to predict affinity itself.
Binding affinity predictions are limited by the accuracy of structural descriptions. In
structural prediction alone, 70-80% accuracy as compared to phylogenetically determined
structures is sufficient to predict the major features of the native mRNA structure [200].
However, when looking at oligonucleotides that might target at most 5% of the mRNA structure
(a 25-mer targeted to a 500 nt mRNA), greater accuracy will be required to increase the
reliability of oligonucleotide hybridization energy predictions. Efforts to extend these
predictions have focused on predicting pseudoknot formation and combining free energy
predictions with other methods such as a comparative analysis or statistical sampling [208-211].
However, the lack of detailed experimental data with which to validate folding algorithms is
likely to limit the development of major improvements in the near future.
When secondary structural features can be more accurately predicted and tertiary
interactions can be accurately modeled and understood [165], it will be possible to further reduce
the fraction of oligonucleotides that should be tested in vitro to be considered viable antisense
candidates. For the time being, predictions of binding affinity will be useful in concert with
accurate in vitro assays. A useful metric for rational selection may be the percentile score
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(Figure 3-3a). For example, the group of oligonucleotides measured to have KD values less than
0.1 nM had average percentile scores of 79%. For the 0.1-1.0 nM and greater than 1.0 nM
groups, respectively, the average scores are 730/0 and 340/0. Selection of potential candidates
from among the set expected to be highest in affinity will enhance considerably the likelihood of
identifying sequences that have high affinity and are expected to have antisense activity [193].
For example, we have experienced marked success testing in vitro sequences selected from the
highest percentile scores (> 95%) [147].
Although we have found that the calculated free energy of binding is a better predictor of
binding affinity than the R A structure alone, or the free energy of folding the RNA into its
structure, one might expect the structure to be more indicative of association kinetics. The
predicted structure of the RBG mRNA is shown in Figure 3-8, with the highlighted regions
representing those targeted by oligonucleotides used in the kinetics experiments. In general, the
oligonucleotides that exhibited the most rapid binding kinetics (33, 259, 139, and 448) target
regions with less structure than those exhibiting slower kinetics. Oligonucleotide 33 exhibited
unusually rapid binding relative to its affinity (Table 3-3). This oligonucleotide is predicted
target a region spanning a bulge and a joint in the RBG RNA, with several non-canonical base
pairs included among the structured region in between. Others have posited that unstructured
regions of the R A should provide necessary accessibility for oligonucleotide binding [178,
211], and this has been shown nicely in a case where the target was carefully genetically
engineered [212]. One study of the correlation between predicted structure and cell culture
effectiveness [174] suggests that an unstructured 5' end of the RNA is particularly important for
initiating hybridization.
Kinetic effects, such as the bias towards nucleation from one side of the oligonucleotide
that is suggested by the results described above, could complicate thermodynamic prediction of
oligonucleotide:mR A affinity, but the close correlation between association kinetics and
affinity suggests that this is probably not a serious limitation. Other effects could alter the
agreement between theoretical prediction and experimental observation of affinity. For example,
it has been suggested that a single minimum free energy structure may not accurately describe
RNA and, instead, an ensemble of structures should be evaluated [169, 213]. We have found
that an ensemble-average free energy is no better predictor of binding affinity in the RBG system
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Figure 3-8: Predicted RBG mRNA structure
The predicted structure of the RBG mRNA was determined using mfold, as described in
the Materials and Methods. The complementary region for each oligonucleotide on
which kinetic experiments was performed is indicated by a gray bar. Particular structural
features, for instance, hairpins as targeted by oligonucleotide 259, tend to be targeted by
the fastest binding oligonucleotides. However, the presence of a great deal of
intramolecular structure does not prevent rapid association kinetics (e.g., oligonucleotide
139). The discrepancy in binding kinetics between oligonucleotides 139 and 147
suggests a minimum of 3 single-stranded bases required for heteroduplex initiation.
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(unpublished results), but qualitative use of structural ensembles has been shown to exhibit
moderate utility in identifying accessible binding sites on the REG mRNA [211].
The thermodynamic model for antisense binding results in calculation of the binding
affinity for an oligonucleotide:mRNA interaction under conditions that mayor may not be
relevant for antisense efficacy in cells. In the latter case, activity is complicated by the need for
rapid kinetics, possible differences in binding thermodynamics and kinetics in the cellular
environment (e.g., presence of RNA binding proteins), and the role of ribonuclease H in
mediating destruction of targeted transcripts in living cells. The interplay among these different
events and phenomena has not been explored extensively and quantitatively. We have sought to
connect prediction of dissociation constants with their measurement, and measured dissociation
constants (KD) with association rate constants (ka), and association rate constants with RNase H
cleavage (kejJ). A very strong correlation was observed between KD and ka, with the notable
exception of oligonucleotide 33, which exhibited unusually rapid kinetics. The region of the
RBG mRNA targeted by this oligonucleotide (Figure 3-8) is extremely flexible (RNA structure
cost 2.7 kcal/mole), and the oligonucleotide itself has no stable structure (Table 3-2); therefore, a
structural origin for such anomalous behavior is suggested.
A correlation between RNase H cleavage and oligonucleotide:RNA association rate is
also indicated by our results, albeit not a uniform linear correlation. Kinetic analysis of the
interplay between oligonucleotide:RNA binding and RNase H-catalyzed cleavage of duplexes
shows that in the binding-limited case, the effective rate constant is equal to the product kaOT
(Appendix 3-1). For the lowest values of ka measured, the corresponding values of kejf appear to
approach this limit (Figure 3-7 and Table 3-3). In the other limit of slow catalysis, the observed
cleavage rate is expected to be independent of ka (Appendix 3-1). Indeed, this was observed
(Figure 3-7), although it was necessary in this case to fit the maximum value of kejf•
In vitro RNase H assays can be reliable predictors of antisense efficacy in living cells.
Several researchers have reported that antisense oligonucleotides that induce cleavage of a target
RNA in the presence of RNase H tend to be effective antisense reagents in cell culture [177,
214]. In RNase H mapping experiments, the amount of both oligonucleotide and RNA is quite
high, resulting in a high rate of binding, and perhaps increasing the number of oligonucleotides
that mediate cleavage. However, many antisense targets in vivo are transcripts expressed in
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relatively low abundance, which will present a much more stringent condition to the association
of oligonucleotides; thus, controlling the oligonucleotide library concentration may help select
for the fastest binding members. It is not yet clear whether measured affinity, binding kinetics,
or RNase H cleavage rates correlate most strongly with effectiveness in cell culture.
The optimization of antisense efficacy with minimal non-specific effects will result from
concerted efforts in oligonucleotide chemistry, delivery, and target site selection. With the
ability to predict high affinity sequences that bind with rapid association kinetics, it is possible to
optimize the target site selection so that downstream modifications and conjugations can be
explored with the greatest hope for success. Modifications that destabilize native mRNA
structure may prove a fruitful avenue for enhancing antisense efficacy, as structural factors
appear to determine which oligonucleotides have the highest binding affinities. With the coupled
dynamics of nuclease degradation and intracellular diffusion acting as kinetic traps for the
effectiveness of antisense oligonucleotides, the ability of an oligonucleotide to access rapidly its
target site becomes even more critical to its activity. While further exploration of these effects in
vivo is required, it may become increasingly possible to rationally engineer highly effective
antisense oligonucleotides for therapeutic and other applications.
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4. Demonstration of Model Applicability to Cellular System
4.A. Abstract
Antisense oligonucleotides are an attractive therapeutic option to modulate specific gene
expression. However, not all antisense oligonucleotides are effective in inhibiting gene
expression, and currently very few methods exist for selecting the few effective ones from all
candidate oligonucleotides. The lack of quantitative methods to rapidly assess the efficacy of
antisense oligonucleotides also contributes to the difficulty of discovering potent and specific
antisense oligonucleotides. The development of a prediction algorithm for identifying high
affinity antisense oligonucleotides based on mRNA-oligonucleotide hybridization has been
previously described. In this study, the antisense activity of these rationally selected
oligonucleotides against three model target mRNAs (human lactate dehydrogenase A and Band
rat gp130) in cell culture is reported. The effectiveness of oligonucleotides was evaluated by
kinetic RT-peR, allowing quantitative evaluation of mRNA levels and thus providing a measure
of antisense-mediated decreases in target mRNA, as occurs through RNase H recruitment.
Antisense oligonucleotides that were predicted to have high affinity for their target proved
effective in almost all cases, comprising tests against three different targets in two cell types with
phosphodiester and phosphorothioate oligonucleotide chemistries. This approach should aid the
development of antisense oligonucleotides for a variety of applications.
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4.B. Introduction
Antisense oligonucleotides are being used to modulate gene expression in a variety of
research, biotechnology, and therapeutic applications [8]. Despite a number of notable successes,
the application of antisense oligonucleotides to modulate gene expression has proven to be more
difficult than originally estimated. The most frequently noted barriers to efficacy involve issues
of oligonucleotide stability and delivery, which are being addressed in many laboratories by
modified oligonucleotide chemistries and by derivatization and/or encapsulation of the
oligonucleotides [16]. In contrast, selection of a highly active oligonucleotide sequence towards
a particular target has only recently been recognized to be a major barrier and, thus far, has
proven to be a much more significant challenge. The most widely utilized strategy for selecting
active oligonucleotides is to synthesize a large number of candidate oligonucleotides
complementary to different regions of the target mRNA and test them all empirically for activity
in an appropriate model system [190, 216].
An alternate approach to oligonucleotide selection is the use of a combinatorial screen,
which typically involves the use of RNase H and a library of oligonucleotides to map the
accessible portions of the target mRNA [177, 183]. The results of these types of experiments, as
well as more detailed studies, increasingly support the view that the activity of antisense
oligonucleotides in cells is related to the structure of the targeted mRNA [174, 175, 212-214].
However, a quantitative understanding of the relationship between structure and activity is
lacking to date, and the resolution of the mechanistic details would greatly aid in the design of
active antisense sequences. At the simplest level, certain sequence motifs have been found to
correlate with antisense activity [158, 159], though it is unclear why such a relationship exists or
whether the correlation is adequate for rational design. Some researchers have argued that a
short run of unpaired nucleotides in a native RNA structure is necessary to initiate binding of the
complementary oligonucleotides [174, 212]; this view essentially says that hybridization is
kinetically limited. We [201] and others [169] have adopted a thermodynamic approach, in
which we account for the complete thermodynamic cycle involved in oligonucleotide binding to
a structured RNA target: unfolding some of the native RNA structure to accommodate the
antisense oligonucleotide, hybridizing the oligonucleotide to the RNA, and rearranging the
bound structure after binding. This approach has been justified on the quality of correlations of
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predictions made with the thermodynamic model to binding data and RNase H mapping results,
and also on observed correlations between affinity and effectiveness in cell culture [193].
In this work, we have used the thermodynamic modeling approach to select antisense
oligonucleotides that are predicted to have high affinity for their targets as candidates for the
inhibition of target gene expression in cell culture. One of the problems with developing
correlations between effectiveness in cell culture and theoretically derived quantities is that
measurements of the former are typically not very sensitive, and the extent of inhibition observed
may be slight relative to the expression level. The need for quantitative differential mRNA
measurement is addressed by kinetic reverse transcription polymerase chain reaction (kRT-
PCR), which is an extremely sensitive technique that allows analysis of expression levels from
very small amounts of RNA [217-219]. In this report, we utilize a kinetic PCR assay to assess
the ability of our prediction algorithm to identify antisense oligonucleotides that are effective
inhibitors of gene expression in living cells. The selection algorithm has been applied to predict
high affinity antisense oligonucleotides complementary to the human lactate dehydrogenase
(LDH) A and B mRNA and the rat gp130 mRNA. The in vitro inhibition of gene expression for
each of these targets by these rationally selected antisense oligonucleotides has been
demonstrated. Furthermore, changes in protein expression were observed to correspond to those
in mRNA for those systems that are transcriptionally controlled.
4.C. Materials and Methods
Cell Culture and Reagents: A sub-clone of the H35 rat hepatoma cell line selected for its
acute-phase responsiveness [220] was grown and maintained in T25 flasks containing
Dulbecco's modified eagles medium (DMEM, Life Technologies, Long Island, NY)
supplemented with 10% fetal bovine serum (Life Technologies) in the presence of Penicillin 200
U/mL, Streptomycin 200 Jlg/mL specific activity, and Gentamycin 10 U/mL in a humidified 5%
CO2 incubator at 37°C. Primary cultures of fibroblasts were isolated from human foreskin [221]
and grown on 100 mm dishes in DMEM supplemented with 10% bovine calf serum (Life
Technologies) in the presence of Penicillin 200 U/mL and Streptomycin 200 Jlg/mL specific
activity. For both cell types, the growth medium was replenished 24 hours prior to the
experiment (after the cells had reached confluence).
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Rational selection of antisense oligonucleotides: In this study, the human lactate
dehydrogenase (LDH) A and B mRNA isoforms and the rat gp130 mRNA were used as the
target molecules. The prediction of the binding affinity of oligonucleotides complementary to
target mRNA was performed as described elsewhere [201]. Briefly, the free energy (LlGOtotal) of
antisense binding to a structured mRNA target was computed from a sum of free energy terms of
the form:
(12)
The negative of the unfolding energy (LlGounjold) was computed as the minimum free
energy secondary structure for the target mRNA as predicted using mfold v2.3 [167, 168] and
was a constant for any target RNA regardless of the oligonucleotide candidate. The energy
required to break up secondary structure in the oligonucleotide (LlGooligo, which frequently is
negligible due to the short size of the oligonucleotides) was computed in the same manner,
except with DNA rather than RNA parameters [186]. Folding calculations were performed using
a temperature of 37°C without correction for ionic strength. The free energy for the
intermolecular interaction of the oligonucleotide and the mRNA was calculated using nearest-
neighbor parameters for RNA:DNA hybrids [185]. The available parameters are based on
phosphodiester oligonucleotides while, in some of our experiments, phosphorothioate
oligonucleotides were used. The energy to refold the RNA with an antisense oligonucleotide
bound (LlGorestruct) was calculated using mfold by constraining the bases bound by oligonucleotide
not to participate in intramolecular base pairing. Except for LlGounfold, each term was computed
for each IS-mer oligonucleotide complementary to the target mRNA, the sums LlGOtotal
determined for each candidate oligonucleotide, and the resulting table of free energies sorted to
choose (rationally design) the most effective (and in some cases, least effective) antisense
candidates based on predicted overall free energy of binding.
A panel of oligonucleotides complementary to the mRNA for rat gp130 was chosen,
including ones among the best (Good1, Good 2, and Good 3) or worst (Bad1 and Bad2) in the
ranking of 3039 possible oligonucleotides (Table 4-1). The gp130-targeting oligonucleotides
were selected from clusters that appeared among the highest and lowest affinity predictions. For
example, oligonucleotides targeting positions 2046 (Good1), 2055, and 2053 were predicted to
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-20.3
-18.1
-19.0
2.2
0.7
1
32
11
3039
3028
Coding
Coding
Coding
Coding
3'-UTR
2046
2812
2414
593
22
Target Name Sequence Position* Target Region Rank# AGTO (kcal/mol)
LDH-A AS-A GGCGGTCGTCGGGGG 44 3'-UTR 1 -22.5
LDH-B AS-B CGCCATGTTCCCCCA 656 Coding 1 -19.6
LDH-A NS-A'" GCGTGGGCGGCGGGT
LDH-B NS-B'" CGCTCACTCGCACTC
gp 130 Good 1 GGGGGTGTGAGGTGA
gp 130 Good2 CCCGCAGGAGCCGGT
gp 130 Good3 TCTGGCCGCTCCTCG
gp 130 Bad 1 GTATAGCCCATCATG
gp130 Bad2 TCCTTATTCAAGATG
gp 130 NS-G I'" GTGGAGTGGGAGTGG
gp130 NS-G2'" CCCGCAGGAGCCGGT
Table 4-1: Properties of candidate oligonucleotides for cellular assays
• Position corresponds to the 5' -terminal base of the targeted region on the mRNA (3' -terminal base of the
oligonucleotide ).
# The rank of the oligonucleotide is out of all the possible oligonucleotides generated for any particular transcript
(1647 for LDH-A, 1258 for LDH-B, and 3039 for gpI30).
'" Nonsense sequences have identical base composition to their antisense counterparts but in scrambled order.
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be those with the highest affinity. Only Goodl was tested among these, as they are relatively
close in target position, and it was desirable to test oligonucleotides predicted to have high
affinity targeting different positions along the mRNA. The sequences NS-G land NS-G2 were
randomly scrambled nonsense controls to Goodl and Good2 and had the same base composition
as the antisense sequences. For human LDH-A and B, a single oligonucleotide was in each case
chosen that was predicted to have the highest affinity (AS-A, out of 1647 and AS-B out of 1258
possible oligonucleotides, respectively; see Table 4-1).
Purification of antisense oligonucleotides: Phosphodiester oligonucleotides (15 bases)
antisense to the human LDH-A and B mRNA were synthesized and HPLC purified at the 200
nmol scale by Life Technologies. Phosphorothioate oligonucleotides (15 bases) antisense to the
rat gp130 mRNA were synthesized at the l11mol scale at the Oligonucleotide Synthesis Core
facility of Massachusetts General Hospital (Boston, MA). The gp130 phosphorothioate
oligonucleotides were dissociated from the solid bead supports by resuspending in 1 mL of lOO%
ammonium hydroxide and incubating overnight at 54°C. Full-length oligonucleotide with the 5'
DMT group was separated on a 10 x 250 mm C-18 reverse phase column as previously described
[60]. The terminal 5' -O-DMT group was detritylated by the addition of 1 mL of 40% aqueous
acetic acid, incubated 20 min on ice, followed by the addition of 1 mL of 50% ethanol, and
evaporated on a rotary vacuum. The oligonucleotide was desalted on a Sephadex G-I0 column
(Pharmacia, Piscataway, NJ), evaporated on a rotary vacuum, and resuspended in 1 mL HPLC
grade water. The purity of the final material was assessed by analytical RP-HPLC on a 10 x 250
mm C-18 column. The concentration of the purified oligonucleotide was estimated from the
absorbance at 260 nm using the following expression for the extinction coefficient:
C260 = (15.34[A] + 12.16[G] + 8.70[T] + 7.60[C]) x 0.9 x 103 M-1 cm-1 [222].
Antisense assays with H35 cells: Antisense inhibition experiments against rat gp130 were
performed with H35 rat hepatoma cells in 24 well plates under serum-free conditions.
Lipofectin@ (Life Technologies, Long Island, NY) was added to DMEM with 1 llM
dexamethasone (Sigma, St. Louis, MO) at an equal charge ratio to the oligonucleotides
(assuming 1 positive charge per molecule of Lipofectin@ and 14 negative charges per 15
nucleotide oligonucleotides), and the medium was incubated for 45 min at room temperature.
97
Phosphorothioate oligonucleotides (600 nM) were added to the Lipofectin@-containing medium
and incubated for another 15 min at room temperature. The cells were washed twice with
phosphate buffered saline (pH 7.20), and the oligonucleotide-containing medium was added to
two sets of plates. After 8 hours, the cells were scraped from one set of plates, washed with
phosphate buffered saline (pH 7.20), and stored at -20°C until further use. The second set of
plates was incubated for another 16 hours (24 hours of antisense treatment) with fresh medium
containing 1 JlM dexamethasone and 10 ng/mL recombinant human interleukin-6 (R&D
Systems, Minneapolis, MN). The supernatants were then collected and stored at -20°C until
further use. For timing experiments, antisense treatment was performed as described above.
Replicate wells of a 24-well plate were sacrificed at various times after treatment, at which the
cells were scraped, washed with phosphate buffered saline (pH 7.20), and stored at -20°C until
further use.
Antisense experiments with human primary fibroblasts: Antisense inhibition experiments
against LDH-A and LDH-B were performed using human foreskin fibroblasts in 6-well plates
under serum-free conditions. The protocol was similar to that used with H35 cells, except that,
prior to the experiment, the cells were switched to serum-free growth medium for 24 hours.
After 4 hours of exposure to antisense oligonucleotides, 20 ng/mL of epidermal growth factor
(Sigma, St. Louis, MO) in a change of fresh medium was added to the cells for another 20 hours.
These cells were then washed with phosphate buffered saline (pH 7.20) and lysed in the plate.
The lysate was centrifuged for 5 min at 10,000 x g at 4°C and stored at -20°C until further use.
Isolation of total RNA: Total RNA was isolated from approximately 2 x 106 hepatocytes
or 0.2 x 105 fibroblasts using the Nucleospin IIRNA isolation kit from Clontech (Palo Alto,
CA), as per the manufacturer's instructions. The RNA was quantified using the absorbance at
260 nm and the purity assessed from the ratio of absorbance at 260 and 280 nm. The RNA used
for all assays had a ratio of A2601A280 greater than 1.90.
Reverse transcription and peR of acute phase response gene transcripts: The mRNA
sequences for rat gp130, rat GAPDH, rat and human LDH (isoforms A & B), and the rat and
human 18S rRNA sequence were derived from their respective cDNA sequences, which were
retrieved from the GenBank database. Gene-specific PCR primers were designed using the
Oligo 4.0 software (Molecular Biology Insights Inc., Cascade, CO). Primer pairs that predicted
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minimal primer-dimer (non-specific, template independent product) formation and those that
yield a PCR product of 200-300 bp were selected (Table 4-1).
For reverse transcription, gene-specific downstream primers (Table 4-1) were used to
generate each cDNA individually using the Access RTPCR system (Promega Corporation,
Madison, WI) according to the manufacturer's instructions. Downstream primers were selected
based on the predicted inability to cross-hybridize with the other transcripts of interest using the
Oligo 4.0 program. The reverse transcribed template was stored at -20°C until further use.
PCR was performed using the Light Cycler v1.3 (Idaho Technology, Salt Lake City, UT)
according to the manufacturer's instructions. A 1:40,000 dilution of SYBR Gold (Molecular
Probes, Eugene, OR) dye was added directly to the PCR reaction mixture for fluorescent
detection after each amplification cycle. The reaction conditions (magnesium chloride
concentration, annealing temperature, and primer concentration) for each transcript were
optimized so that primer-dimer formation was minimized. The specificity of the PCR products
was verified using the melt curve generated by the Light Cycler (i.e., the presence of a single
transition) as well as by electrophoresis on 2% agarose gels (i.e., the presence of a single band of
the appropriate length).
A standard curve of concentration vs. cycle number was generated for each transcript to
determine the copy number of the mRNA in hepatocytes. First, the transcript to be quantified
was amplified and the amount of pure cDNA product estimated using the absorbance at 260 nm.
Serial dilutions of the quantified PCR product were then used as the template for PCR to
generate a standard curve of concentration vs. threshold cycle number and to determine the
concentration of the specific cDNA in any unknown sample that is amplified along with the
standards. This method allows calculation of the total number of cDNA molecules after reverse
transcription. Assuming that the efficiency of reverse transcription is close to 100%, the number
of specific mRNA transcripts/cell was then calculated.
Data analysis: Fluorescence data acquired after each cycle of amplification was extracted
from the Light Cycler software and imported into a Microsoft Excel spreadsheet for further
manipulations. The number of molecules, N, of an amplified transcript after 11 cycles of PCR can
be related to the initial number of molecules No by:
(13)
where e is the efficiency of each cycle; if e=1, then the amount of product doubles in each cycle.
During the early cycles of amplification, the efficiency is constant and close to unity, and the
cycle number, n, at which the fluorescence intensity increases above a predetennined threshold
value (which is somewhat variable, depending on the concentration and yield of the fluorescent
dye, but generally between 0.2 and 0.3), allows computation of the initial number of copies No by
( No )gene _ (1+ereference) Tlrererenre
( No ) reference - ( 1+egene fgene (14)
To calculate changes in antisense-treated mRNA, the amount of specific mRNA is first
nonnalized to that of 18S rRNA in the same sample using equation (3). The fold-change after
antisense treatment is calculated as the ratio of nonnalized mRNA between the treated sample
and the untreated control. In all our calculations, the efficiency has been assumed to be 1.0. All
PCR amplifications were perfonned in triplicate, and the average threshold cycle number was
used for calculating fold-changes in mRNA.
LDH assay: The enzymatic activity of LDH (due to a combination of A & B isoforms)
was measured using the lactate dehydrogenase kit (500-C, Sigma, St. Louis, MO) as per the
manufacturer's instructions.
Western blots: Antisense oligonucleotide-treated H35 cell culture supernatants were
collected, electrophoresed on 4-20% Tris-HCI gels (Bio-Rad, Hercules, CA), and transferred
onto a nitrocellulose membrane (Bio-Rad) according to the manufacturer's protocol. The blots
were blocked with 5% low-fat milk for 1 hour at room temperature, and incubated overnight at
4°C with a 1:2500 dilution of anti-human haptoglobin, goat IgG (ICN Biomedical, Costa Mesa,
CA). Each blot was then washed three times for 5 min each, incubated for 1 hour at 37°C with
an anti-goat IgG, horseradish peroxidase-conjugated secondary mouse antibody (ICN
Biomedical) at a 1:5000 dilution, washed three times, developed using an enhanced
chemiluminescence system (Pierce, Rockford, IL), and imaged on a GS525 Molecular Imager
System (Bio-Rad).
Statistics: Data are reported as the mean and standard deviation of two independent
experiments. Statistical comparisons among groups were performed using ANOV A followed by
Tukeys' honest significant difference test with differences deemed significant at the level
100
(p<0.05). Inferences on correlation of ~Go values with mRNA levels were made using the one-
tailed t test for the slope, Le., on the hypothesis that the slope is positive.
4.D. Results
4.D. 1.Description of kinetic RT-PCR technique and results
Kinetic PCR amplification following reverse transcription (kRT-PCR) is a relatively new
development that takes advantage of the sensitivity of PCR while minimizing the confounding
effects of primer-dimer formation and competitive cross-priming of unintended products. This
technique is well-suited for the evaluation of antisense oligonucleotides, where sensitivity and
precision are important requirements, as the targeted mRNAs are often of low abundance and
only partial inhibition of basal expression levels is typically observed.
First, we calibrated the assay by creating standard curves for each transcript of interest
from its corresponding cDNA, which was generated by primer-specific reverse transcription of
total RNA isolated from primary rat hepatocytes, as described in Material and Methods. In kRT-
PCR, the number of copies of starting material is determined from the early rounds of
amplification, when the efficiency (number of copies of product per copy of template) for each
round is close to unity. An example of kinetic PCR data for the 185 ribosomal RNA (which is
used as a housekeeping standard) is shown in Figures 4-1a - 4-1c. The raw fluorescence is
indistinguishable from background at early cycles, grows exponentially, then plateaus at higher
cycle numbers, where the coupled effects of dNTP depletion, primer-dimer formation and
amplification, and fluorescence quenching result in a plateau fluorescence level that is relatively
insensitive to starting concentration (Figure 4-1a). By correcting for background and choosing a
low threshold level during which the fluorescence is increasing exponentially, a concentration
dependence consistent with theory (i.e., equation 2) is observed (Figure 4-1b). Note that some
product is created at high cycle numbers in the absence of cDNA, which shows that
amplification of primers does indeed occur and constrains the lower limit of detection. For
samples of two different concentrations (N vs. No) amplified at the same average efficiency (e) ,
equation 2 predicts that the threshold cycle number (n) should be linear in the logarithm of
starting concentration:
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Figure 4-1a: Kinetic peR dilution series using 185 cDNA
A) Raw fluorescence data for dilutions of a stock solution of 185 cDNA, ranging in
relative concentration from 1 to lxlO.5, as well as primers only (no cDNA).
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Figure 4-1b: Kinetic peR dilution series using 18S cDNA
B) Background corrected fluorescence showing parallel curves passing a threshold
(arbitrarily set within the regime of exponential growth of fluorescence with respect to
cycle number) at equally spaced intervals of roughly 3.3 cycles/IO-fold change in
concen trati on.
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Figure 4-1c:Kinetic PCR dilution series using 18S cDNA
C) Standard curve of threshold cycle number (n) vs. log(c). Dotted line represents a best
logarithmic fit (n = 3.21 - 3.51Iog(c); r2 = 0.999) to the data.
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1 (N Jn-no = log -10g(1+c) No (15)
Indeed, this was observed, establishing a standard curve valid for nearly five orders of
magnitude (Figure 4-1c). Standard curves were also generated for the albumin, LDH-A, LDH-B,
and gp130 transcripts; these were used in the measurements described below. Assuming that all
these transcripts were reverse-transcribed with similar efficiencies, one can compute an
approximate lower bound for the detection limit of kinetic PCR as 10-100 copies of specific
mRNAlcell (using our protocols).
4.D.2.Dynamics of inhibition of gp130 by antisense oligonucleotides
First, we studied the dynamics of mRNA inhibition using two antisense sequences (Table 4-
1) directed against the mRNA encoding rat gp130 mRNA. Gp130 is a receptor subunit involved
in signaling of IL-6 family cytokines and, as such, plays a critical role in a diverse array of
biological processes including hematopoiesis, neuronal differentiation, activation of anti-
apoptotic pathways in cardiac myocytes, and the hepatic acute phase response [223, 224].
Serum-free medium containing phosphorothioate antisense oligonucleotides at 600 nM, pre-
incubated with an equal charge ratio of Lipofectin, was added to confluent plates of H35 cells.
At various time points, the mRNA was harvested from replicate wells, reverse transcribed, and
subjected to kinetic PCR analysis. Significant decreases in gp130 mRNA were observed after 4
hours of treatment with Good2, predicted by our molecular thermodynamic analysis to be a good
inhibitor of gp130 mRNA, with the maximal inhibition of expression occurring around 8 hours
and a return to basal expression by 24 hours (Figure 4-2). The oligonucleotide Bad1 (predicted
to be an ineffective inhibitor despite being of the same length as Good2 and fully complementary
to the rat gp130 mRNA) appeared to induce slight decreases in gp130 expression at parallel time
points; however, none of these changes was statistically significant.
4.D.3. gp130 mRNA reduced with oligonucleotides predicted to be active
Using the 8 hour time point found to be most effective for Good2, we tested a small panel
of oligonucleotides, including sequences predicted to have high affinity for the gp130 mRNA
(Goodl, Good2, Good3), as well as two that were predicted to have weak affinity (Badl, Bad2)
despite being fully complementary to the gp130 mRNA and of the same length as the "Good"
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Figure 4-2: Time course of inhibition of gp130 mRNA in H35 cells
H35 cells were treated with phosphorothioate antisense oligonucleotides Good2 (filled
circles) and Bad1 (open squares), at 600 nM concentration, under serum-free conditions.
The cells were lysed at the indicated time intervals, after which the total mRNA was
extracted and the level of gp130 mRNA quantified by reverse transcription and kinetic
peR. The mRNA levels are normalized to that of 18S rRNA and the changes in
expression are determined relative to the untreated control. Good2, an oligonucleotide
predicted to have high affinity for the gp130 mRNA show significant inhibition (p<0.05,
as compared to untreated control) between 4-14 hours of exposure with maximal
inhibition occurring after 8 hours. In contrast, Badl, predicted to have low affinity,
showed no significant reduction at any time. Recovery to at least basal levels could
represent feedback in cellular processing in concert with oligonucleotide degradation.
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sequences. Two (Good1 and Good2) of the three selected sequences were able to decrease
gp130 mRNA by 50% after 8 hours; the third sequence was able to cause a 25% decrease in
gp130 mRNA (Figure 4-3). Neither of the sequences predicted as poor antisense
oligonucleotides (Bad1 and Bad2) significantly decreased the levels of gp130 mRNA. The
sequence-specificity of the two most effective oligonucleotides was also evident, since their
nonsense controls (NS-G 1 and NS-G2) did not demonstrate any significant antisense inhibition
(Figure 4-3).
4.D.4. Reduction in protein activity follows reduction of mRNA levels
The effectiveness of the antisense oligonucleotides at inhibiting the biological function of
gp130 was further assessed by Western blot analysis of acute phase proteins using H35 cells.
gp130 is the major signaling receptor for the IL-6 family of cytokine. In H35 cells as well as
normal hepatocytes, gp130 signaling results in the up-regulation of haptoglobin and other
positive acute phase proteins. In this experiment, H35 cells were exposed to oligonucleotide
under serum-free conditions for 8 h (the sum of the earliest significant down-regulation of
mRNA, 4 h, plus the estimated half-life of gp130 protein, 4 h [225]). Cells were subsequently
exposed to IL-6 in a change to serum-containing medium for an additional 16 h, after which the
proteins were extracted and probed for haptoglobin expression by Western blot analysis (Figure
4-4). In the absence of oligonucleotide, IL-6 resulted in an increase in secretion of haptoglobin,
as expected. Good1, Good2, and Good3 all essentially abrogated haptoglobin secretion, whereas
a significant amount of haptoglobin was secreted by cells exposed to Bad1, Bad2, NS-G 1, or NS-
G2.
4.D.5.Dose-dependent inhibition ofLDH A and B mRNA and protein
Lactate dehydrogenase (LDH) is an abundant and well-characterized metabolic enzyme
expressed by many cell types. There is evidence to suggest that the LDH protein is
transcriptionally regulated, particularly in response to stimulation with epidermal growth factor
(EGF) in vitro [226]. We tested the ability of rationally selected antisense oligonucleotides to
modulate mRNA levels of two of its isoforms, LDH-A and B. Human foreskin fibroblasts were
treated with phosphodiester oligonucleotides (Table 4-1) against LDH-A and B mRNA under
serum-free conditions at varying concentrations, with the concentrations of Lipofectin adjusted
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Figure 4-3: Inhibition of rat gpl30 mRNA by predicted antisense oligonucleotides
H35 cells were treated with phosphorothioate antisense oligonucleotides at 600 nM
concentration under serum-free conditions for 8 hours, after which gp130 mRNA levels were
determined as in Figure 4-2. Statistical significance relative to untreated control is indicated
by *(p < 0.05). Of the 3 complementary oligonucleotides tested against the gp130 mRNA
predicted to have high affinity, all resulted in significant inhibition, though Good3 was
decidedly less effective. Concomitantly, neither Badl nor Bad2 (both predicted to have low
affinity) resulted in significant inhibition. Nonsense sequences (non-complementary
oligonucleotides), NS-Gl and NS-G2 showed no significant effect. These results confirm
that predicted binding affinity is a useful tool in locating oligonucleotides that generate an
antisense effect. The nonsense controls provide confirmation of the sequence-specificity of
the acti vity.
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Figure 4-4: Modulation of haptoglobin production by gp130 antisense oligonucleotides
Supernatants were collected from antisense- or control-treated H35 cells 16 hours after
addition of 10 ng/mL IL-6 (24 hours after antisense treatment). Western blot for haptoglobin
was performed as described in Materials and Methods. Data shown represents one of two
similar experinlents. In response to IL-6 binding and signaling complex formation, gp130
transduces a signal resulting in the upregulation of haptoglobin secretion by hepatic cell lines
(compare +IL-6 and -IL-6, above). However, the elimination of gp130 protein interrupts
signal transduction and eliminates haptoglobin upregulation. Nonsense oligonucleotides and
oligonucleotides of low affinity show little if any reduction of haptoglobin upregulation.
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proportionately to maintain a constant charge ratio of 1:1. The degree of antisense inhibition of
LDH-A and B mR A in fibroblasts was dose-dependent, with significant effects observed at
concentrations of 200 nM and higher for AS-A and 60 nM and higher for AS-B; in all cases, the
inhibition of LDH-B by AS-B was greater than the corresponding inhibition of LDH-A by AS-A
(Figure 4-5).
Because of the intracellular instability of phosphodiester oligonucleotides, it is often difficult
to achieve sustained down-regulation of target mRNA and corresponding phenotypic
modulation, without multiple administration of the oligonucleotide. Nonetheless, we observed
changes in LDH enzyme activity of antisense-treated cells that were consistent with the changes
in mRNA expression. To be able to detect changes in LDH activity, fibroblast cultures were
serum-starved for 24 hours prior to the addition of antisense oligonucleotides to deplete
intracellular pools of LDH protein; cells were then treated with antisense oligonucleotides for 4
hours, then challenged with medium containing serum and EGF for an additional 20 hours, upon
which the cells were lysed in their plate and the lysate assayed for LDH activity. As with the
isoform mRNA levels, the LDH enzymatic activity was inhibited in a dose-dependent manner
(Figure 4-6); the greater inhibition using AS-B is also consistent with the mRNA inhibition
results. The lesser extent of inhibition at the enzymatic level is likely due to a combination of
transient mRNA inhibition over the 20 h duration of EGF stimulation before assaying for LDH
activity, and also the fact that multiple isoforms contribute to the total LDH activity, only one of
which was presumably inhibited by a particular oligonucleotide.
4.£. Discussion
The effectiveness of antisense oligonucleotides is limited by several factors, including:
the delivery of oligonucleotides to cells, intracellular trafficking, affinity and specificity of
hybridization to the target mRNA, and the susceptibility of oligonucleotides to degradation by
both serum and intracellular nucleases [16]. The effectiveness of only a low fraction, perhaps
-10% [190, 216], of tested antisense oligonucleotides in vitro points out a sequence dependence,
which suggests that affinity is very important in determining efficacy. We have previously
developed a molecular thermodynamic model that predicts which antisense oligonucleotides will
have the greatest affinity for a target mR A, based on thermodynamics of unfolding existing
secondary structure, duplex base pair stability, and structural rearrangements in the D A:R A
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Figure 4-5: Inhibition of mR A in human fibroblasts by antisense oligonucleotides
Oligonucleotides tested were LDH-A antisense (filled circles), LDH-B antisense (filled
triangles), LDH-A nonsense (open circles), and LDH-B nonsense (open triangles).
Fibroblasts were treated with each oligonucleotide for four hours. The mRNA levels are
normalized to those of 18S rR A, and the changes in expression are reported relative to
the untreated control. Statistical significance relative to untreated control is indicated by
* (p<O.05). In both cases, oligonucleotides predicted to have the highest affinity for their
target mR A showed significant inhibition of their target mRNA at sub-micromolar
concentrations.
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Figure 4-6: Inhibition of LDH enzymatic activity after antisense treatment
Fibroblasts were treated with each oligonucleotide for four hours. Intracellular LDH
activity was measured 20 hours after the addition of 20 ng/mL EGF (24 hours after
antisense treatment). Symbols represent the same quantities as in Figure 4-5. The
activity levels are normalized to the untreated (no oligonucleotide) control, and statistical
significance relative to untreated control is indicated by * (p<0.05). Changes in protein
levels reflect changes in mRNA levels, even in the greater reduction due to AS-B versus
AS-A.
112
duplex [201]. This approach has proven successful in correlating predicted free energy with
observed binding affinity in solution [227] as well as with RNase-accessible sites on target
mRNAs [169]. Here, we have demonstrated the ability of the model to predict (rationally
design) antisense oligonucleotides that are effective inhibitors of target gene expression in living
cells.
We have previously used the quantitative kinetic PCR method to follow the dynamics of
abundant as well as rare mRNA transcripts in rat hepatocytes [228]. In this paper, we have
applied kinetic PCR to evaluating antisense oligonucleotide efficacy. One of the key concerns
regarding quantitative PCR is the potential for variability in the amplification efficiency (and
amount of specific product) due to the characteristics (GC content, secondary structure) of the
region being amplified [219]. With the kinetic PCR technique, we find a high level of
consistency in replicate samples (run on different days), and we have obtained essentially
identical results to those presented here using alternate primer pairs for several transcripts (data
not shown). Furthermore, we have observed very minimal variability in reverse-transcription
process (as inferred from the similar threshold cycle numbers obtained in kinetic PCR using
cDNA generated in different reverse-transcription reactions from a single pool of mRNA). It is
possible that the careful choice of amplification target (40-50% GC content) as well as the use of
specific downstream primers for reverse transcription instead of random primers or oligo-dT
offset any potential variations in amplification efficiency [219]. Therefore, the changes in
mRNA levels of specific transcripts determined with kinetic PCR do not appear to have reverse-
transcription or PCR artifacts. Another issue in quantitative PCR is the choice of appropriate
reference gene for relative quantification of transcripts. The most commonly employed
housekeeping genes are ~-actin, GAPDH, and ribosomal (185 or 285) RNA. Comparison of
expression levels in response to cellular stress indicates that the levels of ribosomal RNAs are
the most stable with respect to environmental perturbations [219]. As a result, for all antisense
experiments, we used 185 rRNA as the reference gene.
Kinetic PCR allows us to compute the number of mRNA copies in a cell or the number of
cDNA molecules in a PCR reaction. Using this approach, we estimated the number of mRNA
molecules per rat hepatocyte for the transcripts of interest in this study (185 rRNA, LDH-A,
LDH-B, and gp130; also GAPDH, albumin, and ~-actin) to range from -107 for 185 rRNA to
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-102 for gp130. In general, the levels are in the range that we would expect, with high
expression of l8S rRNA and albumin and the least for gp130. In general, few absolute
measurements of mRNA levels have been reported, but our measurement for albumin
mRNNhepatocyte of 56,000 is in excellent agreement with Peters [229], who reported 58,000
copies of albumin mRNNhepatocyte. Dilution series with gp130 or LDH cDNA (data not
shown) indicate that we can dilute the starting cDNA material only 10-fold without getting any
interference from primer-dimer. Since the extent of antisense inhibition was generally 60% or
less, this does not pose a major limitation on the applicability of the technique for antisense
evaluation, though it is possible that for gp130 we could be slightly underestimating the
effectiveness of antisense inhibition due to this effect.
The two main mechanisms of antisense inhibition are from steric interference with the
translation process and enzymatic cleavage by RNase H [131]. Steric hindrance would result in
a decrease in protein levels without altering the level of mRNA, whereas, in the enzymatic
mechanism, RNase H recognizes an mRNA-oligonucleotide duplex, cleaves the mRNA, and
thereby reduces the level of mRNA. The use of mRNA expression monitoring, whether by
Northern blot or the kinetic peR assay utilized here, assumes that the antisense is activating
RNase H. Our data clearly shows a decrease in mRNA levels after antisense treatment for all
targets tested, which suggests a strong role for RNase H cleavage in antisense inhibition for these
systems.
Our rational prediction method has been successfully applied with two different
oligonucleotide chemistries and three target mRNA - two isoforms of an abundant metabolic
enzyme, LDH (using phosphodiester oligonucleotides), as well as a relatively scarce receptor
molecule, gp130 (using phosphorothioate oligonucleotides). The free energy parameters used in
predicting oligonucleotides were developed based on phospho diester oligonucleotides, and it is
known that phosphorothioate oligonucleotides exhibit significantly weaker binding for their
targets than corresponding phosphodiester oligonucleotides [230]. However, the sequence
dependence of the difference in phosphodiester and phosphorothioate oligonucleotides has yet to
be quantified. Moreover, the cost incurred due to the restructuring of the RNA is a significant
factor in determining the overall hybridization affinity, and this is completely unrelated to the
choice of oligonucleotide chemistry. Regardless, the relative binding affinities among the
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phosphorothioate oligonucleotides are not expected to be significantly affected by the alternative
backbone chemistry.
The success rate of our model- four of five rationally selected antisense oligonucleotides
proved to be potent inhibitors in cell culture - is striking. Based on -700/0 correlation of
thermodynamic prediction with affinity [201] and a 60-70% correlation of affinity and activity
[193], we might have expected less than 50% effectiveness of our predictions. Furthermore, the
accuracy of our predictions was not restricted to effective oligonucleotides, as the
oligonucleotides that were predicted to be poor antisense inhibitors were not effective against rat
gp130 mRNA. In fact, the predicted I1GOtotal values (Table 4-1) correlate significantly with the
gp130 mRNA levels after 8 hours of antisense treatment (Figure 4-3) (p = 0.019). As in our
previous studies [201], the I1Go values of the individual steps correlated less strongly with
experimental values, e.g., p = 0.117 for ~Gohyb' Nonetheless, thermodynamic prediction of
antisense oligonucleotide effectiveness is an imperfect science. Understanding of the
thermodynamics of RNA folding is still emerging, a situation that is difficult to overcome in the
absence of extensive structural information. It is possible that a single, lowest-energy folded
structure does not exist and that mRNA molecules are continually sampling an ensemble of
folding states. Furthermore, tertiary interactions, which are not captured in secondary structure-
based RNA folding algorithms, may be important [165].
In summary, we have demonstrated the ability to improve selection of antisense
oligonucleotides with potent activity in vitro. Our results suggest that, by using rationally
selected antisense oligonucleotides, one can reduce the number of oligonucleotides to be
screened from the dozens typically employed to a few per target mRNA. The quantitative
evaluation of antisense efficiency confirms a dominant role for enzymatic cleavage in the
observed inhibition. Combining this prediction scheme for oligonucleotides with improved
delivery and targeting schemes will further enhance the efficiency and specificity for their
myriad potential application in functional genomics, biotechnology, and therapeutics.
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5. . 2 -1: E ecuting the thermodynamic predictions
h computational method utilizes the program mfold 2.3 as produced by Michael Zuker
nd colle gu ,a well a Perl cripts, Word and Excel, and Mathematica. A similar method has
b n produc d by Turner' group at the University of Rochester and is available as a self-
cont in d applic tion, R tructure, from their web site. RNAstructure uses an updated folding
algorithm a w 11a updated thermodynamic parameters. However, in comparison, both
m thod p rform imilarly, with p rhaps a slight improvement in overall agreement with
p rim nt 1d t from R tructur . Below, the specific manipulations required to perform
th f lding c leul tion u ing our method will be described.
ginning with the primary equence of the mR AlcDNA, the input file for the mfold
pplic tion i cr ted. Th formatting of this file is very specific, requiring a semi-colon in the
fir t line and th numb r one after the final base of the sequence (Figure 2-A1). Also required is
th n m of the s quence bing fold d on the second line of the file, by itself. As described in
th manual for mfold T ba es are treated as U s, and additional characters can be substituted into
th quen e to indicate particular base pairing features. As the sequences being folded
wer the' lma' program from within mfold was used (as opposed to "cma" for
rom the prompt the required command is:
Prompt: 1m
h cr dit for the program ill app ar, and the user will be asked to press return to continue.
The following choice are s lected in equence when generating the "dot plot" for segment
analy i . Th program i run in regular mode, followed by selecting suboptimal plot mode. The
minimum ector iz i 1 with a window ize of O. The sequence file name is then entered and
quenc numb r 1 cho en. The tarting and ending nucleotides are then selected, with base 1
and the la t ba e app aring a d faults. The seven default energy files are then selected. Printer
output i de ired ith the output going to the terminal with the default 80 columns. 0 ct file or
region table i required. The "Begin folding' option is then selected. The folding counter will
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BetaGlobin.seq - WordPad
file Edit ~ew Insert F.Qrmat
RabbitBetaGlobin
GGGAGA ACAC TTGCTTTTGA CACAACTGTG TTTACTTGCA ATCCCCCAAA
I
[Sequence]
I
ACCTCAAAGG CACCl
1~==;;;:;;;;;;::=;;:;=====::::;;==::::;;;;:'::==::;;::'==:;:::::;;:::=~===:::=:;:O~~~~1I For Help, press F1
Figure 2-Al: Screen shot of sample input file
Specific formatting is required for the input file to mfold. The above screen shot shows
the file format. The leading semi-colon is required, followed by the name of the
sequence on a line by itself, followed by the mRNA/cDNA sequence to be folded. A one
must follow the last base of the sequence and be the last character in the file.
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count to a value .....2X the length of the sequence whereupon the "dot plot" will appear on the
monitor. By using the right mouse button, a menu will appear that allows the user to change the
energy interval over which the suboptimality will be displayed as well as changing the number of
colors used in the display. Each color then represents a fractional energy window within the
selected total increment from the minimum, which is also displayed in the lower left-hand comer
of the "dot plot" that appears, initially. Any regions of self-contained folding are located using
the cross-hairs. The bases at which the segment junctions occur can be selected, and their base
numbers appear on the display. It is desirable to identify any possible segments to reduce
computational time, which scales as the square of the length of the sequence being folded.
Once the lengths of any segments are determined, ~G~N values are calculated for each of
the segments. This can be done using the "dot plot" protocol above and selecting the optimal
folding energy. The program is then used in N-Best mode to generate the output files from
which ~G~E values are obtained for each target region. Again, the selections are made in the
following order. The regular run is chosen followed by N-best mode. The desired percentage is
10 with 1 traceback and a window size of O. The sequence filename is then entered followed by
selecting sequence 1. The start and end bases of the segment are entered and the default energy
files selected. Printer output is desired but not with output to the terminal. The output file name
for the structure file is then entered followed by 80 columns. The ct file is needed and its
filename entered. No region table is required. To specify the target region for the
oligonucleotide as being single-stranded, the "Single-Prohibit" (6) function is selected. The user
is then asked to enter the first base that will be single stranded and the length of the region that
will follow. Hence, the 5' base of the target region and the oligonucleotide length are entered
separated by either a space or return. The "Begin Folding" option is then selected. The counter
will begin and proceed until 2X of the length of the segment being folded. However, upon
completion of the count-up, the output files will be written into the home directory of the
program. This process is repeated for each target region along the mRNA. The output files are
collected in a single directory and the energy values extracted using the "grep" command in
UNIX.
Prompt:> more * .ct I grep EN > outputenergiesfile.txt
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This command writes the filename and line of the file containing the energy value into the
outputfile, which is then transferred to Excel for analysis. Two of the 4 energy parameters are
completed. As this process is quite repetitive, FORTRAN scripts were written to automatically
generate input files for the lma program (Appendices 2-4 through 2-6).
To obtain the ~G;H value for each oligonucleotide:target combination, a Perl script
(Appendix 2-2) and Mathematica file (Appendix 2-3) are used. First the Perl script is run on an
input file containing only the mRNAlcDNA sequence (no spaces or extraneous characters). The
output is controlled via the command line where the oligonucleotide length and progression step
are specified
Prompt:> process_seqs 17 1 inputfilename.txt > outputfilename.txt
where 17 is the length of the oligonucleotides and 1 is the step length. This command will
generate all possible 17-mer target sequences in the mRNA in 5' to 3' order as one single line.
This output file is the input to the Mathematica calculation file that calculates ~G;H' To run the
Mathematica file, it is only necessary to update the input filename to address the appropriate file
and directory as well as to update the length of oligonucleotide (both bolded for emphasis in
Appendix 2-3). From there, selecting compile entire notebook will generate all of the ~G;H
values. The input parameters in the Mathematica file have been structured to take into account
the backwards nature of the input (i.e., that the first base is the 5' base of the mRNA not of the
oligonucleotide) to ensure the calculation of the proper ~G;H value. As a check that the
processing using the Perl script was performed properly, the total number of calculated ~G;H
values is listed at the bottom of the output. The notebook file is then saved as text and opened in
Word where the extraneous characters are replaced to generate a single column listing only the
6.G;H values (Figure 2-A2). These are transferred to Excel for analysis. The only remaining
value to be calculated is ~G;s which will require a number of similar techniques to those
already described for each of the first three components.
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Figure 2-A2: Replacement of unnecessary characters
Mathematica output is converted to list of free energy values by using the "find and
replace" feature to eliminate all extraneous characters from within the list of values. A.)
The list of values as produced by Mathematica. The commas are replaced by carriage
returns. All other characters are deleted (replaced with nothing) to result in B.) the final
list of ~G;H values, which are then imported into Excel for analysis.
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To calculate ~G~s values, the mRNA sequence is first converted to its exact complement
in 5' - 3' order. This is accomplished using the "find and replace" feature of Word to replace
bases by their complementary bases (taking advantage of capitalization to distinguish those bases
that had been converted and those that were not). Subsequently, the order of the bases is
inverted using Excel to generate the 5' - 3' complement. The oligonucleotides must be in 5' - 3'
conformation to ensure use of the proper nearest neighbor pairs in calculating the folding
energies. The Perl script is then applied to generate a list of the oligonucleotide sequences, again
stepping by 1 base at a time. This file can then be used as an input for the lma program run with
DNA parameters. The window of folding is moved in steps the length of the oligonucleotides
such that each of the ~G~s is generated. By grepping for the energy values from the resulting
files, a list of energies can be generated. However, because of the requirement to have the
oligonucleotide sequences in 5' to 3' order, the ~G~s values are in reverse order and are inverted
using Excel. A sample of the Excel table containing all four energy components is shown in
Figure 2-A3. Only the negative ~G~s values are taken into account by applying the summation
formula shown on the formula line (Figure 2-A3).
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A
F3
Position -170.9 UN+RE OH OS Total
58 -165.9 . 5 -21.8 0.4 BITl- -.- ..
59 -165.9 5 -20.6 0.6 -15.6- ~~~. .... - ~~
60 -165.9 5 -21.2 .o:~_.,"..:J~.:.~..~..
61 -165.9 5 -20.3. Q.2 ~~1..~..~.... _
62 -165.9 5 -20.6 -1.7 '-13.9
63 -163.8 7.1_=_19..:6 -1.~_ _-J~.~._ __ :._ 1
64 -163.2 7.7 -20.2 0.2' -12.5 '
65 -163.2 7.7 -20.5 0.6 -12.8
66 -163.2 7.7 -20.1 -0.4 -12
67 -163.2 7.7 -20.9 -0.6 -12.6
68 -162.7 8.2 -21.1 -0.1 -12.8
69 -162.7 8.2 -21.1 0.9 -12.9 _ ..
SIM.t1 r----.,.-c-:::-----:uI:!l!:========::J;:~~
I II f:ll:J ~[jC A
Figure 2-A3: Excel table containing all energy components
Position refers to the 5' base on the mRNA to which the 3' base of the oligonucleotide is
complementary. The second column contains the total folding free energy for the mRNA
or segment (-170.9 kcal/mole) followed by the constrained folding energy for each target
region. The third column has the net folding cost, i.e., the constrained energy minus the
native energy of folding. The values from the Mathematica worksheet are listed in the
fourth column. The energies of folding the oligonucleotides are listed in column five.
The formula in the sixth column accounts for all of the proper signs by subtracting the
folding gains of the native mRNA and oligonucleotide to convert them to "unfolding"
costs. Also, the formula ensures that only negative values of oligonucleotide folding are
taken into account, eliminating possible but unfavorable oligonucleotide conformations.
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5.B. 2-2: Process seqs Perl script
Perl script for generating oligonucleotide files for calculating ~G;s' This Perl script was
first written by Thomas Y. Lee and modified by SPW. The file creates a single-line list
consisting of base segments of a user-defined length that are offset by a user-defined amount
(Figure 2-A4). The appropriate command line for generating the a list of 17mers offset each by
1 base (Figure 2-A4) is:
Prompt:> process_seqs 17 1 inputfilename.txt > outputfilename.txt
............... . . . . . . . . . . . . .
. . . . . . . . . . . . . .. . . . . . . . . . . . . .
#!/usr/athena/bin/perl
# ASSUMES:
# every line of input ends with a "\n"
# INPUTS
#$set_length = 10;
#$offset = 2;
#$input_file = "test_in.txt";
#$output_file = "test_out.txt";
# GET INPUTS
$set_length = @ARGV[O];
$offset = @ARGV[l];
$input_file = @ARGV[2];
$output_file = @ARGV[3];
# DEFAULTS
if ($set_length eq ""){
$set_length = 10;
}
if ($offset eq ""){
$offset = 1;
}
if ($input_file eq ""){
$input_file "&STDIN" ;
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}if ($output_file eq ""){
$output_file = "&STDOUT";
}
#print "$set_length \t $offset \t $input_file \n"; #debug
# CONSTANTS
$end_of_line_marker = "\n";
$i = 0;
@input_array = ();
@sequence_array = ();
$num_input_lines = 0;
$sequence = "11;
$temp = 1111;
$sequence_counter = 1;
open(FILE, lI$input_filell);
# careful! We assume that every line ends with a \n and so
# we use "chop" to get rid of it .... otherwise, you
# must use the s/end_of_line_marker//;
while($line = <FILE» {
# $line =-s/$end_of_line_marker//;
chop ($line) ;
push(@input_array,$line);
}
close (FILE);
open (OUTPUT_FILE, 1I>$output_filell);
">no. of input lines: $num_input_lines\n";
">sequence length: $set_length \t offset:
# OUTPUT_FILE HEADER
# print OUTPUT_FILE
# print OUTPUT_FILE
$offset \t input
filename: $input_file \n"; #debug
# no error checking here. We assume that there is at least one
line
# of input in the file.
# we also assume that the $offset is < $set_length
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# main loop: as long as there is input to read.
while{@input_array){
# initalize:
$temp = join(' ',@sequence_array);
$sequence = join(' ',$temp,shift(@input_array));
@sequence_array = split(' ',$sequence);
$sequence_Iength = @sequence_array;
# while there are still enough bases in the $sequence
while($sequence_length> $set_Iength) {
# print OUTPUT_FILE ">Sequence $sequence_counter\n";
# print the number of bases that are of interest.
for ($i = 0; $i < $set_Iength; $i++) {
print OUTPUT_FILE "$sequence_array[$iJ";
}
# print OUTPUT_FILE "\n" ;
# remove $offset number of bases
for ($j = 0; $j < $offset; $j++) {
shift(@sequence_array);
}
$sequence_Iength = @sequence_array;
$sequence_counter++;
}
# if you get to this point, then the $seguence is now too short
and
# it is time to get the next line of input.
} # end main loop.
# if you get to this point, you are out of input, and you are at
# the last sequence.
$temp = join(' ',@sequence_array);
# print OUTPUT_FILE ">Sequence $sequence_counter\n";
print OUTPUT_FILE "$temp\n";
close (OUTPUT_FILE);
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file fdit Yiew Insert FItrmat tjelp
GGGAGACCGGCCTCGAGGGAGACCGGCCTCGAGCGAGACCGGCCTCGAGCAAGACCGGCCTCGAGCAGGACCGGCCTCGAGCAGC
ACCGGCCTCGAGCAGCTCCGGCCTCGAGCAGCTGCGGCCTCGAGCAGCTGAGGCCTCGAGCAGCTGAAGCCTCGAGCAGCTGAAG:~
CCTCGAGCAGCTGAAGCCTCGAGCAGCTGAAGCTTCGAGCAGCTGAAGCTTCGAGCAGCTGAAGCTTGGAGCAGCTGAAGCTrGG::;:
•AGCAGCTGAAGCTrGGAG CAGCTGAAGCTrGGACCAGCTGAAGCTTGGACTAGCTGAAGC TrGGACTG GCTGAAGCTTGGA~~~
ForHelp,pressFl r~:~
Figure 2-A4: Screen shot of process_seqs output
Each possible oligonucleotide from the mRNA sequence is written to an output file.
Note that these "oligonucleotides" are actually the target sequences on the mRNA in 5' to
3' order, so the oligonucleotides would actually be those sequences complementary to the
above (e.g., 5'-AAAGCAAGTGTICTCCC-3' for the first position on the mRNA). Bold
text has been added to emphasize the overlap that results from movement of the
oligonucleotide sequences one base at a time. The process_seqs program can be run with
any length oligonucleotides with any step size (though it will result in an infinite loop for
a step size of 0). No spaces or other characters (other than return characters) can be
included in the input to the process_seqs algorithm as these characters would be written
into the output.
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5.C. 2-3: Mathematica input file
Mathematica input file for calculating ~G~H. This was first written by Abbey
Perumpanani and modified as needed by SPW.
(***********************************************************************
Mathematica-Compatible Notebook This notebook can be used on any computer
system with Mathematica 3.0, MathReader 3.0, or any compatible application.
The data for the notebook starts with the line of stars above. To get the
notebook into a Mathematica-compatible application, do one of the following:
* Save the data starting with the line of stars above into a file with a
name ending in .nb, then open the file inside the application; * Copy the
data starting with the line of stars above to the clipboard, then use the
Paste menu command inside the application. Data for notebooks contains only
printable 7-bit ASCII and can be sent directly in email or through ftp in
text mode. Newlines can be CR, LF or CRLF (Unix, Macintosh or MS-DOS style).
NOTE: If you modify the data for this notebook not in a Mathematica-
compatible application, you must delete the line below containing the word
CacheID, otherwise Mathematica-compatible applications may try to use
invalid cache data. For more information on notebooks and Mathematica-
compatible applications, contact Wolfram Research: web:
http://www.wolfram.com email: info@wolfram.com phone: +1-217-398-0700
(U.S.) Notebook reader applications are available free of charge from
Wolfram Research.
***********************************************************************)
(*CacheID: 232*) (*NotebookFileLineBreakTest NotebookFileLineBreakTest*)
(*NotebookOptionsPosition[ 12898, 263]*)
(*NotebookOutlinePosition[ 13550, 286]*) (*
CellTagsIndexPosition[ 13506, 282]*) (*WindowFrame->Normal*)
Notebook[{ Cell["(* INPUT PARAMETERS *) ", "Input"], Cell["(* Input the
number of elements in each sublist *)", "Input"], Cell[CellGroupData[{
Cell["n = 17", "Input"], Cell [BoxData[ \(17\)], "Output"] }, Open ]],
Cell[II\<\ (* Input the replacement values here for each pair *) (* Values
below are for 5' -> 3' RNA pairs NOT for \ complementary/oligonucleotide
sequences. *)\ \>", IIInputll], Cell["\<\ vals={{\"a\",\lIa\"}->-
1, {\"a\", \"g\II}->-1.8, {\"a\lI,\"c\II}->-2.1, {\lIa\",\"t\II}-\ >-
o .9,{\IIg\ II,\IIa\"}->-1.3, {\IIg\ ",\"g\ "}->-2.9, {\"g\ ",\"c\"}->-2. 7 ,{\IIg\ II,\"t\"\
}->-1.1,{\lIc\",\lIa\"}->-0.9, {\IIC\",\lIg\"}->-1.7,{\IIC\II,\"C\II}->-
2.1,{\"c\",\"\ t\"}->-0.9,{\"t\",\"a\"}->-0.6,{\"t\",\"g\"}->-
1.6,{\"t\",\"c\"}->-1.5,{\"t\",\ \"t\"}->-0.2,{\"A\",\IIA\"}->-
1, {\"A\", \"G\"}->-1.8, {\"A\", \IIC\"}->-2.1, {\"A\", \ \IIT\II}_>_
0.9,{\"G\",\IIA\II}->-1.3,{\IIG\II,\"G\"}->-2.9,{\"G\",\"C\1I}->-2.7, {\"G\
\",\"T\II}->-1.1,{\"C\II,\"A\"}->-0.9,{\"C\",\IIG\II}->-1.7,{\IIC\II,\"C\II}->-
2.1,{\ \IIC\II,\"T\"}->-0.9,{\IIT\",\"A\"}->-0.6,{\"T\",\"G\"}->-
1.6,{\"T\",\"C\II}->-1.\ 5,{\IIT\II,\IIT\II}->-0.2};\\>11, "Inputll], Cell["(*
----------END OF INPUT-------------------------*)II, "Input"], Cell[lIseq
ReadList[\"RabbitBetaRealOligos.seqs\",Character];", IIInputll], Cell[lItl =
Partition[seq,n];", "Input"], Cell["\<\ summ[j_]:=3.1 + \
Apply[Plus,Table[{tl[[j,i]] ,tl[[j,i+l]]},{i,1,Length[tl[[194lll-1}]/.valsl\
\>", "Input"], Cell ["(* -------------------OUTPUT-------------------------
*)", IIInput"l, Cell [CellGroupData[{
Cell["Table[summ[54],{i,1,Length[tl]}]", "Input"], Cell [BoxData[ \({\(-
19.899999999999995'\), \(-17.1999999999999975'\), \(-
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15.8999999999999985'\}, \(-15.9000000000000003'\),
16.200000000000001'\}, \(-15.8000000000000007'\),
16.8999999999999994'\}, \(-15.6999999999999984'\),
15.8000000000000007'\}, \(-20.3000000000000024'\),
18.9999999999999964'\}, \(-18.3999999999999985'\),
19.6000000000000014'\}, \(-
\(-
\(-
\(-
\(-20.'\),
\ (-
\(-
I
[One value produced for each oligonucleotide]
I
-21.0999999999999943'\), \(-19.7999999999999971'\), \(-
18.3999999999999985'\), \(-19.3000000000000007'\), \(-
18.3000000000000007'\), \(-17.8000000000000042'\), \(-
18.2000000000000028'\), \(-19.0000000000000035'\), \(-
20.9000000000000074'\)}\}], "Output"] }, Open ]], Cell [CellGroupData[{
Cell["Length[t1]", "Input"], Cell [BoxData[ \(317\)], "Output"] }, Open
]] }, FrontEndVersion->"Microsoft Windows 3.0", ScreenRectangle->{{O, 1024},
{O, 702}}, WindowSize->{500, 504}, WindowMargins->{{Automatic, 184},
{Automatic, 11}} ]
(***********************************************************************
Cached data follows. If you edit this Notebook file directly, not using
Mathematica, you must remove the line containing CacheID at the top of the
file. The cache data will then be recreated when you save this file from
within Mathematica.
***********************************************************************)
(*CellTagsOutline CellTagsIndex->{} *} (*CellTagsIndex CellTagsIndex->{} *}
(*NotebookFileOutline Notebook[{ Cell[1709, 49, 39, 0, 30, "Input"],
Cell[1751, 51, 67, 0, 30, "Input"], Cell[CellGroupData[{ Cell[1843, 55, 23,
0,30, "Input"], Cell[1869, 57, 36, 1, 29, "Output"] }, Open ]], Cell[1920,
61, 176, 5, 84, "Input"], Cell[2099, 68, 684, 10, 174, "Input"], Cell[2786,
80, 72, 0, 30, "Input"], Cell[2861, 82, 73, 0, 30, "Input"], Cell[2937, 84,
39, 0, 30, "Input"], Cell[2979, 86, 115, 3, 66, "Input"], Cell[3097, 91, 72,
0, 30, "Input"], Cell[CellGroupData[{ Cell[3194, 95, 48, 0, 30, "Input"],
Cell[3245, 97, 9533, 155, 713, "Output"] }, Open ]], Cell [CellGroupData[{
Cell[12815, 257, 27,0,30, "Input"], Cell[12845, 259,37,1,29, "Output"]
}, Open ]] } ] *}
(*********************************************************************** End
of Mathematica Notebook file.
***********************************************************************)
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5.D. 2-4: Batchlma
program repeat
integer i, j, k, 1, m, counter
character*30 filename
counter = 1
DO 10 i=1,26
DO 15 j=1,26
DO 18 k=1,26
C print *, i
C print *, char(i)
filename='RBGMYT70930Seq/'//char(i+64)//char(j+64)//char(k+64)
C print *, filename
open(unit=30, file=filename)
wr ite (30,20) I0 I
wri te (30,20) '0I
wr ite (3 0 , 2 0 ) '1'
wr ite (30,20) I10 I
wr ite (3 0 , 2 0 ) I 1 I
wr ite (30,20 ) '0I
write (30,20) 'NewT7Seq093000.txt'
wr ite (3 0 , 2 0 ) '1'
wr ite (30,20) I 1 '
wr ite (30,20) I510 '
write (30,20) 'dangle.dat'
write (30,20) 'loop.dat'
write (30,20) 'stack.dat'
write (30,20) 'tstackh.dat'
write (30,20) 'tstacki.dat'
write (30,20) 'tloop.dat'
write (30,20) 'miscloop.dat'
write (30,20) 'y'
write (30,20) In'
if (counter.ge.l0.and.counter.le.99) then
write (30,70) counter,'rbgmyT7seqfull.out'
endif
if (counter.ge.l00.and.counter.le.999) then
write (30,60) counter, 'rbgmyT7seqfull.out'
endif
if (counter.ge.l000.and.counter.le.9999) then
write (30,30) counter,'rbgmyT7seqfull.out'
endif
if (counter.ge.l.and.counter.le.9) then
write (30,80) counter, 'rbgmyT7seqfull.out'
endif
wr ite (30,20) '80 I
write (30,20) Iy'
if (counter.ge.l0.and.counter.le.99) then
write (30,70) counter, 'rbgmyT7seqfull.ct'
endif
if (counter.ge.l00.and.counter.le.999) then
write (30,60) counter, 'rbgmyT7seqfull.ct'
endif
if (counter.ge.l000.and.counter.le.9999) then
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write (30,30) counter, 'rbgrnyT7seqfull.ct'
endif
if (counter.ge.1.and.counter.le.9) then
write (30,80) counter, 'rbgrnyT7seqfull.ct'
endif
write (30,20) In'
write (30,20) '10'
write (30,20) 16'
write (30,40) counter
write (30,20) 117'
write (30,20) ,8'
close (unit=30)
counter = counter + 1
18 continue
15 continue
10 continue
20 format (A)
30 format (I4,A)
40 format (14)
60 format (I3,A)
70 format (I2,A)
80 format (I1,A)
stop
end
This program is used to generate input files for the lma program. The variables that are
adjusted for each run are:
the end values of the i, j, and k loops: The number of input files generated is controlled
by these loops. The output filenames are written with the sequence AAA, AAB,
etc. Each loop controls one of the letters (i.e., i controls the first character, j
controls the second character, k controls the third character). The total number of
generated files then is the product of the value of the 3 loops.
the directory name: This value follows the filename quantity (e.g., RBGMYT70930Seq).
This quantity should be updated to avoid writing over previously generated input
files. The directory must be created from the UNIX prompt prior to running the
compiled, executable file.
the sequence file name: This filename is the appropriately structured sequence file as
generated for lma. (e.g., NewT7Seq093000.txt)
the first base and last base to be folded: These values are found 2 and 3 lines below the
sequence file name (e.g., 1 and 510).
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the output sequence file names: These will be the structure file (e.g., rbgmyt7seqful.out)
and ct file (e.g., rbgmyt7seqful.ct). The leading values of these output files will
be modified by the nested loops so as not to overwrite each other.
the oligonucleotide length: This line follows the counter line near the end of the file (e.g.,
17).
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5.E. 2-5: Batchcreate
program repeat
integer i, j, k, 1, m
character*30 filename
1 1
i = 1
k 1
j 1
DO 10 i=l,l
DO 15 j=1,20
DO 18 k=1,26
C print *, i
C print *, char(i)
filename='EColi5S01igos/'//char(i+64)//char(j+64)//char(k+64)
C print *, filename
open(unit=30, file='EColi5S01igosbatch')
write (30,20) './lrna < '/ /filename
close (unit=i+10)
C print *, 1
1 = 1 + 1
18 continue
15 continue
10 continue
20 format (A)
30 format (14,A)
40 format (14)
stop
end
This program is used to generate the batch file that will run the multiple lma jobs in
succession. The variables that are adjusted for each run are:
the end values of the i, j, and k loops: This will insure that the batch file uses the same
input files that were generated by batchlma.
the directory name: This value follows the filename quantity (e.g., EColi5S0ligos) and
should match the directory used in the batchlma file. This quantity should be
updated to ensure the proper input files are selected.
the batch file name: This file will be created and written with the instructions to run the
lma jobs. This file will need to be made executable from the UNIX prompt prior
to running.
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5.F. 2-6: Batchlfe
program repeat
integer i, j, k, I, m, counter, counternew
character*30 filename
counter = 15
counternew = 1
DO 10 i=l,l
DO 15 j=l,5
DO 18 k=l,26
C print *, i
C print *, char(i)
filename='EColi5S0ligos/'//char(i+64)//char(j+64)//char(k+64)
C print *, filename
open(unit=30, file=filename)
wr ite (3 0 , 2 0 ) I 0 I
wri te (30,20) 10'
wr ite (3 0 , 2 0 ) I 1 I
write (30,20) '101
wr ite (3 0 , 2 0 ) I 1 I
wr ite (3 0 , 2 0 ) '0 I
write (30,20) 'Ecoli5S.seq'
wr ite (30,20) I 1 I
write (30,40) counternew
write (30,40) counter
write (30,20) 'dangle.datd'
write (30,20) 'loop.datd'
write (30,20) 'stack.datd'
write (30,20) 'tstackh.datd'
write (30,20) 'tstacki.datd'
write (30,20) 'tloop.datd'
write (30,20) 'miscloop.datd'
write (30,20) Iyl
write (30,20) Inl
if (counternew.ge.10.and.counternew.le.99) then
write (30,70) counternew,'Ecoli5S0ligo.out'
endif
if (counternew.ge.l00.and.counternew.le.999) then
write (30,60) counternew,'Ecoli5S0ligo.out'
endif
if (counternew.ge.l000.and.counternew.le.9999) then
write (30,30) counternew,'Ecoli5S0ligo.out'
endif
if (counternew.ge.l.and.counternew.le.9) then
write (30,80) counternew, 'Ecoli5S0ligo.out'
endif
wr ite (30,20) ,80 '
wri te (30,20) Iy'
if (counternew.ge.l0.and.counternew.le.99) then
write (30,70) counternew, 'Ecoli5S0ligo.ct'
endif
if (counternew.ge.l00.and.counternew.le.999) then
write (30,60) counternew, 'Ecoli5S0ligo.ct'
endif
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if (counternew.ge.1000.and.counternew.le.9999) then
write (30,30) counternew, 'Ecoli5S0ligo.ct'
endif
if (counternew.ge.1.and.counternew.le.9) then
write (30,80) counternew, 'Ecoli5S0ligo.ct'
endif
write (30,20) In'
wr ite (30,20) '10'
wr ite (30,20) I 8 I
close (unit=30)
counter = counter + 1
counternew = counternew + 1
18 continue
15 continue
10 continue
20 format (A)
30 format (I4,A)
40 format (I4)
60 format (I3,A)
70 format (I2,A)
80 format (I1,A)
stop
end
This program is used to generate the input files that will be used to calculate the
oligonucleotide folding energies. The variables that are adjusted for each run are:
the end values of the i, j, and k loops: These need to be adjusted to generate enough input
files for each oligonucleotide within the mRNA.
the initial value of the "counter" variable: This value should be the oligonucleotide
length.
the directory name: This value follows the filename quantity (e.g., EColi5S0Iigos). This
quantity should be updated to avoid writing over previously generated input files.
The directory must be created from the UNIX prompt prior to running the
compiled, executable file.
the output sequence file names: These will be the structure file (e.g., Ecoli5S0Iigo.out)
and ct file (e.g., Ecoli5S0Iigo.ct). The leading values of these output files will be
modified by the nested loops so as not to overwrite each other.
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5.G. 3-1:Mechanistic Description of RNase H Activity
We found experimentally that the rate of cleavage product formation in RNase H assays
followed first-order (exponential) kinetics. This rate is dependent on an interplay between
association and dissociation of oligonucleotide:RNA duplexes and the kinetics of recognition
and cleavage of duplexes by the ribonuclease H enzyme. Here, we present an analysis of the
functional dependence of cleavage product formation under two regimes: binding limited and
RNase H limited. In each case, we seek to find how the apparent first-order rate constant
depends on measurable parameters of the oligonucleotide:RNA interaction.
We consider, in general, the reaction scheme:
(12)
(13)
where 0 is the oligonucleotide, M is the mRNA, D is the duplex that they form with association
rate constant ka and dissociation rate constant kd, and X is the RNA cleavage product, which is
formed in the presence of RNase H enzyme, E, with Michaelis-Menten parameters Km and kcat.
Under the experimental conditions used, the total concentrations of oligonucleotide and mRNA,
OTand MT, are each 50 nM; as a result, no simplification based on molar excess can be made.
We consider two cases:
Case 1: Binding limited (catalysis » binding)
If the rate of association is slower than catalysis, so must be the rate of dissociation, so
the reaction network is essentially:
O+M~D E ~X+O--, (KM,kca,) •
In this sequence, RNA is removed only by association with oligonucleotide, which is
regenerated during the catalysis step, resulting in a first order decay on mRNA:
M = M re-kaOTf • (14)
Since the duplex is rapidly recognized by ribonuclease H and converted into RNA
cleavage product and regenerated DNA oligonucleotide, the quasi-steady-state approximation
applies on D:
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dD =k OM
dt a
(15)
This equation is simplified since, under the experimental conditions, D «KM• Solving
for D and combining with Eq. 15 and the mass balance MT =M +D +X gives an approximate
profile for X, valid subject to the aforementioned approximations at times after the quasi-steady-
state is established
Thus, first order kinetics are expected, with an effective rate constant
keff = kaOT•
(16)
(17)
The total concentration of oligonucleotide was fixed at 50 nM for all of the RNase experiments
performed here. Therefore, the line corresponding to Eq. 17 is shown in Figure 3-7.
Case 2: Reaction limited (binding » catalysis)
We begin with the rate equation for the formation of cleavage product:
dX = v = kcatEOD ::::::kcatEOD .
dt KM +D KM
(18)
If binding is rapid, the oligonucleotide, mRNA, and duplex forms will essentially be in
equilibrium. The equilibrium relationship among 0,M, and D, along with mass balances on °
and M and the rate equation for X provides four equations in the four unknowns 0,M, D, and X.
The solution for X is:
(19)
Again, first-order kinetics is expected, in this case with a rate constant
(20)
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For all of the oligonucleotides on which RNase assays were performed, the dissociation constant
was significantly less than the oligonucleotide concentration. Therefore,
k ~ kcatEO
eff K
M
(21)
Based on the specifications of the ribonuclease H supplier (Promega) and published value
of the Michaelis constant (0.2 J..lM,[215]), the expected value of keffunder conditions of high
binding is about 0.1 S-l, two orders of magnitude higher than observed (Figure 3-7). Since we
observed the predicted behavior for low ka value and observe the predicted plateau, the
discrepancies in magnitude may be due to loss of activity of the RNase H enzyme through
storage, exposure to buffer, or product inhibition/degradation.
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Protocol for RNase H cleavage assay
As the concentrations of oligonucleotide and mRNA used in the RNase H cleavage experiments
are higher that those for the binding affinity assays, these assays can be performed in
microcentrifuge tubes without concerns of significant loss to binding of the tube walls.
The most critical aspect in the preparation of the RNase cleavage experiments is to have your
RNase H concentration low enough to prevent non-specific degradation from enzymatic and
buffer components while high enough to achieve a binding-limited condition for the slowest
binding oligonucleotides. This balance also depends on the target being used. Of the two targets
that I used, the longer transcript, LDH-A, was much more susceptible to
RNase H cleavage buffer (IX):
0.1 M KCl, 10 mM MgCh, 1 mM DTT, and 50 mM Tris-HCl (pH 8.0)
Protocol:
1. Dilute stock oligonucleotide to the 3X concentration with cleavage buffer and water. Stock
oligonucleotides should be stored at greater than 10 J!M concentration. A good choice for
the final working concentration to be tested is 50 nM oligonucleotide (150 nM initial
dilution). This can be adjusted, as needed. A total volume of the final reaction mixture will
be required such that 3 J!L can be extracted for each time point with greater than 15 J!L of
total volume remaining after the last sample is removed. The excess volume provides ballast
to the system, such that the change in volume due to evaporation is small, precluding the
need for mineral oil.
2. Remove mRNA from -80°C freezer and place at 4°C to thaw.
3. Dilute RNase H (Promega) to 3X working concentration in cleavage buffer. Typical working
concentrations of RNase H were 0.1 to 0.2 units/J!L in the final reaction.
4. Add 1 volume of RNase H dilution to 1 volume of oligonucleotide dilution.
5. Retrieve RNA from refrigerator and dilute to 3X working concentration in cleavage buffer.
6. Place all reagents in 37°C water bath for 10 minutes.
7. At time 0, add 1 volume of RNA to oligonucleotide:RNase H mixture. Mix well and extract 3
J!L for the time 0 sample. Add the sample to 9 J!L of denaturing gel-loading buffer
(Ambion). Different denaturing gel-loading buffers are required depending on the type of gel
being used (see step 9, below). Store the sample on dry ice.
8. Extract samples at approximately 1', 2', 5', 10', 15', and 30'. If the RNA is particularly stable
or the binding particularly slow, longer time points may be required.
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9. Just prior to loading, heat the samples to 50-70°C (again, will change with stability of
transcript). Immediately load on appropriate gel (either formaldehyde/agarose (reagents
available from Ambion) for transcripts> 600 nt or 5/10% TBE-Urea (Bio-Rad) for shorter
transcripts).
10. Electrophorese for .....20-60 minutes (depends on gel type and transcripts/cleavage product
lengths) at 100-150 volts (constant voltage).
11. Stain gel using SYBR Gold (Molecular Probes) (stock at 10,000X concentration). Staining
can require 1 to 16 h (stains longer than 4 h should be performed at 4°C) and should be
protected from light exposure.
12. Measure the fluorescence signal from the gel using the Fluor-S system (Bio-Rad). Use
Multi-Analyst software to measure the intensities of the full-length transcript and the two
cleavage products. These intensities are used to calculate fraction cleaved which is then fit
by a pseudo first-order kinetic equation to calculate kef!.
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5.H. 3-2: mRNA and Oligonucleotide Purity
Oligonucleotide and mRNA purity are critical factors in ensuring the accuracy of the KD
values obtained from the centrifugal technique. In the case of the mRNA, it is essential to verify
the mR A purity from the in vitro transcription reaction prior to proceeding. In the experiments
described here, the first in vitro transcript was produced using the SP6 transcription enzyme
system. However, it was found that this enzyme did not process through the mRNA completely,
instead resulting in a large fraction of incomplete transcription products (Figure 3-A1). When
this was discovered, the insert was cloned into another vector behind the T7 RNA polymerase
promoter, and transcription was performed using the T7 polymerase. In this case, the resulting
transcript was of full-length with no specific contaminants (Figure 3-A1). Depending on the
length of the contaminants, binding affinity results for oligonucleotides that interacted with the
incomplete transcripts could have been biased higher or lower with no consistency. Working
with a single pure transcript of known concentration is essential to accurately measure KD.
The purity of the oligonucleotide was also essential. It is recommended that
oligonucleotides be used within 6 months of being resuspended and stored at -20°C or within 1
year of synthesis and storage at -20°C. However, even within this time frame, a significant
amount of smaller sequences can exist even in HPLC purified oligonucleotide preparations. The
presence of labeled degradation products can significantly affect the measurement of KD by the
centrifugal method. The presence of significant degradation products is suggested when the
measured binding of the oligonucleotide saturates at a level significantly lower than 100%, e.g.
75-85% (Figure 3-A2). The most reliable method found for ensuring complete purification of
the oligonucleotide from any degraded products was ucAway Spin columns (Ambion; Austin,
TX). In addition, PAGE purification was possible, but elution and precipitation of radiolabeled
oligonucleotides proved particularly challenging.
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Figure 3-Al: Confirming RNA Purity from in vitro transcription
Transcription using the SP6 RNA polymerase and promoter results in a significant
fraction (-10-20% by mass) of incomplete transcription products. Some RNA
polymerases are sensitive to local structure and fall off the template prior to completion
of the mRNA. However, use of the T7 polymerase and promoter eliminates this product,
yielding the full length product almost exclusively. Signal intensity exaggerated to prove
elimination of smaller cleavage product not due to lower concentration of T7 product
(last dilution of SP6 RNA comparable to highest concentration of T7).
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Figure 3-A2: Binding Saturation due to Degraded Oligonucleotide
Binding curves are shown for oligonucleotides 139 (circles) and 259 (squares)
complementary to the RBG mRNA. Closed symbols show binding in the presence of
degraded oligonucleotide products. Open symbols show binding following purification
of the full-length oligonucleotide. Saturating fractional binding increased from 78% to
92% and 83% to 95% for oligonucleotides 139 and 259, respectively. In no case was
complete binding seen in the presence of oligonucleotide degradation products, with
saturation values varying between 75 and 85%, typically.
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Linearization of plasmid template for In Vitro Transcription (IVT)
Plasmids prepared from Qiagen prep kits (Mini, Midi, Maxi) are sufficient for application in in
vitro transcription.
1. Add the following reagents in the following order:
17-X-Y J.lL Water
2 J.lL Enzyme Buffer
X J.lL Plasmid*
Y J.lL Restriction Enzyme *
*The volumes are written for a 20 J.lLreaction and can be scaled as needed. The volume
of plasmid added will vary depending on the concentration from the prep. The final
concentration of plasmid in the digestion should be at least 500 JlglmL to ensure
sufficient concentration for the subsequent IVT. Enzyme should be added at a
concentration of ....5-10 units/J.lg of plasmid.
2. Incubate at the appropriate digestion temperature for the enzyme (usually 37°C) for 16 h.
3. Purify linearized plasmid by Wizard DNA cleanup kit (Promega), agarose gel and extraction,
or phenol-chloroform extraction. The Wizard kit provides sufficient recovery/purity and
is the simplest of these methods. Other comparable column-based methods are probably
available from many manufacturers. The Wizard protocol is copied below from the
Promega documentation.
Wizard Protocol (from the Promega Web Site):
Notes:
1. Thoroughly mix the Wizard @ DNA Clean-Up Resin before removing an
aliquot. If crystals or aggregates are present, dissolve by wanning the resin to
37°C for 10 minutes. The resin itself is insoluble. Cool to 25-30°C before use.
2. The binding capacity of Iml of resin is approximately 20jlg of DNA.
Materials to Be Supplied by the User:
80% isopropanol (2-propanol, reagent grade)
Prewarmed (65-70°C) deionized water or TE buffer
Disposable 3ml Luer-Lok @ syringes
Note: The sample volume must be between 50 and 500jll. If the sample volume is less
than 50jll, bring the volume up to at least 50lLIwith sterile water.
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1. Use one Wizard @Minicolumn for each sample. Remove and set aside the plunger from a 3ml
disposable syringe. Attach the Syringe Barrel to the Luer-Lok@ extension of each
Minicolumn.
2. Add Iml of Wizard @DNA Clean-Up Resin to a 1.5ml microcentrifuge tube. Add the sample
(50-500p,1) to the Clean-Up Resin and mix by gently inverting several times.
3. Pipet the Wizard @DNA Clean-Up Resin containing the bound DNA into the Syringe Barrel.
Insert the syringe plunger slowly and gently push the slurry into the Minicolumn with the
syringe plunger.
4. Detach the syringe from the Minicolumn and remove the plunger from the syringe. Reattach
the Syringe Barrel to the Minicolumn. To wash the column, pipet 2 mL of 80%
isopropanol into the syringe. Insert the plunger into the syringe and gently push the
solution through the Minicolulnn.
5. Remove the Syringe Barrel and transfer the Minicolumn to a 1.5ml microcentrifuge tube.
Centrifuge the Minicolumn for 2 minutes at maximum speed (10,000 x g) to dry the
resin.
6. Transfer the Minicolumn to a new microcentrifuge tube. Apply 50JlI (see Table 1) of
prewarmed (65-70°C) water orTE buffer (10mM Tris-HCI [pH 7.6], 1mM EDTA) to the
Minicolumn and wait 1 minute. (The DNA will remain intact on the Minicolumn for up
to 30 minutes.) Centrifuge the Minicolumn for 20 seconds at maximum speed (10,000 x
g) to elute the bound DNA fragment.
7. Remove and discard the Minicolumn. The purified DNA may be stored in the microcentrifuge
tube at 4°C or -20°C.
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Protocol for IVT (from Ambion MegaScript Kit)
Note: The choice of enzyme system used for the IVT does matter. SP6 is "old technology" and
should be considered only as a last resort. T7 and T3 are both very common and reliable.
1. Thaw the frozen reagents -- Place the RNA Polymerase Enzyme Mix on ice, it is stored in
glycerol and will not be frozen at -20°C. Vortex the lOX Reaction Buffer and the 4
ribonucleotide solutions (ATP, CTP, GTP, and UTP) until they are completely in
solution. Once they are thawed, store the ribonucleotides on ice, but keep the lOX
Reaction Buffer at room temperature while assen,bling the reaction. All reagents
should be microfuged briefly before opening to prevent loss and/or contamination of
material that may be present around the rim of the tube.
2. Assemble transcription reaction at room temperature -- The spermidine in the lOX
Reaction Buffer can coprecipitate the template DNA if the reaction is assembled on ice.
Add the lOX Reaction Buffer after the water and the NTPs are already in the tube. The
following amounts are for a single 20 JLl reaction.
3. Mix thoroughly -
12-X p,l Nuclease-free Water
2 p,l ATP solution
2 p,l CTP solution
2 p,l GTP solution
2 p,l UTP solution
2 p,l lOX Reaction Buffer
1 p,g (in X pJ H20) linear template DNA
2 P, 1Enzyme Mix
Gently flick the tube or pipette the mixture up and down gently, and then microfuge tube
briefly to collect the reaction mixture at the bottom of the tube. For convenience, mix
equal volumes of the four ribonucleotides solutions together and add 8 ILlof the mixture
to a standard 20 ILlreaction instead of adding the ribonucleotides separately. Reactions
can be scaled for desired recovery. Typically, 20-40 Jlg/20 Jll reaction (specs for kit say
....100 Jlg, but Inever got that sort of yield).
4. Incubate at 37°C, 2-4 hours -- The first time a new template is transcribed, the
recommended incubation time is 2-4 hours. The optimal incubation time for a given
template will vary depending on the size and transcriptional efficiency of your template.
For short transcripts (less than 500 nt), a longer incubation time (up to ....16 hours) may be
advantageous, since more transcription initiation events are required to synthesize a given
mass amount of RNA, compared to transcription of longer templates.
5. Remove template DNA -- For many applications it may not be necessary to degrade the
template DNA, since it will be present at a very low concentration relative to the RNA.
a. Add 1 ILlDNase 1, and mix well (the reaction may be viscous).
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b. Incubate at 37°C for 15 minutes
6. Phenol:chloroforrn extraction and isopropanol precipitation -- This is the most rigorous
method for purifying transcripts. It will remove all enzyme and most of the free
nucleotides from MEGA script reactions. Since the RNA is precipitated, it can also be
used for buffer exchange.
a. Add 115 JLI Nuclease-free Water and 15 JLI Ammonium Acetate Stop Solution,
and mix thoroughly.
b. Extract with an equal volume of phenol/chloroform (it can be water-saturated,
buffer-saturated, or acidic), and then with an equal volume of chloroform.
(Optional: back-extract the organic phase with 50 JLI dH2 0.)
c. Precipitate the RNA by adding 1 volume of isopropanol and mixing well.
d. Chill the mixture for at least 15 minutes at -20°C. Centrifuge at 4°C for 15
minutes at maximum speed to pellet the RNA. Carefully remove the supernatant
solution and resuspend the RNA in a solution or buffer appropriate for your
application.
e. Store frozen at -70°C.
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5.l. 3-3: Execution of centrifugal and gel-shift assays
In all experiments involving mRNA, freshly autoclaved tips were used. This was found
to be sufficient to eliminate most concerns of RNase degradation of the mRNA. The centrifugal
assay is performed in plates available from Coming specifically designed to have a non-binding
surface that limits absorption of biological molecules to low levels [Product #: 3600]. These
plates were used to ensure that when working with very low oligonucleotide concentrations no
oligonucleotide would be "lost". While the mRNA was generally maintained at a significantly
higher concentration, for the highest affinity oligonucleotides, minimum RNA concentrations
were in the picomolar range and adsorption was also a concern. The use of adhesive plate
sealers limited evaporation over the 16+ hours required for some measurements with generally
>95% of the hybridization volume retained. The only exception was the outermost wells, where
evaporation was a significant problem. Hence, these wells were not used for long-term
incubations in any cases.
For equilibrium KD measurements, hybridization reactions were left for at least 16 hours
but less than 20 hours with no changes in fractional binding having been observed over this time
frame. For each condition, 53 JlL of mRNA at the desired concentration and 53 JlL of
radiolabeled oligonucleotide at the minimum detectable concentration are added to each well of
the plate. Each of the dilutions is performed to a final dilution of IX hybridization buffer so that
following mixing the buffer concentration is still IX. The total volume could be increased to -
250 JlL if additional sensitivity was required, but this was not done in this case to avoid
splashing onto the plate cover or cross contamination of the wells. The concentration of
oligonucleotide prior to addition to the mRNA was diluted to -10-40 cpmlJlL thereby yielding
1000-4000 cpm in the final scintillation count. The sealed plate was then placed at 37°C for 16+
hours after which it was returned to the bench. 100 JlL of hybridization volume were removed
from each well and added to each filter apparatus. The filter was centrifuged for -50 seconds at
8,200 g (10,000 rpm on an Eppendorf microcentrifuge). The membrane is then inverted into a
new centrifuge tube and centrifuged for 30 seconds at 8,200 g to collect the retentate. The
samples are then measured immediately or placed on dry-ice for analysis at a later time. Since
the fractions have been separated, already, complex separation or formation after separation will
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not affect the final scintillation count. No difference was seen between the counts recovered
from frozen or unfrozen samples.
The volumes of each of the fraction are measured using a 10-100JlL pipet. After
collecting the volume at the bottom of the tube (if necessary), the pipet is set to a volume .....5 JlL
below the expected volume of the fraction. The volume is then taken up by the pipet. If solution
remains in the tube, the uptake volume of the pipet is increased by 1 JlL and the process repeated
until the end of the pipet fills with air. The pipet volume is then decreased by 1 J!L, and the step
increases in pipet volume are decreased to 0.2 JlL. The volume on the pipet at which the pipet
tip first begins to fill with air is used as the final volume measured. In tests where a random
volume was placed in the tube and then measured using this method, errors were found to be no
more than 1 J,AL, or in general <3-5% of the total measurement.
Once the volume is recovered completely from the tube, it is added directly to the
scintillation fluid (Ultima Gold, Packard Biosciences). Many scintillation fluids were tested to
ensure complete solubilization of the 1M aCI containing buffer. 5 mL of scintillation fluid
were found to be sufficient to completely solubilize the 30-60 JlL of hybridization volume that
would typically be added. However, following addition of the hybridization solution, the vial
must be mixed vigorously, to eliminate precipitation of the oligonucleotide-containing
hybridization volume. It was found most convenient to write the volume of the sample directly
onto the lid of the scintillation vial and then record them all during/after counting, but this is
certainly not essential. Scintillation counts were run for 10 minutes each to ensure collection of
a sufficient sample size to accurately measure the counts within. This is particularly important at
the highest mRNA concentration where the counts will be contained mostly in the retentate
fraction, little free oligonucleotide being present. The background counts from vials containing
only scintillation fluid were subtracted from all measured points. Background measurements
were performed at least at the beginning of each set of counts, though usually at the beginning,
end, and up to twice internally depending on the total number of samples being counted. No
difference was seen between vials containing only scintillation fluid and those containing IX
hybridization buffer. As the only readout from the scintillation counter was paper printouts, the
values wer hand-transcribed into Excel for analysis. Original printouts were taped into a
laboratory notebook for later reference.
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Oligonucleotide:mRNA hybridization for centrifugal and gel-shift assays
For all manipulations involving RNA, only fresh, sterile tips (had not been opened subsequent to
autoclaving) were used. If concerns of RNase contamination still exist, treat tips with DEPC-
water prior to autoclaving. The work surface and pipets should be wiped with RNaseZap
(Ambion) prior to use with RNA. This further limits RNase contamination. (Side note: I and
others have found that products from Ambion are generally speaking the best among comparable
groups of products, both by price and quality.)
All rnRNA and oligonucleotide dilutions were performed in Non-Binding Surface plates
(Coming), when possible. When dilution volumes exceeded 330 Jll, Eppendorf tubes were used
for the initial dilution and the volume subsequently transferred to an appropriate number of wells
on the plate.
All radioactive materials should be handled and disposed of properly.
Hybridization buffer (from Turner's group information):
1M NaCl, 0.5 mM EDTA, and 20 mM sodium cacodylate, pH 7.0
Procedure:
1. Plan experimental dilutions - These will depend on the age of the radiolabel as well as the
concentration of the stock RNA, but an example of a typical matrix for one of my experiments is
shown below:
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The "Oligo" section at the top of the matrix lists the oligonucleotide name, the current label
concentration (an indicator of the efficiency of the labeling reaction and measured for each
oligonucleotide when labeled and calculated, thereafter), the ratio of the current label
concentration to the minimum/working level, and the total volume required for the
experiment.
The next section shows the dilutions that are necessary for the rnRNA. The columns are as
follows: Final concentration in the hybridization mixture, amount of RNA from the prior
dilution that is required to reach the concentration (except for the first row where it indicates
the amount of stock rnRNA), the amount of 2X hybridization buffer that should be added to
each dilution, the amount of water that should be added to each dilution, the maximum
volume that the dilution achieves (to determine if the use of Eppendorf tubes is necessary),
the volume remaining after extracting the amount required for the next serial dilution, the
needed volume, and the final excess (should not be less than 5 J..lL in any case). The final two
columns show the desired concentration points and the normalized difference between the
actual and the desired. Shading indicates those dilutions that exceed 330 J..lL and will require
Eppendorf tubes.
The third section shows the oligonucleotide dilutions required to reach the final working
concentration and volume required for the experiment. The columns are as follows: the
oligonucleotide name, the amount of the stock, labeled oligonucleotide required, the amount
of 2X hybridization buffer required, and the amount of water required. Thus, both the
rnRNA and oligonucleotide are in IX hybridization buffer at their final dilution.
The final box contains the dilution to obtain the required amount of IX hybridization
required to perform the controls. This dilution, as it contains no nucleic acids, can be
performed in the plate or in an Eppendorf tube depending on the required volume.
2. Plan out the locations on the plate where these dilutions will be performed (example below).
The outermost wells on the plate should not be used for hybridization reactions, as they tend
to evaporate more than their internal counterparts.
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Not having planned the plate beforehand will surely result in a pipetting mistake. The labels
indicate the locations of the mRNA dilutions (e.g., R167), oligonucleotide dilutions (058),
and the hybridization wells (058 +RO.1). Controls were run with oligonucleotides mixed
with IX hybridization buffer (058 +HB).
3. Add 2X hybridization buffer and water to dilution and hybridization wells as delineated by the
experimental plan and plate grid.
4. Remove mRNA from -80°C freezer and place at 4°C to thaw.
5. Remove labeled oligonucleotides from 4°C and add correct volumes to appropriate wells.
Return labeled, stock oligonucleotides to refrigerator.
6. Pipet 55 ilL of diluted oligonucleotide to each appropriate well. To yield 100 ilL for the
centrifugal assay while providing excess for plate wetting, etc., 110 ilL are used. When gel-
shift assays are also being performed, an additional 10 ilL per gel lane should be added.
7. Remove thawed mRNA from refrigerator, spin down, and add to appropriate well. Perform
serial dilutions as described by experimental plan.
8. Pipet 55 ilL of diluted mRNA to each appropriate well. To yield 100 ilL for the centrifugal
assay while providing excess for plate wetting, etc., 110 ilL are used. When gel-shift assays
are also being performed, an additional 10 ilL per gel lane should be added.
9. Seal the plate tightly with an adhesive plate sealer. Incubate in the warm room (37°C) for
desired time. Equilibrium measurements were made between 16 and 20 hours of incubation.
For centrifugal assay (for gel-shift, skip to next section):
10. Prepare and label Microcon tubes. Prepare bucket of dry ice. Add scintillation fluid to the
required number of vials. Either 7mL or 20 mL vials are sufficient.
11. Remove plate from warm room and peel back adhesive sealer to uncover wells to be assayed.
12. Add 100 ilL of hybridization mixture to each filter, pipetting all of the wells for a given
oligonucleotide and the same time.
13. Transfer loaded filters to microcentrifuge and centrifuge at 10,000 rpm (.....8,200 g) for 40-50
seconds. The resulting permeate should be about 50 ilL.
14. Invert the filter into a new tube, placing the collected permeate on dry ice.
15. Collect the retentate by centrifuging the inverted filter for 20 seconds at 10,000 rpm.
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16. Place the filter into a scintillation vial and label the cap. Place the retentate on dry ice.
Retentate and permeate samples can be stored at -20°C for up to 2 days with no appreciable
change in signal recovery.
17. Thaw retentate and permeate samples on ice. Spin down quickly, to collect contents at the
bottom of the tube.
18. Set the pipet at less than the expected volume for the fraction being measured. Pipet up the
volume in the tube, twice. If no air bubble exists in the pipet tip subsequent to the second
uptake, increase the volume setting on the pipet by 1 JlL. When an air bubbles appears,
reduce the pipet uptake setting by 1 JlL and increase in increments of 0.2 JlL. The first
reading at which the air bubble reappears is the volume of the collected fraction. Add this
volume to the scintillation vial and label the cap. This technique was able to measure
volumes within 1-2 JlL, or 2-6% of typical values.
19. Count all vials. Calculate fraction bound for each retentate/permeate pair by:
R-VR(PY)Kmemb [free oligo] Rf"'~f = IVp . K = retentate= /VR
R + P 'memb [free oligo] ~Vpermeate
p
where: P, R = total CPM in permeate, retentate fractions
Vp, VR = volume of permeate and retentate fractions
Kmemb is determined experimentally on the oligonucleotide only sample.
20. Calculate KD from:
f= Mr
Mr+KD
where: MT = the concentration of mRNA used for each sample (assumed constant).
For gel-shift assay:
10. Remove 10 JlL of hybridization volume from the plate and add to 2 JlL of 6X loading buffer
(contains glycerol, xylene cyanole, and bromophenol blue; recipe from Maniatis; Thanks,
AmI!)
11. Add 12 JlL of mixture to each well of a 15-well, 4-20% TBE Ready Gel (Bio-Rad).
12. Electrophorese for ....45 minutes (until the dye front reaches 75% of the way down the gel) at
80-100 volts (constant voltage).
13. Remove gel from apparatus and separate plates, leaving the gel on the larger, plastic plate.
14. Adhere a piece of 2-ply (folded over onto itself) Whatman filter paper to the gel. Trim paper
to size of gel with 1 inch margin.
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15. Dry gel for 45 minutes at 80°C under vacuum.
16. Erase OS-525 beta-imaging cartridge.
17. Transfer dried gel to exposing "darkroom". Tape down gel securely and cover with securely
taped cover foil (Bio-Rad).
18. Expose gel for 16-48 hours, depending on signal required.
19. Scan cartridge using OS-525 Molecular Imager (Bio-Rad).
20. Using Multi-Analyst software (Bio-Rad), measure intensity of bound and free radioactivity
bands. Calculate fraction bound as intensity of bound band divided by the total of the bound
and free bands. Calculate KD as above for centrifugal assay.
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5.1. 4-1: Antisense assay protocol
Materials:
Lipofectin reagent (Gibco/Invitrogen) - A newer product, OligofectAMINE seems to be less
stressful for the cells and should be evaluated for future antisense applications, as that is
it's designated purpose.
Oligonucleotides - Oligonucleotides should be HPLC purified and resuspended in TE (or other
alkaline buffer) to at least 10 JlM concentration. Resuspended oligonucleotides can be
stored at -20°C for 6 months to 1 year. To simplify matters, resuspended
oligonucleotides should be filtered by 4 mm syringe filter into sterile microcentrifuge
tubes for storage.
Serum-Free Medium - DMEM has traditionally been used, but Gibco recommends trying their
Opti -MEM product.
Note: Volumes and concentrations will vary, depending on the cells and plate well size. The
procedure below is used for a 24-well plate and can be scaled as needed. Cells should be fed
with fresh medium on the day prior to use in experiments.
Procedure:
1. Dilute lipofectin in serum-free medium and let stand for 30-45 minutes at room temperature -
to a concentration with positive charges equal to the negative charges of the oligonucleotide.
The stock lipofectin is 746 JlM in positive charges. A total of 15 mL lipofectin media is
sufficient for 1 24-well plate.
2. Aliquot lipofectin media into the appropriate number of tubes, 1 tube per oligonucleotide.
3. Add oligonucleotide directly to lipofectin media. Mix gently. Let stand for 15 minutes.
4. Aspirate medium from cells and wash with 0.5 mL ofPBS or DMEM per well.
5. Add 0.5 mL of oligonucleotide:lipofectin:media to each well of the plate.
6. Incubate at 37°C for the required time. The level of C02 used in culturing should be used for
antisense assays.
For the assays described here, these specific conditions were used:
Fibroblast antisense (LDH-A and LDH-B ):
6-well plates (2 mL media per well)
Prior to the experiment, the cells were switched to serum-free growth medium for 24 hours.
4 hours of exposure to oligonucleotides - Samples for RT-PCR collected.
20 nglmL of epidermal growth factor (Sigma, St. Louis, MO) in a change of fresh DMEM for 20
hours (total of 24 hours from beginning of experiment).
Washed with PBS (pH 7.20) and lysed in the plate. The lysate was centrifuged for 5 minutes at
10,000g at 4°C and stored at -20°C until assayed for LDH activity.
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8-35 rat hepatoma cells (gp130):
24-well plates
Lipofectin was added to DMEM with 1 J..lMdexamethasone
Phosphorothioate oligonucleotides
Cells washed twice with PBS (pH 7.20)
8 hours exposure to oligonucleotides (or other time for kinetic experiments) - RT-PCR samples
collected by scraping, washing with PBS, and storing at -80°C.
16 hours (24 hours of antisense treatment) with fresh medium containing 1 )lM dexamethasone
and 10 ng/mL recombinant human interleukin-6 - Cell supernatants were then collected and
stored at -20°C for Western blotting.
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5.K. 4-2: kRT-PCR Quantification of Gene Expression
The protocol for RT-PCR was developed by AmI Jayaraman and grows from the Access
RT-PCR kit from Promega.
Materials:
Access RT-PCR kit (Promega)
LightCycler Optimizer Kit (Idaho Technologies)
AmpliTAQ DNA Polymerase (Roche)
Notes:
1. RNA was isolated using the ClonTech NucleoSpin RNA ITkit as well as the Qiagen RNeasy
kit with comparable results. For confidence in removing all of the genomic DNA contamination,
the NucleoSpin kit has a step where genomic DNA is cleaved by DNase 1. However, the vortex
shearing step of the Qiagen method appears adequate for most RT-PCR applications.
2. It is important to use the proper amount of RNA template in the RT reaction. Ideally, the
threshold cycle on the LightCycler for the 18S control gene should be around 7 and no fewer
than 5. The gene of interest should have a threshold cycle number of less than 30. The cell
number required to recover this quantity of RNA should be established prior to commencing
with full-scale experiments.
3. RNase free solutions, tips, and tubes should be used for RT-PCR preparation.
4. Prior to RT, RNA templates should be in water and stored at -80°C. Templates should be used
within 2 weeks of RNA isolation to avoid RNase degradation problems.
5. All reagents should be kept on ice during reaction preparations. RNA templates should be
stored at -80°C and thawed on ice. They should be returned to -80°C as soon as reactions are
prepared.
6. AmpliTaq polymerase should be diluted in Idaho Technology enzyme diluent prior to use in
PCR reactions. 1)lL of enzyme is added to 11.5 J.lLof diluent.
Procedure:
Reverse Transcription (RT)
1. Set up the reaction adding the reagents in the following order (amounts for a 15 J.lLreaction
and can be scaled as needed):
Nuclease-Free Water:
AMV fTfl buffer:
dNTPs, 10 J.lMconcentration:
Mg2S04:
Lower Primer, 10 J.lMconcentration:
Template:
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9.3-X J.lL
3.0 J.lL
0.3 J.lL
0.6 J.lL
1.5 J.lL
X J.lL
RTEnzyme: 0.3 J.!L
Note: Where possible, a master mix should be made. Master mixes contain all of the
reagents with the exception of the primer and/or template depending on whether
one gene or multiple genes are being run.
2. Mix the tubes gently, spin down, and incubate for 45 minutes at 48°C.
3. To inactivate the RT, heat the reaction to 94°C for 2 minutes. Return the reactions to 4°C for
immediate use or store at -20oe for PCR at a later time.
Polymerase Chain Reaction (PCR) (All reagents are specifically those provided by Idaho Tech.)
4. Thaw SYBR Gold stock solution and prepare a 1:6000 dilution.
5. Set up the reaction adding the reagents in the following order (amounts for a 10 J.!Lreaction,
maximum for the LightCycler cuvettes):
Nuclease-Free Water:
MgClz Buffer:
dNTPs, 2 J.!Mconcentration:
Upper Primer, 10 J.!Mconcentration:
Lower Primer, 10 J.!Mconcentration:
Template:
Diluted AmpliTaq Polymerase (see Note):
SYBR Gold (1:6000):
4-X J.!L
1.0 J.!L
1.0 J.!L
1.0 J.!L
1.0 J.!L
X J.!L
1.0 J.!L
1.0 J.!L
Note: Where possible, a master mix should be made. Master mixes contain all of the
reagents with the exception of the primers and/or template depending on whether
one gene or multiple genes are being run.
6. Mix well, spin down, and pipet 5-10 J.!Lof reaction mixture into a LightCycler cuvette.
7. Spin briefly at maximum to collect reaction in bottom of reaction cuvette. Adaptors are
available from Idaho Technology to allow the cuvettes to fit into a standard tabletop
microcentrifuge.
8. CAREFULLY seal reaction cuvettes with provided stoppers. Cuvette sealers should be angled
directly into the cuvettes. Any sideways motion will likely snap the cuvettes. Sealing is
important to ensure that the reaction mixture doesn't bubble up and boil away during PCR
cycling.
9. Load cuvettes into LightCycler in a consecutive stretch of wells. Two wells to either side of
the sample tubes should be blocked from light by tape or the blanks provided by Idaho Tech.
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10. Start LightCycler control software, ensuring that the switch on the back of the LightCycler is
in the on position.
11. In the software, choose user and click on LightCycler button.
12. Select appropriate programs, number of cycles (30-40), and the appropriate annealing
temperature for the primer pair.
13. Click unlock at least twice. Move carousel until first sample tube is just to the right of the
arrow.
14. Click load, select the appropriate storage directory and filename, and enter the number of
samples being run.
15. In the software, label each of the samples. Click done.
16. After double-checking that all of the programs/parameters are set correctly, click run/stop.
Data Analysis
17. Exit the LightCycler program and click on Run Profile.
18. Ensure that the user is set properly and locate the filename for the desired run.
19. Using the shift key, select all of the sample profiles and, by visual inspection, make sure they
look correct.
20. Click exit and enter melting curves.
21. Locate the file and select all correct (as determined from run profile) profiles. Ensure that
the peaks are single, sharp, and at the right temperature. Adjust the number of averaged
points to ....10 to verify that the peaks are correct.
22. Click exit and enter quantitation.
23. Locate the file and select all of the correct samples.
24. Click set noise band and adjust level as low as possible while maintaining log-linear behavior
in the lower graph. The scale of the upper graph can be adjusted to improve inspection of
noise level. Record the threshold fluorescence value. Set noise band back to O.
25. Click save and provide the proper storage location/filename.
26. Open the saved QNT file using Microsoft Excel.
27. In columns D-H, enter the following (Capital letters B-H refer to column headings):
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D: "=10I\CX", where X is the row number
E: "=DX-DY", where X is the row number and Y is X-I
F: "=T-DY", where T is the threshold fluorescence as measured in step 24
G: "=FX/EX"
H: "=GX+BY", this is the desired quantity.
Note: The calculations in columns E-H serve to provide the "actual" threshold cycle
number by linearly interpolating between the points that bridge the threshold value. For
simplicity, these equations need only be done for the row corresponding to the row in
column D that first exceeds the value of the threshold.
28. Enter the column H values for the 185 control and the gene of interest for a treated and
control sample into the following formulae to get the normalized ratio of the quantity of
RNA in the treated samples to the quantity of RNA in the control samples (all efficiencies, E,
are assumed to be 1):
- (1+ E fl8S,tfeat
Rgene• treat = 185(1 + E rgene,lreat
gene
- (1+ E fl8s,cootro'
R - 185gene.control - ( r1+ E gene.control
gene
I = Rgene• treat
Rgene• control
where: Rgene is the normalized quantity of RNA in the treatment or control sample
n is the threshold cycle number as obtained from column H of the worksheet for
the gene of interest and the control gene, 185 rRNA
lis the fold-change of the normalized quantity of the gene of interest in the treated
sample relative to the normalized quantity in the control (untreated) sample.
A sample spreadsheet containing the calculations described above is shown below.
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11 16
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12 15
12 16
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Ready
Many of the cycle numbers and fluorescence values have been deleted for clarity. The
threshold fluorescence for these samples was found to be 0.2, a typical value.
160
5.L. 4-3: LDH assay protocol: cell lysis
The protocol for lysing cells was developed in concert with Avi Robinson and is detailed
below.
Materials needed:
• PIOOOPipet; -50 Sterile Blue Tips; 5 or 10 ml serological pipet
• Timer
• Two Eppendorf tube racks; 72 1.5 ml Eppendorf Tubes
• A microcentrifuge at 4C with the head for 1.5-ml tubes inserted (try to change the
head before you start, if possible)
• Lysis Buffer (0.5% NP40, 1mM MgCh, 1XPBS); PBS
• A container with ice to hold the plate (using the cover of a box of blue tips will
allow you to keep the plate on ice as you work with it).
Protocol:
1) Label and organize the tubes. You will need 24 tubes for the collected media, 24 for the cell
pellet, and 24 for the lysate. Spread out the 24 for the media in one rack (your working rack);
store the other 48 in the second rack (your storage rack).
2) Place the PBS in the water bath.
3) Set up your hood with your working materials, including an aspirator flask.
4) Collect your ice and place it in the hood (you will want to do this as late as possible so that
the ice will not melt).
5) [Bring plate to hood.] Collect media into the Eppendorf tubes using a P1000 pipet.
6) Wash cells with - 0.5 ml PBS per well. Aspirate.
7) Pipet -13-14 ml of the lysis buffer into a 15 ml Falcon tube.
8) Place plate on ice.
9) Start timer.
10) At T=20 seconds, add 0.5 ml of lysis buffer to the first well using a P1000 pipet. Continue
adding lysis buffer to the first 12 wells, at 20 second intervals. One should finish with the
twelfth well at T= 4 minutes. Cover the plate and rest it flat on the ice for a few minutes.
11) At T= 8 minutes 20 seconds, begin adding lysis buffer to the second set of twelve wells,
again at 20 second intervals, until T=12 minutes.
12) While you are waiting, spread out the 24 tubes for the cell pellets on the working rack. Also,
make sure that the ice isn't melting too quickly. You may need to pour off some water into
the sink so that the water will not seep into the plate.
13) At T=20 minutes 20 seconds, collect the lysis buffer + cells from the first 12 wells, using a
P1000 pipet, at 20 second intervals. Cover the plate again and leave it on the ice.
14) Take the tubes to the cold room and centrifuge for 5 minutes at 1500 - 2000 rpm.
15) Return to the hood. The timer should read 26-27 minutes.
16) At T = 28 minutes 20 seconds collect the lysis buffer + cells from the second set of 12 wells,
until T= 32 minutes.
17) Return to the cold room. Remove the first 12 tubes from the centrifuge and replace them with
the second set; centrifuge for 5 minutes at 1500 - 2000 rpm.
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18) Decant the lysates from the centrifuged cells into the Eppendorf tubes labeled "lysates"
without disturbing the pellet. It is not necessary to get all of the supernatant, since we use
only 10 JlI per test; it is more important not to decant the pellet together with the supernatant.
19) Store samples for further testing.
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5.M. 4-4: LDH assay protocol: assay execution
The protocol for performing the LDH activity assay in a 96-well fonnat was developed in
concert with Avi Robinson and is detailed below.
Materials needed: 1 Eppendorf Rack
30 1.5 ml EppendorfTubes
Foam "rack" for placing Eppendorf tubes into water bath
Pipets and pipet tips of all sizes
Timer
96 well plate
Sigma Pyruvate Substrate (Lot:068H6067; store at 4C)
Sigma Color Reagent (Lot:058H6094; store at 4C)
Sigma NADH-containing vial (Lot: 127H6049; store dark and
desiccated at RT)
30-35 ml OAM NaOH
Protocol:
1) Label the 24 Eppendorf tubes and set them up in the foam rack.
2) Pipet ....1.0 ml of pyruvate substrate into each of 3 NADH-containing vials. Mix gently.
3) Pipet the 1.0 ml from two of the vials into the third (ensures uniform concentrations).
4) Pipet 100 III from the vial into each of 24 Eppendorf tubes.
5) Incubate the tubes in a 37°C bath for a few minutes. Also incubate the remaining substrate
that is in the vial, so that you can quickly make an extra sample if necessary.
[5) If necessary, thaw the lysate samples.]
6) Retrieve the tubes from the water bath and return them to the workbench.
7) Start timer.
8) At T = 30 seconds, pipet 10 III of sample into the first 1.5ml tube. Proceed to do this over 30
second intervals for all 24 samples, until T=12 minutes.
9) Return the tubes to the water bath.
10) Prepare standards at the following dilutions: 1. 100 J.lI pyruvate substrate, 10 III H20
2.80 30
3.60 50
4.40 70
5.20 90
6. 10 100
11) Return the lysate samples to the freezer and the pyruvate substrate to the refrigerator.
Retrieve the coloring reagent from the refrigerator.
12) At T ....26.5-27 minutes, retrieve the sample tubes from water bath.
13) At T = 28 minutes 20 seconds, add 100 III of coloring reagent to the first standard. Continue
to add to the 6 standards, at 20 second intervals, until T = 30 minutes. Then add to the
samples, at 30 second intervals, starting at 30 minutes 30 seconds, until T= 42 minutes. [One
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thereby adds the coloring reagent exactly 30 minutes after mixing the sample and the
substrate.]
14) At T = 48 minutes 20 seconds add 1 ml 0.4 M NaOH to the first standard, and subsequently
to the rest of the standards at 20 second intervals and to the samples at 30 second intervals,
until T = 1 hour 2 minutes. Mix well by inversion. [One thus adds the NaOH exactly 20
minutes after the addition of the color reagent.]
15) Transfer the samples to the plate for OD reading. Pipet 1OOul! well of each sample into three
wells (triplicate). One will use 90 of the 96 wells (6 std., 24 samples).
16) Set up the plate reader and read the plate.
a) Make sure the plate reader machine is on.
b) Open Softmax (Apple, Applications, Softmax Alias)
c) Go to Setup, Instrument. The wavelength should be Endpoint Ll, 450 nm.
d) Go to Setup, Template, and set up the template. The standards have the following
concentrations: 1. 0
2. 280
3. 640
4. 1040
5. 1530
6. 2000
e) Go to Control, Reader Status to make sure the computer and the plate reader are
connected.
f) Go to Control, Read Plate to read the plate.
17) Analyze the data.
a) Fit the standard curve to a quadratic.
b) Save the data to disk before exiting.[!!]
164
6. Bibliography
1. Holkeri, H. 2000,
http://www.un.org/News/Press/docs/2000/20001129.gasm222.doc.html.
2. American Cancer Society. 1997, http://www.cancer.orgjstatistics/96cff/facts.html.
3. Inflammatory Bowel Disease. 2000, http://familydoctor.orgjhandouts/252.html.
4. Cerra, F.B., M. West, G. Keller, J. Mazuski, and R.L. Simmons, Hypermetabolism/organ
failure: the role of the activated macrophage as a metabolic regulator. Prog Clin BioI
Res, 1988.264: p. 27-42.
5. Beal, A.L. and F.B. Cerra, Multiple organfailure syndrome in the 1990s. Systelnic
inflammatory response and organ dysfunction. Jama, 1994. 271(3): p. 226-33.
6. Isis Pharmaceuticals, Inc., Form 10-K, Decenlber 31, 1998.2001,
http://www.isip.com/l0K_123198/l0K.htm.
7. Lander, E.S., et al., Initial sequencing and analysis of the human genome. Intenlational
Human Genome Sequencing Consortium. Nature, 2001. 409(6822): p. 860-921.
8. Roth, C.M. and M.L. Yarmush, Nucleic Acid Biotechnology, in Annual Review of
Biomedical Engineering, M.L. Yarmush, K.R. Diller, and M. Toner, Editors. 1999,
Annual Reviews: Palo Alto, CA. p. 265-297.
9. Zamecnik, P.C. and M.L. Stephenson, Inhibition of Rous sarcoma virus replication and
cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA, 1978.
75(1): p. 280-4.
10. Roush, W.,Antisense aims for a renaissance. Science, 1997.276(5316): p. 1192-3.
11. Rawls, R.L., Optimistic about antisense. Chemical and Engineering News, 1997.75(22):
p.35-39.
12. Antisense '97: A roundtable on the state of the industry. Nature Biotechnology, 1997. 15:
p.519-524.
13. Tomizawa, J.1., T. Itoh, G. Selzer, and T. Som, Inhibition of ColE1 RNA primer
formation by a plasmid-specified small RNA. Proc Natl Acad Sci USA, 1981.78(3): p.
1421-5.
14. Tomizawa, J.1. and T. Itoh, Plasmid ColE1 incompatibility detennined by interaction of
RNA I with primer transcript. Proc Natl Acad Sci USA, 1981. 78(10): p. 6096-100.
15. Izant, J.G. and H. Weintraub, Constitutive and conditional suppression of exogenous and
endogenous genes by anti-sense RNA. Science, 1985.229(4711): p. 345-52.
16. Walton, S.P., C.M. Roth, and M.L. Yarmush, Antisense Technology, in The Biomedical
Engineering Handbook. 2000, CRC Press LLC: Boca Raton, FL. p. 103-1 - 103-19.
17. Akhtar, S., R. Kole, and R.L. Juliano, Stability of antisense DNA oligodeoxynucleotide
analogs in cellular extracts and sera. Life Sci, 1991. 49(24): p. 1793-801.
18. Geselowitz, D.A. and L.M. Neckers, Bovine serUln albumin is a major oligonucleotide-
binding protein found on the surface of cultured cells. Antisense Res Dev, 1995.5(3): p.
213-7.
19. Biessen, E.A., H. Vietsch, J. Kuiper, M.K. Bijsterbosch, and T.J. Berkel, Liver uptake of
phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol
Pharmacol, 1998.53(2): p. 262-9.
165
20. Chaudhuri, G., Scavenger receptor-mediated delivery of antisense mini-exon
p/zosphorot/zioate oligonucleotide to Leishmania-infected macrophages. Selective and
efficient elimination of the parasite. Biochern Pharmacol, 1997.53(3): p. 385-91.
21. Bijsterbosch, M.K., et al., In vivo fate of phosphorothioate antisense
oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver
cells. Nucleic Acids Res, 1997.25(16): p. 3290-6.
22. Loke, S.L., et aI., Characterization of oligonucleotide transport into living cells. Proc
Natl Acad Sci USA, 1989. 86(10): p. 3474-8.
23. Yakubov, L.A., et al., Mechanism of oligonucleotide uptake by cells: involvement of
specific receptors? Proc Natl Acad Sci USA, 1989.86(17): p. 6454-8.
24. Shoji, Y., S. Akhtar, A. Periasarny, B. Herman, and R.L. Juliano, Mechanism of cellular
uptake of modified oligodeoxynucleotides containing methylphosphonate linkages.
Nucleic Acids Res, 1991. 19(20): p. 5543-50.
25. Thierry, A.R. and A. Dritschilo, Intracellular availability of unmodified,
phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense
activity. Nucleic Acids Res, 1992.20(21): p. 5691-8.
26. Tam, R.C., et al., Biological availability and nuclease resistance extend the in vitro
activity of a phosphorothioate-3'hydroxypropylamine oligonucleotide. Nucleic Acids
Res, 1994.22(6): p. 977-86.
27. Marcusson, E.G., B. Bhat, M. Manoharan, C.F. Bennett, and N.M. Dean,
Phosp/zorothioate oligodeoxyribonucleotides dissociate from cationic lipids before
entering the nucleus. Nucleic Acids Res, 1998.26(8): p. 2016-23.
28. Stein, C.A., Two problems in antisense biotechnology: in vitro delivery and the design of
antisense experiments. Biochirn Biophys Acta, 1999.1489(1): p. 45-52.
29. Wagner, R.W., M.D. Matteucci, D. Grant, T. Huang, and B.C. Froehler, Potent and
selective inhibition of gene expression by an antisense heptanucleotide. Nat Biotechnol,
1996. 14(7): p. 840-4.
30. Crooke, S.T., Molecular mechanisms of action of antisense drugs. Biochim Biophys
Acta, 1999.1489(1): p. 31-44.
31. Monia, B.P., et al., Evaluation of2'-modified oligonucleotides containing 2'-deoxy gaps
as antisense inhibitors of gene expression. J BioI Chern, 1993.268(19): p. 14514-22.
32. de Diesbach, P., et al., Identification, purification and partial characterisation of an
oligonucleotide receptor in membranes of HepG2 cells. Nucleic Acids Res, 2000. 28(4):
p.868-74.
33. Hawley, P. and I. Gibson, Interaction of oligodeoxynucleotides with mammalian cells.
Antisense Nucleic Acid Drug Dev, 1996.6(3): p. 185-95.
34. Caselrnann, W.H., S. Eisenhardt, and M. Alt, Synthetic antisense oligodeoxynucleotides
as potential dnlgs against hepatitis C. Intervirology, 1997.40(5-6): p. 394-9.
35. Dokka, S. and Y. Rojanasakul, Novel non-endocytic delivery of antisense
oligonucleotides. Adv Drug Deliv Rev, 2000. 44(1): p. 35-49.
36. Bergan, R., Y. Connell, B. Fahrny, and L. Neckers, Electroporation enhances C-ll1yC
antisense oligodeoxynucleotide efficacy. Nucleic Acids Res, 1993. 21(15): p. 3567-73.
37. Tonkinson, J.L. and C.A. Stein, PattenlS of intracellular compartmentalization,
trafficking and acidification of 5'-jluorescein labeled phosphodiester and
166
phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res, 1994.22(20):
p.4268-75.
38. Geselowitz, D.A. and L.M. Neckers, Analysis of oligonucleotide binding, internalization,
and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res
Dev, 1992. 2(1): p. 17-25.
39. Li, B., J.A. Hughes, and M.1. Phillips, Uptake and efflux of intact antisense
phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine
adrenal cells. Neurochem Int, 1997.31(3): p. 393-403.
40. Matteucci, M., Oligonucleotide analogues: an overview. Ciba Found Symp, 1997.
209(2): p. 5-14; discussion 14-8.
41. SantaLucia, J., JSLHOME., http://jsl1.chem.wayne.edu/.
42. Walder, R.Y. and lA. Walder, Role of RNase H in hybrid-arrested translation by
antisense oligonucleotides. Proc Natl Acad Sci USA, 1988.85(14): p. 5011-5.
43. Dagle, J.M., D.L. Weeks, and J.A. Walder, Pathways of degradation and mechanism of
action of antisense oligonucleotides in Xenopus laevis embryos. Antisense Res Dev,
1991. 1(1): p. 11-20.
44. Schiedlmeier, B., et al., Nuclear transfonnation of Volvox carteri. Proc Natl Acad Sci
USA, 1994. 91(11): p. 5080-4.
45. Lesh, R.E., A.P. Somlyo, G.K. Owens, and A.V. Somlyo, Reversible penneabilization. A
novel technique for the intracellular introduction of antisense oligodeoxynucleotides into
intact smooth muscle. Circ Res, 1995. 77(2): p. 220-30.
46. Spiller, D.G. and D.M. Tidd, Nuclear delivery of antisense oligodeoxynucleotides
through reversible penneabilization of human leukelnia cells with streptolysin O.
Antisense Res Dev, 1995. 5(1): p. 13-21.
47. Zhao, Q., et al., Comparison of cellular binding and uptake of antisense phosphodiester,
phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides.
Antisense Res Dev, 1993. 3(1): p. 53-66.
48. Boutorine, A.S. and E.V. Kostina, Reversible covalent attachment of cholesterol to
oligodeoxyribonucleotides for studies of the mechanislns of their penetration into
eucaryotic cells. Biochimie, 1993.75(1-2): p. 35-41.
49. Alahari, S.K., et al., Inhibition of expression of the multidrug resistance-associated P-
glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate
antisense oligonucleotides. Mol Pharmacol, 1996.50(4): p. 808-19.
50. Krieg, A.M., et al., Modification of antisense phosphodiester oligodeoxynucleotides by a
5' cholesteryl moiety increases cellular association and improves efficacy. Proc Nati
Acad Sci USA, 1993.90(3): p. 1048-52.
51. Degols, G., J.P. Leonetti, M. Benkirane, C. Devaux, and B. Lebleu, Poly(L-lysine)-
conjugated oligonucleotides promote sequence-specific inhibition of acute HIV-l
infection. Antisense Res Dev, 1992.2(4): p. 293-301.
52. Leonetti, J.P., G. Degols, J.P. Clarenc, N. Mechti, and B. Lebleu, Cell delivery and
mechanisms of action of antisense oligonucleotides. Prog Nucleic Acid Res Mol BioI,
1993. 44: p. 143-66.
53. Lu, X.M., et al., Antisense DNA delivery in vivo: liver targeting by receptor-mediated
uptake. J Nucl Med, 1994. 35(2): p. 269-75.
167
54. Citro, G., et a/., Inhibition of leukemia cell proliferation by receptor-mediated uptake of
c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA, 1992.89(15): p.
7031-5.
55. Deshpande, D., D. Toledo-Velasquez, D. Thakkar, W. Liang, and Y. Rojanasakul,
Enhanced cellular uptake of oligonucleotides by EGF receptor-mediated endocytosis in
A549 cells. Pharm Res, 1996. 13(1): p. 57-61.
56. Bonfils, E., et al., Drug targeting: synthesis and endocytosis of oligonucleotide-
neoglycoprotein conjugates. Nucleic Acids Res, 1992.20(17): p. 4621-9.
57. Wu, G.Y. and C.H. Wu, Specific inhibition of hepatitis B viral gene expression in vitro by
targeted antisense oligonucleotides. J BioI Chern, 1992.267(18): p. 12436-9.
58. Roth, C.M., et a/., Targeted antisense modulation of inflammatory cytokine receptors.
Biotechnology and Bioengineering, 1997.55: p. 72-81.
59. Basu, S. and E. Wickstrom, Synthesis and characterization of a peptide nucleic acid
conjugated to a D-peptide analog of insulin-like growth factor 1for increased cellular
uptake. Bioconjug Chern, 1997.8(4): p. 481-8.
60. Rajur, S.B., C.M. Roth, J.R. Morgan, and M.L. Yarmush, Covalent protein-
oligonucleotide conjugates for efficient delivery of antisense molecules. Bioconjug Chern,
1997.8(6): p. 935-40.
61. Reinis, M., M. Damkova, and E. Korec, Receptor-mediated transport of
oligodeoxynucleotides into hepatic cells. J Virol Methods, 1993.42(1): p. 99-105.
62. Probst, J.C., Antisense oligodeoxynucleotide and ribozyme design. Methods, 2000. 22(3):
p.271-81.
63. Dokka, S., D. Toledo-Velasquez, X. Shi, L. Wang, and Y. Rojanasakul, Cellular delivery
of oligonucleotides by synthetic import peptide carrier. Pharm Res, 1997. 14(12): p.
1759-64.
64. Subramanian, A., P. Ranganathan, and S.L. Diamond, Nuclear targeting peptide scaffolds
for lipofection of nondividing mammalian cells. Nat Biotechnol, 1999.17(9): p. 873-7.
65. Zelphati, O. and F.C. Szoka, Jr., Mechanism of oligonucleotide release from cationic
liposomes. Proc Natl Acad Sci USA, 1996. 93(21): p. 11493-8.
66. Ryser, J.-P. and W.-C. Shen, Drug-poly(lysine) conjugates: their potential for
chemotherapy andfor the study of endocytosis, in Targeting of drugs with synthetic
systems, G. Gregoriadis, J. Senior, and G. Poste, Editors. 1986, Plenum Press
Corporation: New York. p. 103-121.
67. Wu-Pong, S., The role of multivalent cations in oligonucleotide cellular uptake. Biochem
Mol BioI Int, 1996.39(3): p. 511-9.
68. Benimetskaya, L., et al., Mac-1 (CD 11blCD 18) is an oligodeoxynucleotide-binding
protein. Nat Med, 1997.3(4): p. 414-20.
69. Vlassov, V.V., L.A. Balakireva, and L.A. Yakubov, Transport of oligonucleotides across
natural and model membranes. Biochim Biophys Acta, 1994.1197(2): p. 95-108.
70. Bennett, C.F., T.P. Condon, S. Grimm, H. Chan, and M.Y. Chiang, Inhibition of
endothelial cell adhesion molecule expression with antisense oligonucleotides. J
Immunol, 1994. 152(7): p. 3530-40.
71. Lavigne, C. and A.R. Thierry, Enhanced antisense inhibition of human immunodeficiency
virus type 1 in cell cultures by DLS delivery system. Biochem Biophys Res Commun,
1997.237(3): p. 566-71.
168
72. Leonetti, J.P., P. Machy, G. Degols, B. Lebleu, and L. Leserman, Antibody-targeted
liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively
inhibit viral replication. Proc Natl Acad Sci USA, 1990.87(7): p. 2448-51.
73. Lodish, H., et al., Molecular Cell Biology. 3rd ed. 1995, New York: Scientific American
Books, Inc.
74. Zohlnhofer, D., et aI., The hepatic interleukin~6 receptor. Down-regulation of the
interleukin- 6 binding subunit (gp80) by its ligand. FEBS Lett, 1992.306(2-3): p. 219-22.
75. Huang, G.M., J. Farkas, and L. Hood, High-throughput cDNA screening utilizing a low
order neural networkfilter. Biotechniques, 1996.21(6): p. 1110-4.
76. Volz, B., G. Orberger, S. Porwoll, H.P. Hauri, and R. Tauber, Selective reentry of
recycling cell surface glycoproteins to the biosynthetic pathway in human
hepatocarcinoma HepG2 cells. J Cell BioI, 1995. 130(3): p. 537-5l.
77. Ghosh, M.K., K. Ghosh, O. Dahl, and J.S. Cohen, Evaluation of some properties of a
phosphorodithioate oligodeoxyribonucleotide for antisense application. Nucleic Acids
Res, 1993.21(24): p. 5761-6.
78. Manoharan, M., 2'-carbohydrate modifications in antisense oligonucleotide therapy:
importance of conformation, configuration and conjugation. Biochim Biophys Acta,
1999. 1489(1): p. 117-30.
79. Lesnik, E.A., et aI., Oligodeoxynucleotides containing 2'-O-modified adenosine:
synthesis and effects on stability of DNA:RNA duplexes. Biochemistry, 1993. 32(30): p.
7832-8.
80. Monia, B.P., J.F. Johnston, H. Sasmor, and L.L. Cummins, Nuclease resistance and
antisense activity of modified oligonucleotides targeted to Ha-ras. J BioI Chern, 1996.
271(24): p. 14533-40.
81. McKay, R.A., et a1., Enhanced activity of an antisense oligonucleotide targeting murine
protein kinase C-alpha by the incorporation of2'-O-propyl modifications. Nucleic Acids
Res, 1996.24(3): p. 411-7.
82. Nagel, K.M., S.G. Holstad, and K.E. Isenberg, Oligonucleotide pharmacotherapy: an
antigene strategy. Pharmacotherapy, 1993.13(3): p. 177-88.
83. Iribarren, A.M., D.O. Cicero, and PJ. Neuner, Resistance to degradation by nucleases of
(2'S)-2'-deoxy-2'-C- methyloligonucleotides, novel potential antisense probes. Antisense
Res Dev, 1994. 4(2): p. 95-8.
84. Agrawal, S., J. Ternsarnani, W. Galbraith, and J. Tang, Pharmacokinetics of antisense
oligonucleotides. Clin Pharmacokinet, 1995.28(1): p. 7-16.
85. Milligan, J.F., M.D. Matteucci, and J.C. Martin, Current concepts in antisense drug
design. J Med Chern, 1993.36(14): p. 1923-37.
86. Crooke, S.T., et al., Pharmacokinetic properties of several novel oligonucleotide analogs
in nlice. J Pharmacal Exp Ther, 1996.277(2): p. 923-37.
87. Geary, R.S., et al., Phannacokinetic Properties of2'-O-(2-Methoxyethyl)-Modified
Oligonucleotide Analogs in Rats. J Pharmacal Exp Ther, 2001. 296(3): p. 890-897.
88. Galbraith, W.M., W.C. Hobson, P.C. Giclas, PJ. Schechter, and S. Agrawal, Complement
activation and hemodynamic changes following intravenous adnlinistration of
phosphorothioate oligonucleotides in the monkey. Antisense Res Dev, 1994.4(3): p. 201-
6.
169
89. Peyrottes, S., J.J. Vasseur, J.L. Imbach, and B. RaYner, Oligodeoxynucleoside
phosphoramidates (P-NH2): synthesis and thennal stability of duplexes with DNA and
RNA targets. Nucleic Acids Res, 1996. 24(10): p. 1841-8.
90. Heidenreich, 0., S. Gryaznov, and M. Nerenberg, RNase H-independent antisense
activity of oligonucleotide N3 '--> P5 'phosphoramidates. Nucleic Acids Res, 1997.
25(4): p. 776-80.
91. Skorski, T., D. Perrotti, M. Nieborowska-Skorska, S. Gryaznov, and B. Calabretta,
Antileukemia effect of c-myc N3'-->P5' phosphoramidate antisense oligonucleotides in
vivo. Proc Natl Acad Sci USA, 1997.94(8): p. 3966-71.
92. Hawley, P., J.S. Nelson, K.L. Fearon, G. Zon, and I.Gibson, Comparison of binding of
N3'-->P5' phosphoramidate and phosphorothioate oligonucleotides to cell surface
proteins of cultured cells. Antisense Nucleic Acid Drug Dev, 1999.9(1): p. 61-9.
93. Gryaznov, S.M., Oligonucleotide N3'-->P5' phosphoramidates as potential therapeutic
agents. Biochirn Biophys Acta, 1999.1489(1): p. 131-40.
94. Gryaznov, S., et al., Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.
Nucleic Acids Res, 1996.24(8): p. 1508-14.
95. Boulrne, F., et al., Modified (PNA, 2'-O-methyl and phosphoramidate) anti-TAR
antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-l reverse
transcription. Nucleic Acids Res, 1998.26(23): p. 5492-500.
96. Leydier, C., et al., 4'-Thio-RNA: synthesis of mixed base 4'-thio-oligoribonucleotides,
nuclease resistance, and base pairing properties with complementary single and double
strand. Antisense Res Dev, 1995. 5(3): p. 167-74.
97. Kawasaki, A.M., et al., Unifonnly modified 2'-deoxy-2'-fluoro phosphorothioate
oligonucleotides as nuclease-resistant antisense compounds with high affinity and
specificity for RNA targets. J Med Chern, 1993.36(7): p. 831-41.
98. Boiziau, C., B. Larrouy, B.S. Sproat, and J.1. Toulrne, Antisense 2'-0-alkyl
oligoribonucleotides are efficient inhibitors of reverse transcription. Nucleic Acids Res,
1995.23(1): p. 64-71.
99. Johansson, H.E., G.J. Belsharn, B.S. Sproat, and M.W. Hentze, Target-specific arrest of
mRNA translation by antisense 2'-0- alkyloligoribonucleotides. Nucleic Acids Res, 1994.
22(22): p. 4591-8.
100. Brown-Driver, V., T. Eto, E. Lesnik, K.P. Anderson, and R.C. Hanecak, Inhibition of
translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. Antisense
Nucleic Acid Drug Dev, 1999.9(2): p. 145-54.
101. Prakash, T.P., et al., 2'-0-[2-[N,N-(dialkyl)aminooxyjethylj-modified antisense
oligonucleotides. Org Lett, 2000. 2(25): p. 3995-8.
102. Vickers, T.A., J.R. Wyatt, T. Burckin, C.F. Bennett, and S.M. Freier, Fully modified 2'
MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res, 2001. 29(6): p.
1293-1299.
103. Wahlestedt, C., et al., Potent and nontoxic antisense oligonucleotides containing locked
nucleic acids. Proc Natl Acad Sci USA, 2000. 97(10): p. 5633-8.
104. Petersen, M., et al., The confonnations of locked nucleic acids (LNA). J Mol Recognit,
2000. 13(1): p. 44-53.
170
105. Sanghvi, Y.S., et al., Antisense oligodeoxynucleotides: synthesis, biophysical and
biological evaluation of oligodeoxynucleotides containing modified pyrimidines. Nucleic
Acids Res, 1993.21(14): p. 3197-203.
106. Pickering, J.G., et al., Processing of chimeric antisense oligonucleotides by human
vascular smooth muscle cells and human atherosclerotic plaque. Implications for
antisense therapy of rest enos is after angioplasty. Circulation, 1996.93(4): p. 772-80.
107. Maier, M., K. Bleicher, H. Kalthoff, and E. Bayer, Enzymatic degradation of various
antisense oligonucleotides: monitoring and fragment identification by MECC and ES-
MS. Biomed Pept Proteins Nucleic Acids, 1995. 1(4): p. 235-42.
108. Agrawal, S., et al., Mixed-backbone oligonucleotides as second generation antisense
oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci USA, 1997.94(6): p.
2620-5.
109. Hebb, M.D. and H.A. Robertson, End-capped antisense oligodeoxynucleotides effectively
inhibit gene expression in vivo and offer a low-toxicity alternative to fully modified
phosphorothioate oligodeoxynucleotides. Brain Res Mol Brain Res, 1997.47(1-2): p.
223-8.
110. Park, W.S., et ai., Inhibition of HIV-l replication by a new type of circular dumbbell
RNAIDNA chimeric oligonucleotides. Biochem Biophys Res Commun, 2000. 270(3): p.
953-60.
111. Summerton, J., Morpholino antisense oligomers: the case for an RNase H-independent
structural type. Biochim Biophys Acta, 1999.1489(1): p. 141-58.
112. Ekker, S.C., Morphants: a new systematic vertebrate functional genomics approach.
Yeast, 2000.17(4): p. 302-306.
113. Arora, V., et ai., c-Myc antisense limits rat liver regeneration and indicates role for c-
Myc in regulating cytochrome P-450 3A activity. J Pharmacol Exp Ther, 2000. 292(3): p.
921-8.
114. Qin, G., M. Taylor, Y.Y. Ning, P. Iversen, and L. Kobzik, In vivo evaluation of a
morpholino antisense oligomer directed against tumor necrosis factor-alpha. Antisense
Nucleic Acid Drug Dev, 2000.10(1): p. 11-6.
115. Jubin, R., et al., Hepatitis C virus internal ribosome entry site (IRES) stem loop IIId
contains a phylogenetically conserved GGG triplet essential for translation and IRES
folding. J Virol, 2000. 74(22): p. 10430-7.
116. Lacerra, G., et ai., Restoration of hemoglobin A synthesis in erythroid cells from
peripheral blood of thalassemic patients. Proc Natl Acad Sci USA, 2000.97(17): p.
9591-6.
117. Ghosh, C. and P.L. Iversen, Intracellular delivery strategies for antisense
phosphorodiamidate morpholino oligomers. Antisense Nucleic Acid Drug Dev, 2000.
10(4): p. 263-74.
118. Schmajuk, G., H. Sierakowska, and R. Kole, Antisense oligonucleotides with different
backbones. Modification of splicing pathways and efficacy of uptake. J BioI Chern, 1999.
274(31): p. 21783-9.
119. Nasevicius, A., J. Larson, and S.C. Ekker, Distinct requirements for zebrafish
angiogenesis revealed by a VEGF-A morphant. Yeast, 2000.17(4): p. 294-30l.
120. Nasevicius, A. and S.C. Ekker, Effective targeted gene 'knockdown' in zebrafish. Nat
Genet, 2000. 26(2): p. 216-20.
171
121. Shepherd, I.T., C.E. Beattie, and D.W. Raible, Functional Analysis of Zebra fish GDNF.
Dev BioI, 2001. 231(2): p. 420-435.
122. Bauer, H., Z. Lele, G.1. Rauch, R. Geisler, and M. Hammerschmidt, The type I
serine/threonine kinase receptor Alk8/Lost-a-fin is required for Bmp2b/7 signal
transduction during dorsoventral patterning of the zebrafish embryo. Development,
2001. 128(6): p. 849-858.
123. Yang, Z., N. Liu, and S. Lin, A Zebrafish Forebrain-Specific Zinc Finger Gene Can
Induce Ectopic dlx2 and dlx6 Expression. Dev BioI, 2001. 231(1): p. 138-148.
124. Howard, E.W., L.A. Newman, D.W. Oleksyn, R.C. Angerer, and L.M. Angerer, SpKrl: a
direct target of( &bgr;)-catenin regulation requiredfor endoderm differentiation in sea
urchin embryos. Development, 2001. 128(3): p. 365-375.
125. Maran, A., et al., Blockage of NF-kappa B signaling by selective ablation of an mRNA
target by 2-5A antisense chimeras. Science, 1994.265(5173): p. 789-92.
126. Mukai, S., et al., 2-5A antisense telomerase RNA therapy for intracranial malignant
gliomas. Cancer Res, 2000. 60(16): p. 4461-7.
127. Maran, A., et al., 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively
degrade bcr/abl mRNA in chronic myelogenous leukemia cells. Blood, 1998. 92(11): p.
4336-43.
128. Kushner, D.M., et al., 2-5A antisense directed against telomerase RNA produces
apoptosis in ovarian cancer cells. Gynecol Oncol, 2000. 76(2): p. 183-92.
129. Verheijen, J.C., et ai., Synthesis and RNAse L binding and activation of a 2-5A-(5')-DNA-
(3')-PNA chimera, a novel potential antisense molecule. Nucleosides Nucleotides Nucleic
Acids, 2000. 19(10-12): p. 1821-30.
130. Verheijen, J.C., et aI., 2,5-oligoadenylate-peptide nucleic acids (2-5A-PNAs) activate
RNase L. Bioorg Med Chern, 1999. 7(3): p. 449-55.
131. Baker, B.F. and B.P. Monia, Novel mechanisms for antisense-mediated regulation of
gene expression. Biochim Biophys Acta, 1999. 1489(1): p. 3-18.
132. Ma, M., et ai., Intracellular mRNA cleavage induced through activation of RNase P by
nuclease-resistant external guide sequences. Nat Biotechnol, 2000. 18(1): p. 58-61.
133. Stein, C.A., Is irrelevant cleavage the price of antisense efficacy? Pharmacol Ther, 2000.
85(3): p. 231-6.
134. Helene, C. and J.1. Toulme, Specific regulation of gene expression by antisense, sense
and antigene nucleic acids. Biochim. Biophys. Acta, 1990.1049: p. 99-125.
135. Cook, P.D., Medicinal chemistry of antisense oligonucleotides--future opportunities.
Anticancer Drug Des, 1991. 6(6): p. 585-607.
136. Uhlmann, E. and A. Peyman, Antisense oligonucleotides: A new therapeutic principle.
Chern. Rev, 1990.90: p. 544-584.
137. Verma, S. and F. Eckstein, Modified oligonucleotides: synthesis and strategy for users.
Annu Rev Biochem, 1998.67: p. 99-134.
138. Svinarchuk, F.P., D.A. Konevetz, O.A. Pliasunova, A.G. Pokrovsky, and V.V. Vlassov,
Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to
lipophilic groups. Biochimie, 1993.75(1-2): p. 49-54.
139. Letsinger, R.L., G.R. Zhang, D.K. Sun, T. Ikeuchi, and P.S. Sarin, Cholesteryl-
conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of
172
replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci USA,
1989. 86(17): p. 6553-6.
140. de Smidt, P.C., T. Le Doan, S. de Falco, and T.J. van Berkel, Association of antisense
oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue
distribution. Nucleic Acids Res, 1991. 19(17): p. 4695-700.
141. Reed, M.W., D. Fraga, D.E. Schwartz, J. Scholler, and R.D. Hinrichsen, Synthesis and
evaluation of nuclear targeting peptide-antisense oligodeoxynucleotide conjugates.
Bioconjug Chern, 1995.6(1): p. 101-8.
142. Woolf, T.M., D.A. Melton, and C.G. Jennings, Specificity of antisense oligonucleotides
in vivo. Proc Natl Acad Sci USA, 1992.89(16): p. 7305-9.
143. Altschul, S.F., et al., Gapped BLAST and PSI-BLAST: a new generation ofprotein
database search programs. Nucleic Acids Res, 1997.25(17): p. 3389-402.
144. Smith, L., K.B. Andersen, L. Hovgaard, and J.W. Jaroszewski, Rational selection of
antisense oligonucleotide sequences. Eur J Pharm Sci, 2000. 11(3): p. 191-8.
145. Andreyev, H.J., P.J. Ross, D. Cunningham, and P.A. Clarke, Antisense treatment directed
against mutated Ki-ras in human colorectal adenocarcinoma. Gut, 2001. 48(2): p. 230-7.
146. Monia, B.P., et al., Sequence-specific antitumor activity of a phosphorothioate
oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense
mechanism of action in vivo. Proc Natl Acad Sci USA, 1996.93(26): p. 15481-4.
147. Jayaraman, A., S.P. Walton, M.L. Yarmush, and C.M. Roth, Rational selection and
quantitative evaluation of antisense oligonucleotides. Biochim Biophys Acta, 2001.
1520(2):' p. 105-14.
148. Clever, J., C. Sassetti, and T.G. Parslow, RNA secondary structure and binding sites for
gag gene products in the 5'packaging signal of human immunodeficiency virus type 1. J
Virol, 1995.69(4): p. 2101-9.
149. Koeller, D.M., et al., A cytosolic protein binds to structural elements within the iron
regulatory region of the transferrin receptor mRNA. Proc Natl Acad Sci USA, 1989.
86(10): p. 3574-8.
150. Stull, R.A., G. Zon, and F.C. Szoka, An in vitro messenger RNA binding assay as a tool
for identifying hybridization-competent antisense oligonucleotides. Antisense Nucleic
Acid Drug Dev, 1996.6(3): p. 221-8.
151. Zhu, T., S. Pooyan, Z. Wei, MJ. Leibowitz, and S. Stein, Gel shift assay: demonstration
of enhanced binding of oligo( delta)-L-ornithine-oligodeoxynucleotide conjugates to
complementary DNA and RNA. Antisense Nucleic Acid Drug Dev, 1996.6(1): p. 69-74.
152. Bruice, T.W. and W.F. Lima, Control of complexity constraints on combinatorial
screening for preferred oligonucleotide hybridization sites on structured RNA.
Biochemistry, 1997.36(16): p. 5004-19.
153. Ho, S.P., et aI., Potent antisense oligonucleotides to the human multidrug resistance-1
mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide
libraries. Nucleic Acids Res, 1996.24(10): p. 1901-7.
154. Ho, S.P., D.H. Britton, Y. Bao, and M.S. Scully, RNA mapping: selection of potent
oligonucleotide sequences for antisense experiments. Methods Enzymol, 2000. 314(6): p.
168-83.
155. Southern, E.M., et al., Arrays of complementary oligonucleotides for analysing the
hybridisation behaviour o/nucleic acids. Nucleic Acids Res, 1994.22(8): p. 1368-73.
173
156. Milner, N., K.U. Mir, and E.M. Southern, Selecting effective antisense reagents on
combinatorial oligonucleotide arrays. Nat BiotechnoI, 1997.15(6): p. 537-41.
157. SohaB, M., et al., Antisense oligonucleotides selected by hybridisation to scanning arrays
are effective reagents in vivo. Nucleic Acids Res, 2001. 29(10): p. 2041-51.
158. Tu, G.C., Q.N. Cao, F. Zhou, and Y. Israel, Tetranucleotide GGGA motif in primary RNA
transcripts. Novel target site for antisense design. J BioI Chern, 1998.273(39): p. 25125-
31.
159. Matveeva, G.V., et al., Identification of sequence motifs in oligonucleotides whose
presence is correlated with antisense activity. Nucleic Acids Res, 2000. 28(15): p. 2862-
5.
160. Wakita, T. and J.R. Wands, Specific inhibition of hepatitis C virus expression by
antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J BioI
Chern, 1994.269(19): p. 14205-10.
161. Tsiang, M., C.S. Gibbs, L.C. Griffin, K.E. Dunn, and L.L. Leung, Selection of a
suppressor mutation that restores affinity of an oligonucleotide inhibitor for thrombin
using in vitro genetics. J BioI Chern, 1995. 270(33): p. 19370-6.
162. Castier, Y., et al., The activity of c-myb antisense oligonucleotide to prevent intimal
hyperplasia is nonspecific. J Cardiovasc Surg (Torino), 1998.39(1): p. 1-7.
163. Wyatt, J.R., et al., Combinatorially selected guanosine-quartet structure is a potent
inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl
Acad Sci USA, 1994. 91(4): p. 1356-60.
164. Zarrinkar, P.P. and J.R. Williamson, The kinetic folding pathway of the Tetrahymena
ribozyme reveals possible similarities between RNA and protein folding. Nat Struct BioI,
1996. 3(5): p. 432-8.
165. Wu, M. and I.Tinoco, RNAfolding causes secondary structure rearrangement. Proc Natl
Acad Sci USA, 1998. 95(20): p. 11555-60.
166. Silverman, S.K., M. Zheng, M. Wu, I.Tinoco, Jr., and T.R. Cech, Quantifying the
energetic interplay of RNA tertiary and secondary structure interactions. Rna, 1999.
5(12): p. 1665-74.
167. Walter, A.E., et al., Coaxial stacking of helixes enhances binding of oligoribonucleotides
and improves predictions of RNAfolding. Proc Natl Acad Sci USA, 1994. 91(20): p.
9218-22.
168. Zuker, M., Onfinding all suboptimalfoldings of an RNA molecule. Science, 1989.
244(4900): p. 48-52.
169. Mathews, D.H., M.E. Burkard, S.M. Freier, J.R. Wyatt, and D.H. Turner, Predicting
oligonucleotide affinity to nucleic acid targets. Rna, 1999. 5(11): p. 1458-69.
170. Zuker, M. and P. Stiegler, Optimal computer folding of large RNA sequences using
thermodynamics and auxiliary information. Nucleic Acids Res, 1981. 9(1): p. 133-48.
171. Jaeger, J.A., D.H. Turner, and M. Zuker, Improved predictions of secondary structures
for RNA. Proc Natl Acad Sci USA, 1989.86(20): p. 7706-10.
172. Jaeger, J.A., D.H. Turner, and M. Zuker, Predicting optimal and suboptimal secondary
structure for RNA. Methods Enzymol, 1990. 183: p. 281-306.
173. Turner, D.H., et al., Improved parameters for prediction of RNA structure. Cold Spring
Harb Symp Quant BioI, 1987.52(2): p. 123-33.
174
174. Patzel, V., U. Steidl, R. Kronenwett, R. Haas, and G. Sczakiel, A theoretical approach to
select effective antisense oligodeoxyribonucleotides at high statistical probability.
Nucleic Acids Res, 1999.27(22): p. 4328-34.
175. Jaroszewski, J.W., J.L. Syi, M. Ghosh, K. Ghosh, and J.S. Cohen, Targeting of antisense
DNA: comparison of activity of anti-rabbit beta-globin oligodeoxyribonucleoside
phosphorothioates with computer predictions of mRNA folding. Antisense Res Dev,
1993.3(4): p. 339-48.
176. Laptev, A.V., Z. Lu, A. Colige, and D.J. Prockop, Specific inhibition of expression of a
human collagen gene (COL1A1) with modified antisense oligonucleotides. The most
effective target sites are clustered in double-stranded regions of the predicted secondary
structure for the mRNA. Biochemistry, 1994. 33(36): p. 11033-9.
177. Ho, S.P., et ai., Mapping of RNA accessible sites for antisense experiments with
oligonucleotide libraries. Nat Biotechnol, 1998. 16(1): p. 59-63.
178. Sczakiel, G., M. Homann, and K. Rittner, Computer-aided search for effective antisense
RNA target sequences of the human immunodeficiency virus type 1. Antisense Res Dev,
1993. 3(1): p. 45-52.
179. Stein, C.A., How to design an antisense oligodeoxynucleotide experiment: a consensus
approach. Antisense Nucleic Acid Drug Dev, 1998. 8(2): p. 129-32.
180. Prati, E.G., P. Scheidegger, A.R. Sburlati, and J.E. Bailey, Antisense strategies for
glycosylation engineering of Chinese hamster ovary (CH 0) cells. Biotechnol Bioeng,
1998.59(4): p. 445-50.
181. Peyman~ A., et al., Inhibition of viral growth by antisense oligonucleotides directed
against the IE110 and the UL30 mRNA of herpes simplex virus type-1. BioI Chern Hoppe
Seyler, 1995. 376(3): p. 195-8.
182. Lefebvre d'Hellencourt, C., L. Diaw, P. Comillet, and M. Guenounou, Inhibition of
human TNF alpha and LT in cell-free extracts and in cell culture by antisense
oligonucleotides. Biochim Biophys Acta, 1996.1317(3): p. 168-74.
183. Lima, W.F., V. Brown-Driver, M. Fox, R. Hanecak, and T.W. Bruice, Combinatorial
screening and rational optimization for hybridization to folded hepatitis C virus RNA of
oligonucleotides with biological antisense activity. J BioI Chern, 1997.272(1): p. 626-38.
184. Ramsay, G., DNA chips: state-of-the art. Nat Biotechnol, 1998. 16(1): p. 40-4.
185. Sugimoto, N., et al., Thennodynamic parameters to predict stability of RNAIDNA hybrid
duplexes. Biochemistry, 1995. 34(35): p. 11211-6.
186. SantaLucia, J., H.T. Allawi, and P.A. Seneviratne, Improved nearest-neighbor
parameters for predicting DNA duplex stability. Biochemistry, 1996.35(11): p. 3555-62.
187. Zuker, M. and A.B. Jacobson, "Well-detennined" regions in RNA secondary structure
prediction: analysis of small subunit ribosomal RNA. Nucleic Acids Res, 1995.23(14): p.
2791-8.
188. Hines, W.W. and D.C. Montgomery, Probability and statistics in engineering and
management science. 3 ed. 1990, New York: John Wiley & Sons, Inc. 732.
189. Goodchild, J., et al., Inhibition of human immunodeficiency virus replication by antisense
oligodeoxynucleotides. Proc Natl Acad Sci USA, 1988.85(15): p. 5507-11.
190. Gewirtz, A.M., D.L. Sokol, and M.Z. Ratajczak, Nucleic acid therapeutics: state of the
art andfuture prospects. Blood, 1998.92(3): p. 712-36.
175
191. Mologni, L., P. leCoutre, P.E. Nielsen, and C. Gambacorti-Passerini, Additive antisense
effects of different PNAs on the in vitro translation of the PMURAR-a gene. Nucleic
Acids Res, 1998. 26(8): p. 1934-8.
192. Sclavi, B., M. Sullivan, M.R. Chance, M. Brenowitz, and S.A. Woodson, RNAfolding at
millisecond intervals by synchrotron hydroxyl radical footprinting. Science, 1998.
279(5358): p. 1940-3.
193. Matveeva, 0., et a1., Prediction of antisense oligonucleotide efficacy by in vitro methods.
Nat Biotechnol, 1998. 16(13): p. 1374-5.
194. Montarras, D., et al., Autonomous differentiation in the mouse myogenic cell line, e2,
involves a mutual positive control between insulin-like growth factor II and MyoD,
operating as early as at the myoblast stage. J Cell Sci, 1996. 109(Pt 3)(4): p. 551-60.
195. Walton, S., C. Roth, and M. Yarmush, Antisense Technology, in The Biomedical
Engineering Handbook. 2000, CRC Press LLC: Boca Raton, FL. p. 103-1 - 103-19.
196. Andreyev, H.J., P.J. Ross, D. Cunningham, and P.A. Clarke, Antisense treatment directed
against mutated Ki-ras in human colorectal adenocarcinoma. Gut, 2001. 48(2): p. 230-
237.
197. Eckardt, S., P. Romby, and G. Sczakiel, Implications of RNA structure on the annealing
of a potent antisense RNA directed against the human immunodeficiency virus type 1.
Biochemistry, 1997.36(42): p. 12711-21.
198. Lima, W.F., B.P. Monia, D.J. Ecker, and S.M. Freier, Implication of RNA structure on
antisense oligonucleotide hybridization kinetics. Biochemistry, 1992.31(48): p. 12055-
61.
199. Zuker, M., J.A. Jaeger, and D.H. Turner, A comparison of optimal and suboptimal RNA
secondary structures predicted by free energy minimization with structures determined by
phylogenetic comparison. Nucleic Acids Res, 1991. 19(10): p. 2707-14.
200. Mathews, D.H., J. Sabina, M. Zuker, and D.H. Turner, Expanded sequence dependence
of thermodynamic parameters improves prediction of RNA secondary structure. J Mol
BioI, 1999.288(5): p. 911-40.
201. Walton, S.P., G.N. Stephanopoulos, M.L. Yarmush, and C.M. Roth, Prediction of
antisense oligonucleotide binding affinity to a structured RNA target. Biotechnol Bioeng,
1999. 65(1): p. 1-9.
202. Cazenave, C., N. Loreau, N.T. Thuong, J.J. Toulme, and C. Helene, Enzymatic
amplification of translation inhibition of rabbit beta-globin mRNA mediated by anti-
messenger oligodeoxynucleotides covalently linked to intercalating agents. Nucleic Acids
Res, 1987.15(12): p. 4717-36.
203. Goodchild, J., E.d. Carroll, and J.R. Greenberg, Inhibition of rabbit beta-globin synthesis
by complementary oligonucleotides: identification of mRNA sites sensitive to inhibition.
Arch Biochem Biophys, 1988.263(2): p. 401-9.
204. Schwille, P., F. Oehlenschlager, and N.G. Walter, Quantitative hybridization kinetics of
DNA probes to RNA in solution followed by diffusional fluorescence correlation analysis.
Biochemistry, 1996.35(31): p. 10182-93.
205. Patzel, V., J. zu Putlitz, S. Wieland, H.E. Blum, and G. Sczakiel, Theoretical and
experimental selection parameters for HBV-directed antisense RNA are related to
increased RNA-RNA annealing. BioI Chern, 1997.378(6): p. 539-43.
176
206. Helene, C. and J.J. Toulme, Specific regulation of gene expression by antisense, sense
and antigene nucleic acids. Biochim Biophys Acta, 1990. 1049(2): p. 99-125.
207. Bommarito, S., N. Peyret, and J. SantaLucia, Thermodynamic parameters for DNA
sequences with dangling ends. Nucleic Acids Res, 2000. 28(9): p. 1929-34.
208. Tabaska, J.E., R.B. Cary, H.N. Gabow, and G.D. Stormo, An RNAfolding method
capable of identifying pseudoknots and base triples. Bioinformatics, 1998.14(8): p. 691-
9.
209. Rivas, E. and S.R. Eddy, A dynamic programming algorithm for RNA structure
prediction including pseudoknots. J Mol BioI, 1999. 285(5): p. 2053-68.
210. Juan, V. and C. Wilson, RNA secondary structure prediction based on free energy and
phylogenetic analysis. J Mol BioI, 1999.289(4): p. 935-47.
211. Ding, Y. and C.E. Lawrence, Statistical prediction of single-stranded regions in RNA
secondary structure and application to predicting effective antisense target sites and
beyond. Nucleic Acids Res, 2001. 29(5): p. 1034-1046.
212. Vickers, T.A., J.R. Wyatt, and S.M. Freier, Effects of RNA secondary structure on
cellular antisense activity. Nucleic Acids Res, 2000. 28(6): p. 1340-7.
213. Scherr, M., J.J. Rossi, G. Sczakiel, and V. Patzel, RNA accessibility prediction: a
theoretical approach is consistent with experimental studies in cell extracts. Nucleic
Acids Res, 2000. 28(13): p. 2455-61.
214. Matveeva, 0., B. Felden, S. Audlin, R.F. Gesteland, and J.F. Atkins, A rapid in vitro
method for obtaining RNA accessibility patterns for complementary DNA probes:
correlation with an intracellular pattern and known RNA structures. Nucleic Acids Res,
1997.25(24): p. 5010-6.
215. Haruki, M., Y. Tsunaka, M. Morikawa, S. Iwai, and S. Kanaya, Catalysis by Escherichia
coli ribonuclease HI is facilitated by a phosphate group of the substrate. Biochemistry,
2000. 39(45): p. 13939-44.
216. Myers, K.J. and N.M. Dean, Sensible use of antisense: how to use oligonucleotides as
research tools. Trends Pharmacol Sci, 2000. 21(1): p. 19-23.
217. Kang, J.J., G.A. Kaysen, H. Jones, Jr., and M.J. Holland, Rat liver transcript profiling in
normal and disease states using a kinetic polymerase chain reaction assay. Methods,
1997. 13(4): p. 437-43.
218. Fink, L., et al., Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med,
1998. 4(11): p. 1329-33.
219. Freeman, W.M., SJ. Walker, and K.E. Vrana, Quantitative RT-PCR: pitfalls and
potential. Biotechniques, 1999. 26(1): p. 112-22, 124-5.
220. Baumann, H., K.R. Prowse, S. Marinkovic, K.A. Won, and G.P. Jahreis, Stilnulation of
hepatic acute phase response by cytokines and glucocorticoids. Ann NY Acad Sci, 1989.
557: p. 280-95.
221. Ronnov-Jessen, L., B. van Deurs, J.E. Celis, and O.W. Petersen, Smooth muscle
differentiation in cultured human breast gland stronlal cells. Lab Invest, 1990. 63(4): p.
532-43.
222. Schweitzer, M. and J.W. Engels, Analysis of antisense oligonucleotides, in Antisense --
From Technology to Therapy, R. Schlingensiepen, W. Brysch, and K.H. Schlingensiepen,
Editors. 1997, Blackwell Wissenschaft: Berlin. p. 79-103.
177
223. Hunter, J.J. and K.R. Chien, Signaling pathways for cardiac hypertrophy andfailure. N
Engl J Med, 1999. 341(17): p. 1276-83.
224. Kishirnoto, T., S. Akira, M. Narazaki, and T. Taga, Interleukin-6 family of cytokines and
gp130. Blood, 1995. 86(4): p. 1243-54.
225. Gerhartz, C., et al., Biosynthesis and half-life of the interleukin-6 receptor and its signal
transducer gp130. Eur J Biochern, 1994.223(1): p. 265-74.
226. Matrisian, L.M., G. Rautrnann, B.E. Magun, and R. Breathnach, Epidermal growthfactor
or serum stimulation of rat fibroblasts induces an elevation in mRNA levels for lactate
dehydrogenase and other glycolytic enzymes. Nucleic Acids Res, 1985. 13(3): p. 711-26.
227. Walton, S.P., G.N. Stephanopoulos, M.L. Yarmush, and C.M. Roth, Thermodynamic and
Kinetic Characterization of Antisense Oligodeoxynucleotide Binding to a Structured
mRNA. Biophys J (in press), 2001.
228. Jayararnan, A., M.L. Yarmush, and C.M. Roth, Dynamics of gene expression in rat
hepatocytes under stress. Metab Eng, 2000. 2(3): p. 239-51.
229. Peters, T., Jr., Serum albumin. Adv Protein Chern, 1985.37: p. 161-245.
230. Stein, C.A., C. Subasinghe, K. Shinozuka, and J.S. Cohen, Physicochemical properties of
phosphorothioate oligodeoxynucleotides. Nucleic Acids Res, 1988. 16(8): p. 3209-21.
178
\
